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Abstract 
Gelatin, chitosan and bioactive nanoceramic based composite scaffold with tailored 
architectures and properties has great potential for bone regeneration. Herein, we aimed to 
improve the physico chemical, mechanical and osteogenic properties of 3D porous scaffold 
by incorporation of bioactive ceramic phase into biopolymer matrix with variation in 
composition in the prepared scaffolds. Scaffolds were prepared from the slurry containing 
gelatin, chitosan and synthesized bioactive nanoceramic particulate using lyophilisation 
technique. Bioactive nanocermics such as hydroxyapatite, β-tricalcium phosphate and 58 S 
bioactive glass were synthesized and used in different concentration varying between 10-30 
wt% to prepare GCH, GCB and GCT scaffolds. GCH scaffold having HA:Chi:Gel ratio of 
28:42:30 with 78% average porosity showed a pore size distribution between 75–100 μm and 
exhibited a compressive strength of 3.45 MPa, which is within the range of that exhibited by 
cancellous bone. With increase in nanocaramic phase content from 10 wt% to 30 wt%, the 
compressive strength in the scaffold increased. GCH 30 showed the highest average 
compressive strength of 3.46 MPa whereas the lowest average compressive strength of 2.2 
MPa was registered by GCB 30 scaffold. Higher cellular activity was observed in GCB 30 
scaffold as compared to GCB 0 scaffold suggesting the fact that 58S bioactive glass 
nanoparticles addition into the scaffold promoted better cell adhesion, proliferation and 
differentiation. A Higher degree of lamellopodia and filopodia extensions and better 
spreading behaviour of MSC’s were observed in FESEM micrographs of MSC cultured GCB 
30 scaffold. Scaffolds prepared from 30 wt% 58S nano bioactive glass exhibited the highest 
bioactivity among all the scaffolds as evident from MTT assay, RUNX-2 and osteocalcin  
expression from mesenchymal stem cells cultured on the scaffold. Strongly positive 
osteocalcin signalling within 14 days of cell culture supported the fact that the prepared 
scaffolds stimulated new bone tissue regeneration. Moreover, by reverse-transcriptase (RT-
PCR) analysis, it was observed the expression of osteogenic gene markers from cultured 
MSCs were relatively high in GCB 30 as compared to GCH 30 and GCT 30 composite 
scaffolds. In coherence with the in vitro appearance, histological analysis and fluorochrome 
study in a rabbit tibia model showed a significantly greater amount of new bone formation in 
GCB30 compared to other composite scaffold. The results demonstrated that the prepared 
GCB30 scaffold could be a good candidate as a synthetic substitute for bone tissue 
engineering. 
Keywords: Hydroxyapatite, β-TCP, 58s Bioglass, Chitosan, Gelatin, scaffold, 
compressive strength, bioactivity, in vitro ,in vivo  
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General Introduction 
 
 
 
 
 
 
 
 
 
 
 
                            
 
 
 
                           Review your goals twice every day in order to be focused on achieving them. 
                                                                                                                        - Les Brown 
 
 
 1.1 General Introduction 
Human beings across the globe are likely to face serious problems such as tissue damage and 
degeneration caused by diseases, accidents and aging during their lifetime. However, there 
was limited choice on biomaterial in past for solving these medical problems with removal of 
the damaged and diseased body parts or tissues being the most frequently applied solution. 
Today, advances in science and technology of medical materials significantly altered the 
choices of researchers for the solution of the implantation problems [1]. 
1.2 Background and Significance of the Study 
To visualize and estimate the extent and prevalence of bone tissue related diseases and 
disorders, it is important to note that the World Health Organization, on January 13, 2000 
finally launched a Bone and Joint decade for the period of 2000-2010 [14] More than 43 
million people in United States of America suffer form of arthritis and it is estimated that this 
number will increase to 60 million by the end of 2020 [2].India is the second largest 
emerging economy and second most populated (1.2 billion people) country in the world with 
life expectancy is 67 years and is expected to increase to 71 years by 2025 and to 77 years by 
2050. Indian Council for Medical Research (ICMR) carried out a large multicenter study, 
which confirmed data from smaller, single cantered studies, and showed that Indians have 
lower BMD than their North American counterparts [3]. Reasons ascribed for lower BMD in 
Indians include possible genetic differences, nutritional deficiency, and smaller skeletal size 
[4]. In private hospitals, the total cost of hip surgery is between Rs 150,000 to 250,000 
(2,360-3,860 USD), and in public hospitals the cost is approximately Rs 50,000 (772 USD) 
However, each year approximately 170,000 fractures do not heal and are diagnosed as “non-
unison” thus requiring some form of bone substitute to address this problem [5]. Hence, a 
great need for bone tissue substitute in the form of bone grafts and subsequent tissue 
engineering could be a viable option. 
In this introductory chapter the chemical and biological composition of bone tissue 
engineering will briefly be discussed. Different materials, techniques and technologies that 
have been used for scaffold fabrication are outlined and explained. The ultimate theme of the 
thesis is to combine materials and technologies to create improvised functional scaffolds in 
terms of ability to provide physical and chemical cues to the in vivo neo bone tissue 
regeneration. 
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1.3 Tissue Engineering 
Tissue engineering is an interdisciplinary field that applies the knowledge of principle of 
engineering and life science in order to construct biological substitutes to repair 
damaged/diseased tissues. In order to achieve successful tissue regeneration, three important 
key issues need to be considered; the isolation and cultivation of cells, the use of tissue-
inductive biomolecules and the incorporation of cells in suitable scaffolds to support 3-D 
tissue regeneration as shown in Figure.1.1 [6]. In a traditional tissue engineering approach, 
cells are cultured and seeded on a scaffold and then implanted into the defect site to 
regenerate new tissue [7]. In this approach, the cells provide the main source for new tissue 
regeneration. The scaffolds act as three-dimensional matrices for cell growth and degrade 
away as the tissues are regenerated [8]. Despite the encouraging earlier research outcomes [9, 
10], the limited number of donor cells and low quality of regenerated tissues remained two 
hurdles in tissue engineering approaches[11]. Scaffolds are required to provide various 
additional functions besides providing structural support and suitable degradation kinetics. 
Another approach is to implant a cellular scaffold in the defect site with the capability of 
delivering appropriate biomolecules in a controlled manner, thereby recruiting progenitor 
cells to the defect site and promoting cell proliferation and differentiation, inducing tissue 
regeneration [12].Cell supportive factor-releasing scaffolds are gaining popularity and have 
recently been used along with incorporated cells [13, 14]. These scaffolds are often called 
bioactive scaffolds [15, 16]. 
 
 
Figure.1.1.The basic principle of Tissue Engineering [17]. 
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1.4 Bone 
Bone is a highly vascularised mineralized tissue which ultimately provides a skeletal support 
to the body, including protection of various internal organs [18, 19]. Therefore, entire body 
functionality and thus lifestyle too are affected by major defects in its structure [20]. Bone 
tissue regeneration provides intricate factors one of which is to mimic the microenvironment 
of natural bone. Though bone tissue has intrinsic ability to regenerate to certain extent, but 
larger defects or disorders in bony sites make healing improper and thus may start damaging 
themselves in a long run [21].  
1.4.1 Structure and Composition of Bone 
Bone comprises three types of bone cells with specific functions with surrounding 
extracellular matrix (ECM). Collagen I being the major component of bone ECM, occupies 
almost 95% of bone’s organic part of ECM. Proteoglycans and non-collagenous proteins 
contribute only 5% [22]. Glycosaminoglycan [GAG] is a kind of proteoglycans which is 
found in bone and cartilage. Calcium phosphate like minerals in the matrix provides rigidity 
and strength to bone [23]. All the properties of bone are directionally and regionally 
dependent. The composition of bone is given in Table 1.1. 
Table.1.1. Composition of Bone 
Component Amount (wt.%) 
Hydroxyapatite 69% 
Organic matrix 22% 
Water 9% 
1.4.2 Types of bone 
Bones are of two types namely cortical (hard) and cancellous/trabecular bone (spongy). The 
cortical bone typically occupies the outer layers of most of the bones and various long bones 
with 80-90% mineralization [24]. It is mainly responsible to provide mechanical strength to 
the entire skeleton. cancellous bone having 15-20% minerals generally occupies the interior 
parts of bones [25]. The cancellous bone is highly vasculaturized and hence metabolic actions 
are taken care by it. The mineral containing fibres form lamellar sheets which are arranged in 
concentric rings to form osteon [26] as shown in Figure 1.2.  
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Figure.1.2. Structure of mature bone. Note the differing structure of compact and spongy bone types [27]. 
1.4.3 Types of Bone Cells 
Three major types of bone cells that contribute to bone formation are the osteoblasts (bone-
forming cells), osteoclasts (bone resorbing cell) and osteocytes (matured bone cells). The 
various types of bone cells and their functions are represented in Table 1.2 and Figure 1.3. 
Table.1.2. Types of Bone cells and their function. 
Cell Type Morphology Function Reference 
Osteoblast Cuboidal in shape; located at the 
bone surface with their precursors 
Synthesis and regulation of 
bone ECM deposition 
[28] 
Osteocytes Stellated shaped Calcification of osteoid 
matrix 
[29] 
Osteoclast  Multinucleated cells  Bone resorption [30] 
 
 
Figure.1.3. Different type of bone cells [31]. 
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1.4.4 Mechanical Properties of Bone 
Bone tissue is a highly dynamic form of connective tissue which undergoes required regular 
remodelling (the orchestrated removal of bone by osteoclasts followed by the formation of 
new bone by osteoblasts) to optimally adapt its structure to changing functional demands 
(mechanical loading, nutritional statusetc.). The mechanical properties mostly depend on the 
bone composition (porosity, mineralisation etc.) as well as the structural organisation 
(trabecular or cortical bone architecture, collagen fibre orientation, fatigue damage etc.) [32]. 
The resulting mechanical properties of the two types of bone tissue, namely the cortical bone 
and cancellous bone, are shown in Table 1.3. 
Table.1.3. Mechanical properties of compact and spongy bone . 
Type of Bone 
Longitudinal 
Plane 
Transverse 
Plane 
Elastic 
Modulus 
Reference 
Compact Bone 
Compression 
Tensile  
Shear 
131-224 MPa 
106-133 
MPa 
13.7 GPa 
[33] 
78.8-151 MPa 51-56 MPa 
53.1-70MPa 
 
Spongy/Cancellous 
Bone 
Compression 
Tensile 
Shear 
3-30 MPa <5MPa 
1.5 GPa 
[34] 
3-20 MPa <5MPa 
<5MPa <5MPa 
1.4.5 Mechanism of Bone Healing 
The architecture of damaged bone tissue is primarily restored by regeneration of normal cell 
and ECM rather by repair of injured area as it occurs in some other connective tissues [35]. 
The healing mechanism starts with immediate bleeding and blood clotting, which provides 
the basic platform for inflammation [36]. The neo bone tissue produced then replaces the 
blood clot with formation of soft callus (fibrous tissue and cartilage) and later on replaced by 
hard callus as shown in Figure 1.4. Finally the compact tissues grow and remodelling 
continues to occur. 
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Figure.1.4.Preliminary bone healing mechanism [42].  
1.5 Bone Grafts 
1.5.1 Autograft 
Autografts are considered as the gold standard for the bone replacement, mainly because they 
offer minimal immunological rejection, complete histocompatibility and provide the optimum 
osteoconductive, osteogenic and osteoinductive properties [37].The main advantages of 
autograft are their excellent success rate and low risk of disease transmission. Autogenous 
cancellous bone graft has been considered more osteogenic as compared to cortical bone graft 
because of their porous structure and allows the diffusion of nutrients and limited 
revascularization by microanastomosis of its circulating vessels. In an experimental study on 
Dog, it was observed that fresh autografts are incorporated rapidly and possess 
osteoinductive, osteoconductive and osteogenic properties. 
1.5.2 Allograft 
Allograft cortical bone grafts have little or no osteoinductive properties and are mostly 
osteoconductive, but the surviving osteoblast does provide some osteogenic properties as well 
as describe in Table 1.4 [38]. Vascularize cortical grafts heal rapidly at the host-graft-
interface, and their remodelling is similar to that of normal bone[39]. However, 
disadvantages include potential morbidity at donor site, availability in limited quantities, risk 
of wound infection, increased blood loss and prolonged anaesthetic time [40]. 
Table.1.4. Bone graft and graft substitute [41]. 
Class Description Examples Properties of action 
Autograft based Used alone  
•Osteoconductive 
•Osteoinductive 
•Osteogenic 
Allograft based 
Allograft bone used 
alone or in 
combination 
with other materials 
Allegro, Orthoblast, 
Grafton 
•Osteoconductive 
•Osteoinductive 
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Cell based 
Cells used to generate 
new tissue alone or 
seeded onto a support 
matrix 
Mesenchymal stem 
cells 
•Osteogenic, 
•Both osteogenic 
and 
osteoconductive 
with carrier 
materials 
Ceramic based 
Includes calcium 
phosphate, calcium 
sulfate, and bioactive 
glass used alone or in 
combination 
Osteograf, ,Osteoset, 
NovaBone 
•Osteoconductive 
•Limited 
osteoinductive when 
mixed with bone 
marrow 
Polymer based 
Includes degradable 
and nondegradable 
Polymers used alone or 
with other materials 
Cortoss, OPLA, 
Immix 
• Osteoconductive 
• Bioresorbable in 
degradable polymer 
 
1.6 Biomaterials Classifications 
1.6.1 Based on material-tissue interactions 
Depending on the nature of scaffolding material, tissue reacts towards the implant in a variety 
of ways. The tissue response to the implant biomaterial surface ultimately governs activity 
and efficiency of implant material inside the body to regenerate damaged/diseased bone 
tissue. In general, biomaterials may be described in or classified into four categories such as 
bio-inert, bioactive, surface active and bio-resorbable depending on their interaction with 
tissues and cells as shown in Figure 1.5. 
1.6.1.1 Bioinert 
Materials when implanted inside the human body exert minimal biological interaction with its 
surrounding tissue. Generally, a fibrous capsule is formed around the Bioinert implants and 
hence bio-functionality of this kind of material depends on tissue integration. Examples of 
Bioinert biomaterials are stainless steel, titanium, alumina, partially stabilized zirconia, ultra 
high molecular weight polyethylene etc [42]. 
1.6.1.2 Bioactive 
The material, when placed inside the human body interacts with the surrounding bone and 
soft tissues through the time dependent kinetic modification of the construct surface. A 
biologically active carbonate apatite (CHA) layer is formed and deposited on the bioactive 
implant surface by the ion exchange reaction between the bioactive implant and surrounding 
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body fluids. This biologically active carbonated apatite (CHA) layer is chemically and 
crystallographically equivalent to the mineral phase of natural bone tissue [43]. Prime 
examples of these bioactive materials are synthetic hydroxyapatite [Ca10(PO4)6(OH)2], glass 
ceramic A-W and bioglass. 
1.6.1.3 Surface active 
Surface active biomaterials form a bioactive layer on exposure to physiological environment 
and thus undergoes direct interactions with host bone through physicochemical and biological 
bonds without formation of fibrous capsule [43]. In biological environment, the surface layer 
of this kind of biomaterials consists of calcium and phosphorous that is crystallographically 
similar to inorganic part of natural ECM of bone[44]. The materials include bioactive glasses 
, bioactive glass ceramics , bioactive composites and bioactive coatings [45]. 
1.6.1.4 Bioresorbable 
Materials are the one which is capable of being dissolved or resorbed and slowly replaced by 
advancing tissues, such as bone, when used as an implant material inside the body. Common 
examples of bio-resorbable materials are tri-calcium phosphate [Ca3(PO4)2] and polylactic–
polyglycolic acid copolymers [46]. 
 
 
Figure.1.5 Classification of bioceramics according to their bioactivity; (a) bioinert, (alumina dental 
implant), (b) bioactive, hydroxyapatite (Ca10(PO4)6(OH)2) coating on a metallic dental implant, (c) 
surface active, bioglass or A-W glass, (d) bioresorbable tri-calcium phosphate implant [Ca3(PO4)2][46]. 
1.6.2 Based on type of materials 
Depending on the type of materials, biomaterials can primarily be divided into three 
categories- metals, ceramic and biopolymer. Sometimes a combination of these materials is 
used as composite structure to mimic ECM of natural bone tissue. Application of these 
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materials includes replacement of hips, knees, teeth, tendons and ligaments; repair of 
periodontal disease; maxillofacial reconstruction; spinal fusion, and bone repair. 
1.6.2.1 Metal as biomaterial 
Metallic biomaterials have been extensively used for load-bearing implants, such as hip and 
knee prostheses and fracture fixation wires, pins, screws, and plates [47]. Metals also find 
attractive application as parts of artificial heart valves, as vascular stents, and as pacemaker 
leads [48]. Metallic alloys with tailored materials properties, such as strength and corrosion 
resistance, are sometimes used as implant instead of pure metal. The main considerations in 
selecting metals and alloys for biomedical applications are biocompatibility, appropriate 
mechanical properties, corrosion resistance, and reasonable cost. 
The mechanical properties of materials are of great importance when designing load-bearing 
orthopaedic and dental implants as alternative substitute. Mechanical properties of some of 
the most commonly used metallic implants are listed in Table 1.5. 
 
Table.1.5. Select Properties of Metallic Biomaterials [49]. 
Materials Young Modulus 
E(GPa) 
Yield Strength 
σy,(MPa) 
Tensile Strength 
σUTS, (MPa) 
Fatigue 
Limit 
σend,(MPa) 
Stainless steel 190 221-1,213 586-1,351 241-820 
Co-Cr alloys 210-253 448-1,606 655-1,896 207-950 
Ti 110 485 760 300 
Ti-6Al-4V 116 896-1,034 965-1,103 620 
Cortical bone 15-30 30-70 70-150  
 
The elastic moduli of the metals listed in Table 1.5 are at least seven times greater than that 
of natural bone. This mismatch of mechanical properties of implants can cause stress-
shielding associated with bone resorption (loss of bone) in the vicinity of implants [50]. 
Compared to the elastic moduli of either stainless or cobalt-chromium molybdenum alloys, Ti 
and Ti-6Al-4V have much lower moduli that are still almost an order of magnitude higher 
that of bone. Another advantage of Ti-based metals as bone implants is their favourable 
strength-to-density ratio [51]. 
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1.6.2.2 Ceramic as Biomaterial  
Bioceramics are employed as components of hip implants, dental implants and heart valves 
[52]. They are also designed and fabricated for repair and reconstruction of diseased, 
damaged or “worn out” parts of the body tissue. Some of the ceramics that have been used for 
biomedical applications are listed in Table 1.6.  
Table.1.6. Ceramics Used in Biomedical Applications [53]. 
Ceramic Chemical Formula Types of Attachment Comment 
Alumina Al2O3 Mechanical interlock 
(morphological 
fixation) 
Bioinert 
Zirconia ZrO2 
Bioglass Na2O CaOP2O3-SiO 
Interfacial bonding 
with tissues 
(Bioactive fixation) 
Bioactive 
Highly dense pure 
Hydroxyapatite 
Ca10(PO4)6 
(OH)2 
Hydroxyapatite (sintered 
low temperature) 
Ca10(PO4)6 
(OH)2 
Ingrowths of tissues 
in pores (Biological 
fixation) Biodegradable 
Tricalcium phosphate Ca3(PO4)2 
Replacement with 
tissues 
 
Bioceramics are corrosion resistant, but may be susceptible to other forms of degradation 
when exposed to a physiological environment. The mechanism and rate of degradation vary 
depending on the type of bioceramics. Even alumina, a predominantly bioinert ceramic, 
suffers from time-dependent deterioration in strength when placed in physiological 
environment in vitro and in vivo. Calcium Phosphate (CaP) based bioactive ceramics are also 
degraded in the body by virtue of its dissolution in physiological fluid and osteoclasts 
mediated bioresorption. The rate of degradation of CaP ceramics will vary depending on their 
phase, chemical composition, and crystal structure. Table 1.8 shows different types of 
Calcium orthophosphate ceramics. 
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Table.1.7. Different types of calcium phosphates (CaP) [54]. 
Chemical Name Abbreviati
on  
Chemical formula  Phase  Ca/P  Solubility  
Monocalcium Phosphate MCP  Ca(H2PO4), H2O  --------  0.50  1X 10-3  
Dicalcium Phosphate Hydrate  DCPD  CaHPO4, H2O  Brushite 1.00  1.87X 10-7  
Dicalcium Phosphate Anhydrous  DPCA  CaHPO4  Monetite 1.00  1.26 X 10-7  
Octacalcium Phosphatepenta 
hydrate 
OCP  Ca8H2(PO4).5 
H2O  
 1.33 5.1 X 10-15  
 
Tricalcium Phosphate 
α-TCP  Ca3 (PO4)2   1.50  
β-TCP  Ca3 (PO4)2  Whitlockite 1.50  2.83X10-30  
Hydroxyl Apatite  HAp  Ca10 (PO4)6(OH)2  Hydroxyapatite 1.67 2.35 X 10-59  
Tetracalcium Phosphate 
monoxide  
TTCP  Ca4O(PO4)2  Hilgenstockite 2.00  
The solubility of different CaP minerals changes in the following order.  
ACP > DCP >TTCP > α-TCP > β-TCP >> HAp . 
The slowest rate of dissolution of HAp among all the CaP ceramics listed above is not 
surprising, because it is highly stable CaP compound at and above pH 4.2. The applications of 
CaP based bioresorbable ceramics include drug delivery vehicle, repairing damaged bone, 
repairing and fusion of spinal and lumbo-sacral vertebrae, repairing maxillofacial and dental 
defects.  
Bioactive ceramics mostly include CaP based materials and bioactive glasses. A common 
characteristic of all bioactive implant is the formation of a hydroxyl carbonated apatite 
(HCA) layer on their surface when implanted. Depending on the nature of bioactive ceramics, 
the formation of HCA layer may take from days to weeks. The application of bioactive 
ceramics includes coating on prostheses, reconstruction of dental defects, bone plate and 
screws, replacements of middle ear ossicles and correcting periodontal defects. 
Among the CaP ceramics discussed here, hydroxyapatite, and tricalcium phosphate are 
important as structural biomaterials because of their stability at high temperature, sinterability 
of the powders and comparatively higher mechanical properties of the dense bodies. 
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A. Hydroxyapatite 
Figure.1.6 illustrates a schematic diagram of the structure of hydroxyapatite (HAp). The 
structure shown here is the stoichiometric composition of HAp whereby the unit cell is 
composed of Ca10(PO4)12(OH)4. The core framework of the HAp structure is constituted 
mainly of the PO43- tetrahedron, with two types of channel structures that lie parallel to the c 
–axis. The OH ion  and Ca2+ ion  lie within each of these structures [55]. Eight of the 20 Ca2+ 
in the unit cell are located at the Ca2+ site (Ca I), with the remaining Ca2+ located on the 
second site (Ca II), which is also the peak of the equilateral triangle that is constructed from 
the OH- ion channels. This Ca2+ is exposed on the crystal surface, thus playing a large role in 
the physical properties of HA, such as surface charge, and in interactions with organic 
compounds. 
 
Figure.1.6. Crystal structure of Hydroxyapatite [56]. 
Β. β−Tricalcium phosphate  
Tricalcium phosphate Ca3(PO4)2(TCP ) is frequently used as bone graft substitutes in many 
surgical fields like the orthopaedic, dental, plastic surgeries [57]. It forms calcium deficient 
hydroxyapatite on exposure to physiological fluids that confers to its excellent 
biocompatibility and osteointegration properties. Moreover, its efficient resorbability in the 
human biological environment allows significant recolonisation of the operational site by 
advancing bone growth with the progressive degradation of this material. TCP can exist 
under two polymorphs, such as: β-TCP stable below 1120°C, α-TCP stable between 1120 and 
1470 ◦C [58]. β-TCP is stable at room temperature and reconstructively transforms at 1125°C 
into α-TCP, which is metastably retained until room temperature during the cooling [59]. The 
ideal Ca/P ratio of β-TCP is 1.5. As reported by Dickens and al [60]. The β -TCP crystallizes 
in the rhombohedral space group R3C with unit-cell parameters a = 10.4121(3); c = 
37.3517(5) Å [61]. 
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Figure.1.7. Crystal structure of Tri-calcium phosphate [62]. 
The major drawback of bioceramics based is that they fail catastrophically due to the 
presence of cracks or other defects [63]. Although some of the bioceramics exhibit 
outstanding strength when loaded in compression, they fail at low stress in tensile or bending 
environment [64]. The mechanical properties of CaPs and bioactive glasses make them 
unsuitable as load-bearing implants. Table 1.8 shows some of the mechanical properties of 
ceramic based biomaterials used for fabricating scaffold. Among the biomedical ceramics, 
alumina has the best mechanical properties, but its tensile properties are still below those of 
metallic biomaterials [63]. Additional advantageous properties of alumina are its low 
coefficients of friction and wear rate. Because of these properties, alumina has been used as a 
bearing surface in joint replacements. 
Table.1.8. Mechanical properties of ceramic biomaterials [65]. 
Bioceramics  Young’s Modulus  
E (GPa)  
Compressive 
Strength, (MPa)  
Tensile Strength,  
 (MPa)  
Alumina  380  4500  350  
Bioglass-ceramics  22  500  56-83  
Calcium Phosphate  40-117  510-896  69-193  
Pyrolytic carbon  18-28  517  280-560  
C. Bioactive glasses and glass-ceramics 
Ceramics include various glasses and glass-ceramics. Gong et al. fabricated glass implants 
with 5% porosity and pores that ranged from 100–200 µm, and also glass-ceramic implants 
with macropores (100–200 µm) and micropores (0.5 µm). Glassy carbon pellets with 40% 
porosity induced bone growth in tibia defects in rabbits [66]. Bioglass (materials with 
different compositions of SiO2,CaO, Na2O, and P2O5  scaffolds have an inter-connected 
network, 10–500 µm and have been shown to support culture of human primary osteoblasts . 
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In other studies Bioglass implants with pores ranging from 100 to 600 micron induced 
ectopic bone formation in dogs [67]. Silica/calcium phosphate scaffolds with different 
porosities (51%, 47% and 43% generated by decreasing the silica content) and a broad 
distribution of pore sizes (10–300 µm) helped to regenerate bone in femoral defects in rabbits 
. Upon retrieval, the silica-rich scaffolds were almost filled with new bone and showed higher 
resorbability than scaffolds with lower silica content. This stronger osteogenic outcome was 
attributed to the chemical composition (high content of pyrophosphate) and not to differences 
in porosity. Properties of amorphous glass and glass-ceramic scaffolds are summarized in 
Table 1.9. 
Table.1.9. Porosities and pore sizes of amorphous glass and glass-ceramic scaffolds for bone regeneration 
[68]. 
Material Fabrication 
technique 
Pore size 
(µm) 
Porosit
y (%) 
Application 
Glasses Sintering 100–200 5-40 Tibia defects in rabbits 
Bioglass Foaming 10–500  Primary human osteoblasts in vitro 
 Sintering 100–600  Ectopic bone formation in dogs 
Glass-ceramics Sintering 100–200   
 Phase 
transformati
on 
10–300 51, 47 
and 43 
Femoral defects in rabbits 
1.6.2.3 Polymer as Biomaterial 
Owing to their excellent biocompatibility, tunable chemical composition, good biological 
reorganization and adjustable biodegradation, biopolymers, including both natural and 
synthetic polymer composites, have been widely used as biomaterials for the fabrication of 
medical devices and tissue-engineering scaffolds [69]. 
1.6.2.3.1 Synthetic and natural polymer 
The most often utilized biodegradable synthetic polymers for 3D scaffolds in tissue 
engineering are saturated poly-a-hydroxy esters, including poly(lactic acid) (PLA) and 
poly(glycolic acid) (PGA), as well as poly(lactic-coglycolide) (PLGA) copolymers [70]. 
Natural polymers used in bone tissue engineering include chitosan, collagen, fibrin, alginate, 
silk, hyaluronic acid, and gelatin [71]. Some of the synthetic polymers exhibit high 
mechanical properties suitable for application in bone implant, but their bioactivity is inferior 
to that of natural biopolymer. Again, most natural polymers are biocompatible, degradable, 
and readily solubilized in physiological fluid which can be used alone as a growth factor 
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delivery carrier or combined with other delivery materials such as synthetic polymers and 
inorganic materials. Despite higher biocompatibility, natural polymers are mechanically weak 
and undergo rapid degradation upon implantation. Therefore, optimization of degradation rate 
and molecular properties in natural polymer based bone implants are required to enhance 
their efficacy in application of bone tissue engineering. Research in this direction has been 
made by crosslinking collagen based implants with appropriate chemical reagents [72]. Here, 
we specially emphasize on the basic properties of two of the most important natural polymers 
such as chitosan and gelatin. 
A. Chitosan 
As the degree of deacetylation of chitin reaches about 50% (depending on the origin of the 
polymer), it becomes soluble in acidic aqueous media and is called chitosan. The 
solubilisation occurs by protonation of the –NH2 functional group (Figure1.8) on the C-2 
position of the D-glucosamine repeat unit, whereby the polysaccharide is converted to a 
polyelectrolyte in acidic media [73]. This polymer has been extensively investigated for 
industrial application based on film and fibre formation. Numerous derivatives of chitin have 
been developed to alter biological functions of chitosan, including enhancement of cellular 
interactions for tissue engineering approaches. Chitosan has been functionalized with sugar 
residues such as fructose or galactose for culture of hepatocytes and with proteins such as 
collagen, gelatin and albumin for neural tissue engineering [74]. 
 
 
Figure.1.8. Chemical formulae of chitosan [74]. 
B. Gelatin 
Gelatin comprises of heterogenous mixture of single or multi –stranded polypeptides, 
containing between 50-1000 amino acids [75]. Each peptide strand is conformed with 
extended left-handed proline helix. The triple helix of type I collagen, extracted from skin 
and bones, one of the sources of gelatin, is composed of two α1(I) and one α2(I) chains. Each 
helix is associated with molecular mass of of ~ 95 kD, width of ~1.5 nm and length of ~0.3 
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µm. The mixtures of these strands together with their oligomers and other breakdown 
polypeptides from the core of gelatin structure, as shown in Figure.1.9. 
 
Figure.1.9. Chemical structure of Gelatin [75]. 
The mechanical properties of polymeric implants depend on several factors, including 
the composition and structure of the macromolecular chains and their molecular weight. 
Compared to ceramic and metals, polymers have much lower strength but they can be 
deformed to a greater extent before failure [76]. Table 1.10 shows some of the mechanical 
properties of selected polymeric biomaterials. Ultra high molecular weight polyethylene is 
used for bearing surface in hip and knee replacements. 
Table.1.10. Mechanical properties of polymers [77]. 
Polymers  Tensile strength (MPa)  Young’s Modulus E (GPa) % Elongation  
Polymethylmethacrylate 30  2.2  1.4  
Nylon 6/6  76  2.8  90  
Polylactic acid  28-50  1.2-3  2-6  
Polypropylene  28-36  1.1-1.55  400-900  
Polytetrafluoroethylene  17-28  0.5  120-350  
Silicone rubber  2.8  Up to 10  160  
Collagen  141.2-85.7  5-11.5  250-450  
Chitin 0.0650 0.0001098 ̶ 
Alginate 71 ± 9  0.85 ± 0.08 ̶ 
 
Current applications of biomedical polymers include vascular grafts, heart valves, artificial 
hearts, contact lenses, intraocular lenses, sutures, adhesives. Table 1.11 shows some of the 
polymers and their uses. 
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Table.1.11. Examples of biomedical applications of polymers [78]. 
Applications Polymers 
Cardiovacular implants 
Polyethylene, Polyvinyl chloride (PVC), polyester, 
silicone rubber, polytetrafluoroethylene 
Orthopedic implants 
Ultra-high-molecular-weight polyethylene (UHWMPE), 
polymethylmethacrylate 
Drug release Polylactide-co-glycolide 
Tissue engineering 
Polylactic acids, polyglycolic acid, Polylactide-co-
glycolide 
1.7 Summary 
As it is evident from the above discussion, each material type has advantages and 
disadvantages and a combination of two or more materials would result in a final product 
with much improved characteristics in terms of bioactivity and desired mechanical properties. 
As bone chemically consists of an organic (predominantly collagen) and inorganic (biological 
apatite ) phase, a combination of natural or synthetic polymer and a calcium phosphate 
ceramic in the form of composite or hybrid construct is a strategy that is currently used to 
create tissue engineering scaffolds for neo bone tissue regeneration. 
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Chapter 2 Literature Review 
2.1 Introduction 
Generation of neo bone and cartilage by transplantation of autogenous cell is considered as 
one of the most promising techniques in orthopedic surgery and biomedical engineering [79]. 
Treatment concepts based on these techniques would eliminate problems of donor site 
scarcity, immune rejection and pathogen transfer. Cells such as Osteoblasts, chondrocytes 
and mesenchymal stem cells derived from the patient's hard and soft tissues can be expanded 
by in vitro culture, and then seeded onto a scaffold that will slowly degrade and resorb as the 
tissue structures grow in vitro or in vivo. The scaffold or three-dimensional (3-D) construct 
provides the necessary support for cells to proliferate and maintain their differentiated 
function. The architecture of the scaffold defines the ultimate shape of the new bone and 
cartilage. Several scaffold materials have been developed and investigated for tissue 
engineering bone and cartilage including hydroxyapatite (HAp), bioactive glass,β-TCP and 
natural polymers such as collagen and chitosan. Several reviews have been published on the 
general properties and design features of biodegradable and bioresorbable polymers and 
scaffolds [80]. The aim of this review is to complete the information collected so far, with 
special emphasis on the evaluation of biomaterials and their properties which are of specific 
interest in tissue engineering based strategies of bone and cartilage tissues. 
2.2 Stem Cells for Tissue Engineering  
Stem cells are playing a major role in tissue regeneration and orchestrate tissue remodelling. 
Multilineage differentiation ability of mesenchymal stem cells (MSCs) makes them potential 
cell source for tissue regeneration applications [81]. The various sources to obtain MSCs 
include placenta, umbilical cord blood (UCB), blood, adipose tissue and bone marrow. 
Depending upon ease of handling and considering it as cheaper hospital waste product, UCB 
is considered as one of the promising sources for the isolation of MSCs [82]. Stem cells and 
their usage for curing tissue related defects/diseases are expected to continue as a foremost 
area of development for successful tissue engineering applications. 
2.2.1 Embryonic stem cells  
Embryonic stem cells (ESC) are derived from the inner cell mass of blastocyst from which 
the embryo derive and develop. The unique properties of the embryonic stem cells include 
their self-renewal potential and capacity to differentiate via precursor cells. ESC has the 
differentiation ability to adipocytes , chondrocytes , neuron , hepatocytes and osteocytes [83]. 
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2.2.2 Adult stem cells  
Apart from ESC, adult stem cells (ASC) are also considered as the most potential cell source 
for tissue engineering. These cells can be derived from bone marrow, periosteum, muscle, fat 
and skin. The prime role of ASC is to maintain and repair the tissue in which it is found [84]. 
2.2.3 Mesenchymal stem cells (MSCs)  
Mesenchymal stem cells (MSCs) also known as somatic cells are undifferentiated and present 
in any tissue or organ. These cells are of mesodermal origin and develop into various 
connective tissue types like blood, muscle, bone, cartilage, tendon, and ligament [85]. These 
cells have the capacity of self-renewal and can differentiate into specialized cell types of 
different tissues. MSCs can be easily isolated, cultured and expanded under in-vitro 
conditions. MSCs, under culture conditions possess morphology similar to fibroblasts like 
spindle shape and exhibit good affinity to adhere over the tissue culture substrate. So, MSCs 
are good choice for tissue engineering applications including cell based therapies. 
 
 
 
 
 
 
 
Figure.2.1. Mesenchymal stem cells differentiation in osteogenic, chondrogenic, adipogenic and neuronal 
lineages [86]. 
2.3 Scaffold  
Scaffold is an artificial ECM which is vital to enable the cells to produce specific tissues of 
desired shape, size and functionality, therefore scaffold design and fabrication are the major 
areas of biomaterials research and important subjects to research related to tissue engineering 
and regenerative medicine [87]. The scaffold behaviour is heavily dependent on the several 
design variables such as microstructure, pore size and porosity, mechanical properties and 
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surface chemistry. Scaffold microstructure should mimic native tissue structure containing 
extracellular matrix for successful tissue regeneration. It should possess sufficient porosity 
and the pores should be well interconnected for transport of nutrient and waste [88]. While 
tissue regeneration is in progress, influx and efflux of nutrient and toxic by product through 
diffusion is limited to 100–200 μm and therefore, scaffold should have enough porosity so 
that cells in the scaffold can reside within 200 μm of capillary transports . Besides, scaffold 
should have a pore size depending on type of tissue engineering. For bone, muscle and skin, 
the required pore sizes are 100-300 μm, 100-200 μm and 20-120 μm respectively [89]. 
Another important aspect of scaffold designing is consideration of its mechanical properties. 
The scaffold must possess adequate mechanical properties to withstand stress and 
physiological load and mediate cues for new tissue regeneration. Generally, scaffold’s 
mechanical properties should be similar to mechanical properties of corresponding tissues for 
which the scaffold is intended to. Surface chemistry of the scaffold is also important and 
should induce cell attachment, proliferation, migration and differentiation. Moreover, surface 
of the scaffold should possess specific functional groups for biomolecule attachment and 
mediate signalling cues for tissue regeneration. The topology of scaffold should be able to 
guide the orientation of cells for effective cell based construct formation. Scaffold materials 
should be endowed with some of the above properties and therefore, material selection is 
very important for intended tissue engineering using scaffolds. 
2.4 Scaffold Fabrication Techniques 
To engineer desired functional tissues and organs successfully, the scaffolds have to be 
designed to facilitate cell distribution and guide tissue regeneration in three dimensions. The 
potential for scaffolding techniques in spectrum of tissue engineering are still in their 
burgeoning stage and need to be established further to achieve excellence. Each method is 
unique in terms of its principle and working conditions. Depending upon the prerequisite 
requirement and application, fabrication techniques can differ. Various method currently in 
use for scaffold fabrication include electro spinning, phase separation, solvent casting, freeze 
drying, gas foaming, rapid prototyping [90] ,which are described below. 
2.4.1 Particulate-leaching techniques 
Particulate leaching is a technique that has been widely used to fabricate scaffolds for tissue 
engineering applications [91]. Briefly, porogen such as salt is first ground into small particles 
and those of the desired size are transferred into a mold. A polymer solution is then cast into 
the salt-filled mold and freezed. The freezed samples were then washed in a non-solvent but 
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solvent for porogen. After the evaporation of the solvent, the salt crystals are leached away 
using water to form the pores in the scaffold. The process is easy to carry out. The pore size 
and total porosity can be controlled by the size of salt crystals and salt/polymer ratio. 
However, certain critical variables such as pore shape and inter-pore openings can not be 
controlled. To overcome these shortcomings, new techniques are being developed. 
2.4.2 Gas foaming 
Gas foaming has been commonly employed to produce microcellular foams of thermoplastic 
polymers [92] such as polymethyl methacrylate and polystyrene, but only in 1994 Mooney et 
al. applied this method for the production of PLA50GA50 scaffolds for tissue engineering 
[93]. Since then gas foaming has become an appealing technique for fabricating microporous 
scaffolds. 
2.4.3 Lyophilization 
Lyophilization or freeze drying is one of the most promising techniques to fabricate 
microporous scaffold where scaffolding materials were dissolved and cast in mold followed 
by freezing and drying at lower temperature at low vacuum. Finally, polymer solution 
separates into two phases, a polymer-rich phase and a polymer-lean phase. After the removal 
of solvent, the polymer-rich phase solidifies and 3D porous scaffold is obtained. Phase-
separation techniques have been used to fabricate porous membranes for filtration and 
separation by the following two methods [94]. 
 2.4.3.1 Solid-liquid phase separation  
Solid-liquid phase separation can be achieved at lower temperature to induce solvent 
crystallization from a polymer solution. And this process is defined as a solid-liquid phase 
separation (solid phase formation in a liquid phase). After the removal of the solvent crystals 
(sublimation or solvent exchange), the space taken by the solvent crystals becomes pores. 
This technique can be used to fabricate scaffolds from many types of polymers and polymeric 
composite materials [95]. 
2.4.3.2 Liquid-liquid phase separation 
Liquid-liquid phase separation of a polymer solution occurs when temperature of the solution 
is reduced below upper critical solution temperature. When such a process leads to the 
formation of a bi-continuous structure (both the polymer-rich and polymer-lean phases are 
continuous), a scaffold with an open-pore structure is formed after the removal of the solvent. 
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For example, a mixture of di-oxane and water has been used for liquid-liquid phase 
separation to fabricate PLA and PLGA scaffolds [96].  
2.4.4 Electro-spinning 
Electro spinning was first introduced in the early 1930s and used to fabricate industrial or 
household nonwoven fabric textile products [97]. The technique has been further improved 
over the past decade to process biodegradable and/or biocompatible polymers in order to 
fabricate fibrous fabrics with an average fiber diameter at micrometer or nanometer scales for 
tissue engineering scaffolds. To form such fibers using electrospinning, a polymer solution is 
forced through a capillary, forming a drop of polymer solution at the tip. As the polymer jet 
travels through the air under applied high voltage, the solvent evaporates and a nonwoven 
polymer fabric is deposited on the target. However, there are challenges in using this 
technique to fabricate complex three-dimensional scaffold shapes and internal pore networks.
 
Figure.2.2. (a)Schematic diagram of polymer nanofiber formation using electro spinning method 
[32].(b)SEM image of electrospun nanofiber [54]. 
2.4.5 Solid freeform fabrication techniques (SFFT) 
SFFT, such as fused deposition modeling or rapid prototyping, have been successfully 
employed to fabricate highly reproducible artificial ECM scaffolds with fully interconnected 
porous networks [98]. Using digital data produced by an imaging source such as computer 
tomography or magnetic resonance imaging accurate design of the scaffold structure can be 
executed. Solid free form (SFF) manufacturing coupled with conventional foam scaffold 
fabrication procedures (phase separation, emulsion-solvent diffusion or porogen leaching) 
might be used to create frameworks with controlled microscale and macroporous structures. 
Such biomimetic internal structures may demonstrate significant impact for multi tissue and 
structural tissue interface engineering [99]. 
 
(a) 
(b) 
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Figure.2.3. (a) Photograph of the newly developed scaffold fabrication system using the axiomatic 
approach. (b) SEM images of fabricated microstructure using the newly designed fabrication system 
[100]. 
 
Table.2.1.Fabrication routes for 3D composite scaffolds with high pore interconnectivity and their 
advantages and disadvantages. 
Fabrication route Advantages Disadvantages 
Thermally induced phase 
separation (TIPS) [101]] 
High porosities (95%) 
Highly interconnected pore 
structures. 
Anisotropic and tubular pores 
possible. 
Control of structure and pore 
size by varying. 
preparation conditions. 
Long time to sublime solvent (48 hours) 
Shrinkage issues. 
Small scale production. 
Use of organic solvents. 
Solvent casting/particle leaching[102] Controlled porosity Controlled interconnectivity (if particles 
are sintered) 
Structures generally isotropic 
Use of organic solvents 
Solid free-form [103] 
Porous structure can be tailored 
to host tissue. 
Protein and cell encapsulation 
possible. 
Good interface with medical 
imaging. 
Resolution needs to be improved to the micro-scale. 
Some methods use organic solvents. 
Microsphere sintering 
[104] 
Graded porosity structures 
possible Controlled porosity 
Can be fabricated into complex 
shapes 
Interconnectivity is an issue 
Use of organic solvents 
Scaffold coating [105] Quick and easy 
Clogging of pores, sometimes organic solvents used, coating adhesion to 
substrate can be too weak 
(a) (b) 
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2.5 Structural Design  
It is very much accepted that a scaffold with a permeable structure favours tissue ingrowth, 
the mass-transportation of supplements and osteointegration with the host bone, and in 
addition long-term stable fixation of bone inserts [106]. To encourage recovery of damaged 
bone tissue desired bone tissue regeneration, the parameters for structural configuration of the 
scaffold such as porosity, pore size and shape, the orientation of the interconnected channel 
and a progressive control of structure are often considered. 
2.5.1 Porosity 
Porosity is characterized as the percentage of void space in a solid [31] and it is a 
morphological property independent of the material. Pores are fundamentals for bone tissue 
development since they permit relocation and proliferation of osteoblasts and mesenchymal 
cells . Moreover a permeable and porous surface enhances mechanical interlocking between 
the scaffold biomaterial and encompassing normal bone, giving noteworthy mechanical 
stability at this basic interface. The most widely recognized strategies used to make porosity 
in a biomaterial are salt leaching, gas foaming, phase separation, freeze-drying and sintering 
depending on the material used to fabricate the scaffold. In hydroxyapatite/chitosan-gelatin 
composites (with most pores between 300 and 500 µm) porosity can be increased by 
decreasing the chitosan gelatin concentration and increasing the chitosan 
gelatin/hydroxyapatite ratio [107]. These scaffolds supported the proliferation and 
mineralization of rat calvarial osteoblasts in vitro [58]. Higher porosity did not affect cell 
attachment, but resulted in increased cell proliferation, since pore space increased with 
porosity and facilitated transport of oxygen and nutrients [108]. 
2.5.2 Pore Size 
The impact of various porosities and pores sizes on the degree of osteogenesis in vitro has 
been demonstrated both with osteoblasts and undifferentiated cells. In composites of apatite 
and collagen with pores ranging from 50 to 300 µm, higher apatite contents diminished the 
porosity, yet not significant contrast were observed in MC3T3-E1 osteoblast proliferation 
[109]. A extremely fascinating part of the impact of pore size on bone regeneration, is the 
effect of the progression toward osteogenesis. Regular honey-combed like hydroxyapatite 
scaffolds with small (90–120 µm) and large tunnel (350 µm) diameters were utilized for 
BMP-2 delivery and were implanted subcutaneously in rats [110]. In small diameter tunnels 
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scaffold chondrogenesis happened before osteogenesis; conversely, in tunnels with large 
diameter bone was formed directly. 
2.6 Mechanical Properties 
Although higher porosity and pore size encourage bone ingrowth, however the outcome is a 
reduction in mechanical strength, since this compromises the structural integrity of the 3D 
matrix. In tissue engineering applications, permeable scaffolds with higher porosity must 
have adequate mechanical quality to hold their underlying structures after implantation, 
especially in the reconstruction of hard, load-bearing tissues, for examples, bones and 
ligaments. The structure must not pack together under physiological pressure, which causes 
damage cells inside the scaffold.  
Chitosan based sponges with a pore size of 100 µm were developed inside hydroxyapatite/β-
tricalcium phosphate 3D scaffolds with macropores between 300 to 600 µm having both 
compressive modulus and yield stress increased about four times [111]. Porous foams like 
structure were fabricated after sintering poly(lactide- co-glycolide) microspheres and increase 
in in larger median pore size from 72 to 164 µm had no significant effect on total porosity 
(>30%) [112]. Similarly, higher porosity leads to the lower mechanical properties of porous 
poly (L-lactide-co-D,L-lactide) scaffolds, with compressive strength decreased from 11.0 to 
2.7MPa and modulus from 168.3 to 43.5MPa [113]. 
The stability of various biomaterial based scaffold after implantation depends on factors such 
as strength, elasticity, absorption at the material interface and chemical degradation. 
Therefore, the investigation of mechanical properties such as compressive strength is of 
primary importance in determining the suitability of the designed scaffold. Firstly, it should 
be considered that at the end the scaffolds would be utilized in the physiological environment 
where the primary loading is compressive in case of bone or cartilage. Secondly, the presence 
of numerous tiny voids in the porous solid poses significant structural flaws to magnify the 
effect of crack propagation in stretching or bending. Therefore, the majority of research 
findings on tissue engineering scaffolds are focused on their compressive properties when 
reporting scaffold’s mechanical properties. 
The deformation behaviours of porous solids under compressive loads for honeycombs are 
shown in Figures 2.4 and 2.5. The mechanical properties of honeycombs are classified in two 
groups in-plane properties and out-of-plane properties. The in-plane properties are those 
relating to loads applied in the X1 and X2 plane. Responses to loads applied to the faces 
normal to X3 are referred to as out-of-plane properties. 
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Figure.2.4 In-plane compression of honeycomb pores; (a) Initial elastic bending of pore walls, (b) 
Buckling of pore edges at higher stress levels and (c) Out-of plane compression of honeycomb pores. 
 
Figure.2.5. A schematic diagram for a honeycomb loaded in compression, showing linear elastic, collapse 
and densification regimes, and the way the stress-strain curves changes with t/l; (a) compressed in X1 – 
X2 plane, (b) compressed in axial (X3) direction [114]. 
When a honeycomb is compressed in-plane, the pore walls at first bend (Figure 2.4a), giving 
linear elastic deformation (shown on stress-strain curves in Figure 2.5a). Beyond a critical 
strain the pores collapse by elastic buckling, plastic yielding (Figure 2.4b), creep or brittle 
fracture, depending on the nature of the pore wall material. Pore collapse ends once the 
opposing pore walls begin to touch each other; as the pores close up, the structure is densified 
and its stiffness increases rapidly. On loading the honeycomb out-of-plane, the pore walls 
experience compression under both axial and bending stresses. The moduli and collapse 
stresses are much larger. Figure 2.5b shows the family of curves of honeycombs with 
different relative density, compressed out-of-plane. 
 
2.7 Composite scaffold material 
The term composite is normally considered for materials that contain two or more different 
constituent materials at larger scale. The physical and mechanical properties of these 
materials are modified fundamentally, and henceforth, these are more beneficial in 
comparison with homogeneous material. 
(a) (b
) 
(a) 
(b) 
(c) 
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Biocomposites can be fabricated using nontoxic material and possesses desirable scaffold 
properties able to simulate new bone regeneration. Thus, for biocomposites the biological 
compatibility appears to be more important than any other type of compatibility [115]. Thus, 
bioceramics based biocomposites and hybrid functional biomaterial appears to be new for 
efficient tissue regeneration ability. The most common properties from the bioorganic and 
inorganic domains are combined in biocomposites and have been summarized in Table 2.2. 
Table.2.2. General respective properties from the bioorganic and inorganic domains, to be 
combined in various composites and hybrid materials [116]. 
Inorganic Bioorganic 
Hardness, brittleness Elasticity, plasticity 
High density Low density 
Thermal stability permeability 
hydrophilicity hydrophobicity 
High refractive index Selective complexion 
Mixed valance state Chemical reactivity 
strength bioactivity 
Various human tissues such as human hard tissues like bone, consist of inorganic-organic 
component [117]. In specifically, the property of a composite material relies upon the size 
and morphology of the heterogeneities, relative proportion of the components and nature of 
interfaces among the constituents. Among composite materials, bioceramics and biopolymer 
based composites have been found to possess significant biological characteristic and found 
to be suitable for tissue engineering applications as a biomaterial. The important properties 
and applications of some of the composites are summarized in Table 2.3.  
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Table.2.3. Important properties and applications of the nano composite. 
S. 
No. 
Name of the 
composite 
Properties Application Reference 
1. Nano HAp/ 
collagen 
HAp nanocrystals are regularly 
aligned along collagen fibrils 
Synthetic bone materials in 
Medical applications[118] 
Kikuchi et 
al. 2004 
3. HAp/SA 
nanocomposite 
beads 
The well-swelling, drug loading 
and controlled release behaviour 
Drug- controlled release[119] Zhang et 
al. 2009 
5. Nano HAp/ 
Chitosan composite 
scaffold 
Good biocompatibility and 
sufficient porosity 
Bone tissue engineering[120] Kong et al. 
2005 
6. Chitosan/ 
nanocrystalline 
calcium phosphate 
Increased proliferation of 
osteoblast cells and improved 
mechanical strength 
Bone regeneration[121] Chesnutt et 
al. 2009 
7. HAp/chitosan– 
gelatin (CG) 
composite 
Enhanced protein and calcium ion 
adsorption and improved initial 
cell adhesion and long term 
growth 
Development of human stem 
cell[122] 
Zhao et al. 
2006 
 
2.7.1 Synthetic biopolymer/CaP composite scaffold 
Synthetic polymer such as Poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and their 
copolymers poly(lactic acid-co-glycolic acid) (PLGA) are commonly considered in tissue 
engineering to fabricate artificial ECM [123]. These polymers degrade through hydrolysis of 
the ester bonds that act as backbone of polymer structure [80]. 
Furthermore various linear aliphatic polyesters, such as poly(ε-caprolactone) (PCL) [124] and 
poly(hydroxy butyrate) (PHB), are also commonly considered in tissue engineering research. 
However, the degradation rate of PCL is significantly slower rate than PLA, PGA, and PLGA 
[125]. Thus slow degradation significantly affects utility of PCL for tissue engineering 
applications, however suitable for long-term implants and controlled release of functional 
molecules. Therefore, PCL-based copolymers are also synthesized to improve degradation 
properties. 
Porous 3D scaffold of calcium phosphate ceramics with interconnected macropores (> 200 
µm), micropores (~5 µm) and high porosities (~ 80%) have been produced by firing 
polyurethane (PU) foams coated with calcium phosphate bioceramic at 1200°C [126]. The 
micropores of the developed scaffold were infiltrated with poly (lactic-co-glycolic acid) 
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(PLGA) to achieve an interpenetrating bioactive ceramic/biodegradable polymer composite 
structure. Miao et al. [127] reported development of highly porous HA/TCP composite 
scaffolds having 87% porosity, infiltrated with PLGA to form bioceramic-polymer 
interpenetrating microstructures. However, in these composites PLGA provides significant 
improvement of the compressive strength. Furthermore, polycaprolactone (PCL) based 
scaffold also reported to be coated with HA and possess appropriate cell supportive property  
[128]. Chen et al. [129] demonstrated fabrication of Bioglass®-based scaffolds coated with 
PDLLA that provided appropriate osteogenic potential for healing of bone damage.  
Polyhydroxyalkanoate (P(3HB) has also been investigated for preparation of scaffolds for 
tissue engineering application [38]. Bretcanu et al. [130] reported the use of natural bacteria 
derived P(3HB) to infiltrate into 45S5 Bioglass® scaffolds. The mechanical properties of 
these novel scaffolds were investigated it was shown qualitatively that the work of fracture 
increased dramatically with the P(3HB) coating [131]. 
2.7.2 Natural Biopolymer/Bioactive ceramic Based Composite 
Because of excellent biocompatibility and biological characteristics that are similar to human 
bone , natural biopolymer and CaP based composites were investigated extensively. Agarose, 
alginate, silk, hyaluronic acid, collagen, chitosan, gelatin are some of the well known natural 
biopolymers that have been used for tissue engineering application. Agarose, a polysaccharide, 
was used for making injectable scaffold that provided a three-dimensional environment to 
maintain the round shape of the chondrocyte. Furthermore, BCP (HA + β-TCP)/agarose 
macroporous scaffolds with high degree of interconnected open porosity and tailored pore 
size were prepared for application in bone tissue engineering [132]. Biocompatibility of this 
BCP/agarose system was studied using mouse L929 fibroblasts and human SAOS-2 
osteoblasts during different colonization times [133]. In another study, porous HA/ alginate 
composites based on hydrogels were prepared both biomimetically [134] and using a freeze-
drying technique [135]. The prepared HA-alginate scaffold exhibited high degree of.in vitro 
biocompatibility and controlled biodegradability. Osteoinductive properties of porous hybrid 
scaffolds prepared from β-TCP, alginate-gelatin was reported elsewhere [136].  
A wide range of properties of silk fibroin  such as their size, shape, crystallinity and 
mechanical properties[137]. A functionally graded HA/silk fibroin biocomposite was 
prepared by pulse electric current sintering [138, 139] that showed excellent mechanical 
strength and osteoconductivity. The 3D mesh of fibrin sealant was found to interpenetrate the 
macro- and microporous structure of calcium orthophosphate ceramics [140]. Le et al 
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proposed that the physical, chemical and biological properties of calcium orthophosphate 
bioceramics and the fibrin glue might cumulate in biocomposites suitable for preparation of 
advanced bone grafts [141]. Hyaluronic acid and derivatives have been used as therapeutic 
aids in the treatment of osteoarthritis as a means of improving lubrication of articulating 
surfaces and thus reducing joint pain [142]. Chitosan-gelatin-hyaluronic acid based scaffolds 
were found to be suitable for preparing a bilayer skin substitute[143]. 
Gea et al.[144] 
 
prepared HAp/chitin composite materials with HAp content varying between 
25% to 75% wt% and studied in vivo bone regeneration ability in rat. Moreover, Lee et 
al[145] proposed in their research the use of chitosan/TCP sponges as tissue engineering 
scaffolds for bone regeneration. Bioglass-chitosan composite also exhibited the potential to 
support the growth of osteoprecursor cells in vitro and to favour differentiation of osteoblast 
after stimulating the synthesis of phenotypic markers such as alkaline phosphatase, Type I 
collagen, and osteocalcin [146]. Table 2.1 shows the properties of various CS based 
composite in various forms such as 3D porous scaffold, fibrous, films etc developed for tissue 
engineering applications. 
Table 2.4. Chitosan-bioactive ceramic based composite scaffolds with enhanced properties. 
Composite Out come 
CS/ALRGDN-peptide Promoted biocompatibility[147] 
CS/Gelatin/β-TCP Increased osteoblast attachment and proliferation[148] 
CS/Alginate/Carboxy methyl cellulose Increased compressive modulus[149] 
CS/RGD/ UV cross-linking Increased proliferation [GAG and DNA][150] 
CS/nHAp Increased mechanical strength[151] 
CS/PLGA Increased stiffness of scaffold, Biocompatibility[152]  CS/gelatin/TCP/Glutraldehyde Increased cell spreading[153] 
CS/PLAGA/Fibrin Increased mechanical strength, Osteoblast cell proliferation[154] 
CS/Fibroin Enhanced stiffness and biocompatibility[155] 
CS/Ca3P04 
Increase in cell attachment, proliferation and phenotypic 
expression of osteoblastic markers[156] 
 
HAp/collagen composite materials are promising candidates for bone replacement purposes 
because of their resemblance to bone in point of view of their bioactivity and 
biodegradability. Chang et al [157].reported a simple method to produce CaPs/collagen 
composites by adjusting the reaction conditions and the ratio of components. The mechanical 
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properties of these types of composites are still very poor and requires further improvement 
for its effective use in bone tissue engineering [158]. Collagen based implants are crosslinked 
to improve its mechanical properties and regulate cellular behavior when they are used in as 
processed form to prepare scaffolds [159]. Various crosslinking treatments including 
physical, [160], chemical [161],enzymatic [162] and combination treatments have been 
developed to tailor their mechanical and degradation properties. A composite scaffold formed 
by combining gelatin with bioceramics can yield tailored degradation rates, while also having 
improved biological and mechanical and physical properties. Yaylaoglu et al [163] developed 
a CaPs/gelatine composite implant that released drugs and growth hormone into the implant 
site to assist in bone healing. 
Porous gelatin/collagen scaffolds especially gelatin sponges containing bioceramic particles 
were synthesized by the lyophilisation of a gelatin/calcium phosphate mixture [164]. Usually, 
gelatin/collagen scaffolds are highly cross-linked for better mechanical stability, but this can 
reduce the biocompatibility since crosslinking agents like glutaraldehyde leads to a cytotoxic 
reaction [165]. To prevent this limitation, a colloidal β-TCP/collagen composite was prepared 
for which further treatment was not required [166]. Further, collagen type I was also used as a 
matrix for CaP mineralization to obtain a collagen/CaP composite [167]. In another study, a 
10% gelatin composite scaffold was formed by soaking a macroporous HAp to allow gelatin 
penetration to the bulk of the ceramic [168]. To maintain biocompatibility of the scaffold, 
cross-linker was used at a low concentration to prevent diffusion of gelatin out of the 
scaffold. 
With the hopes of increased cytocompatibility and elucidation of desirable cellular response, 
a porous chitosan/gelatin network scaffold was developed for cartilage tissue engineering and 
artificial skin [169].Further, biomimetic 3D HA/chitosan–gelatin network composite 
scaffolds were prepared for bone tissue engineering [170]. The aim of this work was focused 
on improving the mechanical and biological properties of chitosan based scaffolds through 
incorporation of bioceramics such as hydroxyapatite (HA), β-tricalcium phosphate, calcium 
phosphate [171] and biopolymers like gelatin [172], alginate [173] or inorganic material such 
as wollastonite [174]. Incorporation of calcium phosphate into the chitosan matrix improved 
biocompatibility and hard tissue integration and assisted in tailoring degradation and 
resorption kinetics. 
A biodegradable composite scaffold was developed using β-tricalcium phosphate (β-TCP) 
with chitosan (CS) and gelatin (Gel) in the form of a hybrid polymer network (HPN) via co-
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crosslinking with glutaraldehyde. The macroporous composite scaffolds exhibited different 
pore structures with improved compressive modulus from 3.9-10.9 MPa. 
 
Figure.2.6. Possible interactions between a chitosan-gelatin (CG) network and HA crystals in HA/CG 
biocomposites: ( A ) In the case of a nano-dimensional HA (nHA); ( B ) In the case of a micro-dimensional 
HA (mHA) [175]. 
Another challenging aspect that needs to be focussed is the fabrication of scaffolds using a 
simple and cost effective method. Freeze-drying is one of the simplest scaffold development 
techniques that is time and energy saving [176].The amount of residual solvent and formation 
of surface skin is limited freeze-gelled scaffolds that helps in better growth of cells cultured 
on these [176]. Furthermore, scaffolds prepared using freeze drying technique usually possess 
interconnected porosity and better mechanical properties [177]. Earlier research suggests that 
freeze drying method is useful in developing 3D scaffolds from various biopolymers like 
collagen [178], carboxy methyl cellulose [179], poly (d,l-lactic-co-glycolic acid) [180], 
chitosan [181], pectin [182] and silk fibroin [137]. Chitosan can be easily modified in 
combination with other bio-materials to achieve required mechanical and surface properties 
of scaffold [183].  
 
2.8 Challenges and Opportunities 
2.8.1 Mechanical integrity of porous scaffolds 
Till date manmade porous scaffolds suffer from insufficient mechanical integrity and various 
other properties relevant for bone tissue engineering. For comparison, data of elastic modulus 
and the compressive strength of dense bioactive ceramic, biodegradable polymers, cancellous 
and cortical bone and their porous monophasic scaffolds and composites were taken from Ref 
[184]. It can be found that some dense polymers match cancellous bone properties and 
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approach cortical bone properties. Moreover, mechanical properties of some of bioactive 
ceramics closely resemble the properties of cortical bone as well. Porous scaffolds however 
are at least one order of magnitude weaker than cancellous bone and orders of magnitude 
weaker than cortical bone. 
2.8.2 In vitro degradation 
Since tissue engineering aims at regeneration of new tissues, biomaterials are expected to be 
degradable and absorbable with a proper rate to match the speed of new tissue formation. The 
degradation behaviour has a crucial impact on the long-term performance of a tissue 
engineered cell/polymer construct. The degradation kinetics may affect arrange of process, 
such as cell growth, tissue regeneration, and host response. Gelatin containing chitosan 
scaffold has faster degradation rate due to the hydrophilicity of gelatin [185]. Bioglass and 
Calcium phosphates have been introduced to retard the degradation [186]. 
2.8.3 In vitro and in vivo characterization 
Though a good number of in vitro and in vivo studies have already been carried out for 
biodegradable polymers and bioactive ceramics separately, in vitro studies for 
polymer/ceramic composites have just been started recently. Limited numbers of composite 
systems have been investigated in in vivo up to date. More research needs also to be directed 
at assessing the suitability of the reviewed bioactive composite scaffolds in hard-tissue 
engineering. Further investigations of the effect of dissolution products from the bioactive 
phase on vascularization and in vivo new tissue growth need to be carried out. 
2.9. Discussion and Future Aspects 
Bioactive ceramic based composite will be promising biomaterial for bone tissue engineering. 
The combination of bioactive ceramic such as HAp, bioactive glass and β-TCP with natural 
biopolymer like gelatin and chitosan is one of the best approaches to construct artificial bone. 
Combination of biopolymer with bioactive ceramic can result in the expected three 
dimensional scaffolds as bonegraft substitute with sufficient bone tissue construct properties 
such as mechanical strength, pore size and osteoconductivity. However, cell-material 
interaction, mechanical strength and biological response of bioactive ceramic based 
nanocomposites need to be analyzed in detail and further be investigated for their biomedical 
significance. In addition, clinical studies are needed to be performed on the bioactive ceramic 
based composite scaffold for further biophysichochemical implications. 
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Chapter 3 Scope of the Work 
3.1 Future Prospects of Tissue Engineering  
Tissue engineering is an offset of regenerative medicine that can cater to the need of millions 
of patient’s worldwide suffering from various tissue diseases. Though tissue engineering is 
promising as an exciting industry with a potential market, it is still facing numerous 
challenges like the establishment of a quality control program that can ensure the safety of 
the ultimate tissue engineered bone or other implant [17]. Recently, efforts to address these 
issues are on track and this technology is expected to have a major boom in cell based 
remedies. Thus, this promising wing of future medicine will enable us to enlighten lives of 
needful patients and prevail as an alternative to traditional bone and other grafting 
methodologies. 
3.2 Current Status of Bone Tissue Diseases and Defects  
Bone defects and diseases because of consequences of trauma, injury and infections are of 
major concerns in the field of health sector [187]. It is estimated that more than 50% of all 
osteoporotic hip fractures will occur in Asia alone by the year 2050 [188]. In India, the 
number of osteoporosis patients alone has been expected to increase to 46 million by 2023. 
Surgical reconstruction, transplantation (auto and allografts), drug therapy, artificial 
prostheses and medical devices are current clinical treatment options for various tissue related 
disorders including bone tissue [189]. These treatment options have disadvantages such as 
severe pain, risk of infections, hematoma, immune rejection, donor site morbidity, 
transmission of viral (HIV, hepatitis-B) and prion proteins [190]. In this context, in recent 
years bone tissue engineering has emerged as an appropriate strategy to repair and/or replace 
damaged and/or diseased bone tissue defects.   
3.3 The main hypotheses of this thesis  
Since natural bone matrix is a composite of natural apatite and collagen, a scaffold material 
that can closely mimic the natural extracellular matrix of bone can be a potential candidate 
for making artificial bone substitute material for bone replacement. Gelatin being a 
dehydrated derivative of collagen can ideally suit as a matrix for such scaffold material. 
Apart from gelatin, another natural polymer chitosan can closely resemble the structure of 
GAGs present in extracellular matrix of bone. Thus combination of gelatin and chitosan can 
play an useful role to form a bone scaffold where bone cell can find an appropriate 
environment for proliferation and differentiation. Moreover, incorporation of bioactive 
nanoceramic phase into gelatin-chitosan based matrix is important not only to serve as 
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reinforcing particulates of polymer based scaffold, but also for enhancement of 
mineralization of extracellular matrix, mesenchymal stem cell attachment and its 
differentiation into bone cell. The bioceramic phases such as hydroxyapatite, β- tricalcium 
phosphate and bioactive glass are supposed to aid to mineralization and subsequent 
differentiation of mesenchymal stem cell into matured osteoblast by releasing different ions 
in the surrounding environment that triggers enhanced activity of bone cells. Here we 
hypothesize, that by judicious variation in composition of gelatin, chitosan and bioactive 
nanoceramics, we can enhance mechanical, physicochemical and biological properties of the 
prepared scaffold with ideal porosity and pore size distribution suitable for osteoinduction, 
bone tissue in growth, and angiogenesis. 
3.4 The specific objectives  
i. Systematic investigation on the effects of compositional variation on the microstructure, 
mechanical strength of prepared scaffolds with varying composition.   
ii. Study on physico-chemical, mechanical and in-vitro biological properties of the prepared 
composite scaffolds with variation in bioceramic phase content.  
iii. Comparative in vitro and in vivo analysis on biocompatibility and osteogenic potentiality 
of the developed composite scaffolds prepared using nanophasic hydroxyapatite, β-tricalcium 
phosphate and 58S bioactive glass as reinforcing particulate in gelatin, chitosan matrix. 
iv. Investigation on cryogenic treatment on the prepared gelatin based scaffolds in retention 
of mechanical strength and bioactivity under physiological environment.  
v. To develop gelain-chitosan-hydroxyapatite/ β-TCP / 58S bioactive glass based composite 
scaffolds with improved biological and mechanical properties. 
3.5 The scope of the research work is enumerated as follows  
1. To optimize relative composition of gelatin, chitosan & bioceramic nanoparticles that will 
give better physico-chemical properties such as; porosity, pore size distribution, 
biodegradation and mechanical properties like compressive strength and young modulus of 
the composite scaffold.  
2. Once the composition of the scaffold for better physico-chemical and mechanical strength 
is optimized, a comparative study on bio-activity, osteogenic potential and protein adsorption 
behaviour of the scaffold was performed using different bioceramic particles such as: 
hydroxyapatite (HAp), β-Tri calcium phosphate (β-TCP) and 58s bioactive glass as 
reinforcing phase in chitosan-gelatin biopolymer matrix. 
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3. Gelatin being sparsely soluble in water, the mechanical strength of gelatin based scaffold is 
to deteriorates on exposure to physiological environment due to constant uncontrolled bio-
degradation. In this research work, measures have been taken to retard dissolution of gelatin 
and retain the mechanical strength of gelatin based scaffold within short period of exposure to 
physiological environment without compromising on its osteogenic potential. 
3.6 Dissertation Overview 
Chapter 2 provides a general literature review of the nanostructured biomaterials 
used in tissue regeneration. Emphasis is placed on two aspects: (1) Materials used in 
fabrication of porous 3D scaffold and fabrication using Freeze Drying and temperature 
induced phase separation, (2) evaluation of mechanical and biological properties in various  
3-D porous scaffolds. 
Chapter 4 begins the research part of this thesis with the fabrication of novel 
Gelatin-Chitosan-Hydroxyapatite (GCH) scaffolds. Here, in-situ hydroxyapatite-chitosan 
nanoparticles were incorporated into Gelatin matrix. The mechanical and biological 
characterization of the scaffolds were examined and both short term and long term in-vitro 
bioactivity study was reported. This work was published in Journal of Biomaterial science 
,Polymer edition and Transaction of Indian Ceramic Society [17]. 
Chapter 5 details the development of Gelatin-Chitosan-Bioglass(GCB) scaffold 
 and their mechanical and biological characterization. This work was published in 
International journal of biomaterials and Transaction of Indian Ceramic Society. 
Chapter 6 deals with the preparation and characterization of Gelatin-chitosan-β-TCP (GCT) 
scaffold. The composite scaffolds were prepared using freeze drying technique. 
Physicochemical, mechanical and biological properties were evaluated for 3D porous 
scaffold. Osteoblast proliferation and differentiation were studied to characterize cellular 
response on addition of β-TCP nanoparticles. Biocompatibility of these GCT scaffolds was 
studied in a subcutaneous implantation model.  
Chapter 7 presents a comparative study of the mechanical and biological properties of GCH, 
GCT and GCB composite scaffold. Bioactivities of three different type of scaffolds were 
compared both in vitro and in vivo using a defect site in rabbit tibia. 
Chapter 8 represents the effect of cryogenic treatment on GCB scaffolds on its strength 
retention capacity in physiological environment. 
Chapter 9 summarizes the thesis work with major conclusions and discusses some possible 
future directions of the research work carried out in this dissertation. 
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Chapter 4- GCH composite caffold 
4.1 Abstract 
Bone tissue engineering, using a porous scaffold material to induce formation of bone from 
the surrounding tissues has some distinct advantages over autografting and allografting, and it 
is a rapidly growing alternative approach to heal damaged bone tissue. The current study 
focuses on fabrication and characterization of hydroxyapatite and natural biopolymer 
composite scaffold for improving bone repair and regeneration at the sites of musculoskeletal 
disorder. The porous composite scaffold with varying weight per cent of hydroxyapatite 
(HAp), chitosan and gelatin was fabricated using freeze drying method. Glutaraldehyde was 
used as a cross linker between chitosan and gelatin matrix in the polymer based scaffolds. 
The prepared scaffolds exhibited 3D network of interconnected pores with total porosity 
varying between 70- 79% and an average pore size between 43- 165 µm. Microstructural 
analysis using field emission scanning electron microscopy (FESEM) showed an 
interconnected porous network in the scaffold where HAp-Chi composite nanoparticles were 
found to be randomly dispersed in the biopolymer matrix. Characteristic IR band for (–C=N–
) group observed in IR spectra of the prepared scaffold, indicated crosslinking ability of 
glutaraldehyde with chitosan and gelatin. An optimum composition with HA: Chi: Gel ratio 
of 28:42:30 was obtained in GCH30 scaffold with an average pore size of 94 µm and the 
highest compressive strength. GCH30 scaffold having 78% porosity with pore size 
distribution between 75–100 μm exhibited a compressive strength of 3.46 MPa, which is 
within the range of that exhibited by cancellous bone. Thick bone like apatite layer deposition 
was observed on the surface of the scaffold on immersing it into simulated body fluid (SBF) 
at 37oC for 7 days. The bioactivity of the scaffold was evaluated after investigating 
mesenchymal stem cell (MSC)–materials interaction and MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bro-mide) assay using cultured MSCs. The scaffold was found to be 
conducive to MSC’s adhesion, proliferation, and differentiation up to 14 days of cell culture. 
These types of composite scaffolds find application as efficient biomaterial for natural bone 
tissue regeneration and bone tissue engineering. 
4.2 Introduction 
Research on biomaterials for bone replacement and bone healing has expanded considerably 
over the last four decades [191, 192]. In recent years, significant progress has been made in 
the area of bone replacement to treat the loss or failure of bone. Natural bone consists of 
organic and inorganic substances [193, 194]. Calcium deficient carbonated apatite is the 
major component in bone minerals [189, 195-198]. Hydroxyapatite (HAp), the most 
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commonly used calcium phosphate bioceramic, has excellent biocompatibility and is 
osteoconductive. It has been successfully used as bone fillers, coating of orthopaedic implant, 
filler of inorganic/polymer composites, cell culture carrier and so on but the application of 
pure HAp as structural bioceramic is being limited due to its brittle nature. Moreover, 
sintered HAp shows lower bioactivity as compared to its poorly crystalline particulate 
counterpart. In fact, natural bone is a biocomposite, composed of nano-hydroxyapatite (n-
HAp) crystals dispersed in collagen matrix. Therefore, in the recent years, development of 
nano HAp-biopolymer composites has gained much more attention because of their analogy 
to bone matrix as well as good biological and mechanical performances to meet the specific 
clinical response. Natural biopolymers have received much more attention in the field of 
orthopaedic and other biomedical applications due to their excellent biocompatibility and 
biodegradability. Various kinds of polymer/ceramic composite system such as HAp/collagen 
[199, 200], HAp/chitosan [201], HAp / collagen / poly (lacticacid) [202], HAp / alginate / 
collagen [203], HAp / gelatin [198, 203-205] were employed for preparation of scaffolds for 
bone tissue engineering. A combination of Hap chitosan-gelatin seems to be a very 
interesting material for preparing bone scaffold as it can mimic natural bone matrix very 
closely. Chitosan (poly-1,4-D-glucosamine), a partially deacetylated form of chitin, is 
structurally similar to glycosamino glycan present in the extracellular bone matrix, and 
exhibits wound healing property [205]. Gelatin as a binding agent or matrix seems to be very 
attractive because it is derived from collagen and contains a lot of biological functional 
groups, such as amino acids within its backbone which can enhance cell growth and 
proliferation. Gelatin not only shows excellent biocompatibility and biodegradability, but also 
exhibits superior plasticity and adhesiveness, that is essential for developing mechanical 
strength in the scaffold. Moreover, its degradation rate and mechanical strength can be 
regulated after cross-linking with suitable cross linker such as glutaraldehyde. Again, uniform 
dispersion of the bioactive ceramic phase in the polymer matrix is often a critical challenge. 
Without proper interfacial adhesion between bioceramic and biopolymer, nonuniform phase 
distribution or segregation of phases and bioceramics agglomerates in different parts of the 
composite are common problems. To address this, in the present case, finely dispersed HAp–
chitosan nanocomposite powder was synthesized which interacted with gelatin matrix 
through chitosan to develop intimate bonding between particle and polymer matrix and 
promoted uniform dispersion of HAp nanoparticles throughout the matrix. The aim of this 
study was to optimize the composition for the development of bioactive bone scaffold with 
controlled porosity and mechanical strength using gelatin, chitosan, and HAp. Porous HAp–
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chitosan/gelatin (HAp:Chi:Gel) scaffold was prepared using lyophilization technique and 
post-cross-linking with glutaraldehyde that is the most common synthetic cross-linking 
reagent and can form intermolecular cross-links between protein molecules. These composite 
bone scaffolds with various compositions were compared in terms of their physical, 
mechanical properties. This study also assessed MSC’s responses to the porous HAp:Chi:Gel 
bone scaffolds. The investigation represents a successful contribution toward the 
development of superior scaffolds for bone tissue engineering. 
4.3 Materials and Methods 
4.3.1 Materials 
Chitosan (deacetylation: 85%, medium molecular weight) and gelatin (Type B) were 
purchased from Sigma Aldrich (USA). Di-ammonium hydrogen phosphate 
((NH4)2HPO4)and calcium nitrate tetra-hydrate (Ca(NO3)2.4H2O) were purchased from 
Merk (Germany). Glacial acetic acid and ammonia solution (NH4OH) were procured from 
LOBA chemical (India). Sodium Chloride (NaCl), Potassium Chloride (KCl), Calcium 
Chloride (CaCl2), Magnesium Chloride (MgCl2), Di-potassium Hydrogen Phosphate 
(K2HPO4), Sodium bi-Carbonate (NaHCO3), Sodium Sulphate (Na2SO4) , glutaraldehyde 
(C5H8O2), ethanol (C2H5OH) were procured from Sigma Aldrich (USA). 
 4.3.2 Preparation of HAp/Chitosan composite nanopowder 
Figure 4.1 illustrates the whole experimental set up for fabrication of GCH scaffold. The 
HAp-Chi composite nanopowders were synthesized using co-precipitation method. A 2 wt% 
chitosan solution was prepared by dissolving 2 gm of medium molecular weight chitosan in a 
solution containing 2 mL of acetic acid and 96 mL of deionized water with continuous 
stirring for 5 h to get a perfectly transparent solution. After that 100 ml of (NH4)2HPO4 
(0.019 M) solution was added to 2 wt% 100 ml chitosan solution. The mixed chitosan 
(NH)2HPO4 solution was then dropped slowly into the solution of calcium nitrate (0.031 M) 
with vigorous stirring and the pH was adjusted to 10 using NH4OH solution. The dropping 
speed of chitosan/(NH)2HPO4 solution was about 4 ml min–1and the reaction was carried out 
in ambient condition at 25oC. After titration, the stirring was continued for 24 h and the 
obtained slurry was aged for another24 h. Finally, the precipitate was washed  through 
centrifugation at 15,000 rpm using deionized water and freeze dried at 253K and 77 torr 
pressure to obtain nearly 10 gm of HAp-Chi nanopowders. A typical flow diagram for the 
preparation of HAp-Chi composite nanopowders is described in Figure 4.2. Similarly, bulk 
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quantity nearly 50 gm of HAp-Chi nanopowders were prepared to carry forward its 
characterization and prepare 3D porous scaffolds for in vitro and in vivo studies. 
 
Figure.4.1. Schematic of experimental set up for the fabrication of GCH scaffold. 
 
Figure.4.2. Flow diagram for synthesis of HAp-Chi nanopowders. 
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4.3.3 Preparation of porous HAp/Chitosan-Gelatin composite scaffold 
Gelatin containing 1.4 gm in deionized water was heated up to 40oC under continuous stirring 
for 4 hr. Two gram of HAp-chitosan composite nano powder was then added to gelatin 
solution with constant stirring for 40 min using an overhead mixer to disperse the HAp-
chitosan nanoparticles. HAp-Chi powders were mixed together with gelatin solution based on 
the value of HAp to chitosan ratio as shown in Table 4.1. The mixed solution was then 
sonicated (IUltrasonic) for 30 min to remove any air bubble. A glutaraldehyde solution was 
prepared by dissolving 0.5 ml glutaraldehyde (50%) in 100 ml deionized water. Required 
amount aqueous solution of glutaraldehyde (0.25 vol%) was added to the slurry at 4oC under 
manual agitation. The resulting slurry was put in 10 ml PTFE cylindrical mould and then 
rapidly pre-freezed at–20oC (Labfreeze, FL1150) to solidify the water into ice and kept 
overnight. Next, the frozen samples were lyophilized using a freeze-dryer (Labconco, South 
Korea) at –50oC for 48 h to form a composite 3D porous scaffold. Excess glutaraldehyde and 
residual acetic acid were removed from the lyophilized scaffold after washing it with 5% 
sodium borohydride and then with NaOH solution for three times for 2h. Finally, the freeze 
dried scaffolds were kept in the vacuum desiccator (size-150mm, Tarson) for further 
characterization. A typical flow diagram for the preparation of HAp-Chi composite 
nanopowders is described in Figure 4.3. 
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Figure.4.3. Flow diagram for the fabrication process of Gelatin/Chi-HAp scaffold. 
 
 
 
 
 
 
 
 
 
 
Gelatin Solution at 40˚C  Hap/Chitosan composite powder 
Mixing for 5 hr at 500rpm 
Put the slurry into a mould 
Freezing(-20˚C) 
Lyophilize for 32 hr 
Freeze dried Scaffold 
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Table.4.1. Composition of Gelatin/Chi-HAp composite scaffold. 
HAp/Cht(%) 
 
Gel/(HAp/Chi) Gel/Cht/HAp 
Gelatin 
(gm) 
Chitosan(gm) HAp(gm) 
20/80 
GCH18 10/90 10/72/18 0.22 1.6 0.4 
GCH16 20/80 20/64/16 0.5 1.6 0.4 
GCH14 30/70 30/56/14 0.85 1.6 0.4 
 30/70 
GCH27 10/90 10/63/27 0.22 1.4 0.6 
GCH24 20/80 20/56/24 0.5 1.4 0.6 
GCH21 30/70 30/49/21 0.85 1.4 0.6 
40/60 
GCH36 10/90 10/54/36 0.22 1.2 0.8 
GCH32 20/80 20/48/32 0.5 1.2 0.8 
GCH28* 30/70 30/42/28 0.85 1.2 0.8 
70/30 
GCH63 10/90 10/27/63 0.22 0.60 1.40 
GCH56 20/80 20/24/56 0.5 0.60 1.40 
GCH49 30/70 30/21/49 0.85 0.60 1.40 
*For the ease of experiment, we rename GCH28 scaffold as GCH30 and GCH21 as GCH20  
4.4 Characterization 
4.4.1 XRD analysis HAp-Chi nanopowders 
The phases of HAp-Chi composite nanopowders were analysed using X-ray diffraction 
(XRD) with fully automated X-ray diffractometer (Philips PAN analytical, USA) fitted with 
Ni-filter. The diffraction patterns were recorded with a XRD analyser using CuKα radiation 
(λ = 1.542 nm) at 35 kV and 10 mA. All samples were scanned from 10o to 70o in 2θ (where 
θ is the Bragg angle) in a continuous mode with a scanning speed of 0.02degree/sec. The 
peak position, phase purity, peaks for different atomic planes and their relative intensities in 
the powder diffraction pattern were identified in comparison with the reference powder 
diffraction data (JCPDS-09-0432). For phase evaluation of composite scaffold, the sample 
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was ground into powders, and the powder samples were characterized using XRD (Philips 
PAN analytical, USA). 
4.4.2 FTIR analysis HAp-Chi nanopowders 
The characteristic peaks of pure HAp and its composites were analysed using Fourier 
transform infrared (FTIR) (PerkinElmer, USA) spectroscopy. The pellet for the FTIR 
measurement was prepared by mixing 2 mg the sample with 200 mg of IR grade KBr at a 
pressure of 3 ton. The scaffolds were put in a vacuum oven at 50oC for 48 h before they were 
ground to suitable size for IR analysis with spectrometer. The absorption spectra were 
measured using UV spectrometer in the wave number between 4000 to 400 cm–1 with a 
resolution of 1 cm–1. 
4.4.3 Particle size analysis of HAp-Chi nanopowders 
The particle size and its distribution were estimated through zetasizer (Zetasizer nano zs, 
Malveron). The refractive index for both Hap-Chi nanopowders and water was considered as 
1.65 and 1.33. The dispersed HAp-Chi nanoparticles were used for particle size analysis.  
4.4.4 Transmission Electron Microscopy (TEM) of HAp-Chi nanoparticles 
The particle size, morphology and crystallinity of as synthesized HAp-Chi powders were 
studied by TEM (FEI, Nederland), SAED (Selected Area Electron Diffraction) pattern. The 
TEM samples were prepared by dispersing a small amount of powder in acetone using 20 
kHz and 500W ultrasonic energy for 30 minute. A well dispersed suspension was dropped on 
a carbon coated copper grid and dried to evaporate the solvent. The powder morphology was 
observed from TEM micrograph in bright field mode. 
4.4.5 Thermo gravimetric analysis of HAp-Chi nanoparticle 
Thermal analysis technique is an excellent approach to determine the decomposition 
behaviour which depends on the remaining mass content of the sample with respect to 
temperature. The thermo gravimetric (TG) analysis of the composite powders was studied on 
50 mg of powder samples using a TG analyser (Netzsch, Germany) and measurements were 
recorded from 50o-1000oC at 10oC.min–1 heating rate in air.  
4.4.6 FESEM observation of scaffold 
The microstructure of the scaffold was observed using field emission scanning electron 
microscopy (FESEM) Novanano 450, FEI, USA). The surface of the scaffolds was gold 
coated using sputter coater (FEI,USA), and then placed inside the FESEM chamber. 
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4.4.7 Apparent porosity of scaffold  
The porosity of composite scaffold was measured using Archimedes principle [68] with 
xylene as liquid medium using the following equation. 
 
Where W1 is the weight of the sample in air, W2 is the weight of the soaked sample with 
liquid in pores, and W3 is the weight of the sample suspended in xylene. Dry weight of all 
freeze dried scaffolds was taken accurately using a digital balance. Scaffold with a defined 
shape kept inside a beaker filled with ethanol and placed this beaker inside a vacuum 
desiccator to remove entrapped air present inside the scaffold. 
4.4.8 Mercury Intrusion Porosimetry 
The characteristics of pore size and pore size distribution were evaluated using mercury (Hg) 
porosimetry (Porosimeter-33, Quanta chrome, USA). The freeze dried GCH scaffold samples 
were placed in a penetrometer and infused with mercury under increasing pressure. The pore 
morphology behaviour was measured on the approached theory by Washburn [68]. 
Mathematically Washburn equation is given as: 
 
 
 
4.4.9 Mechanical testing of GCH scaffold 
The mechanical properties of the composite scaffolds were determined using a Universal 
Testing Machine (Tinius Olsen, UK)[206]. For compressive testing, the samples were 
cylinders of approximately 5 mm in diameter and 12 mm in height using the load cell of 10 
KN with a cross head speed of 1mm/min and determined by the following formula: 
 
 
Porosity (%)= 
𝒘𝒘𝟐𝟐−𝒘𝒘𝟏𝟏
𝒘𝒘𝟐𝟐−𝒘𝒘𝟑𝟑
 × 100  . . . . . . . . . . .(i) 
P = Pressure of Hg 
r = Radius of the pore 
б = Surface tension of mercury 
θ = Contact angle. 
P = Load in KN 
A = Cross sectional area of the cylindrical sample 
P= 𝟐𝟐𝝈𝝈 𝐜𝐜𝐜𝐜𝐜𝐜𝜽𝜽
𝒓𝒓
. . . . . . . . . . . . . . .  (ii) 
𝐂𝐂𝐜𝐜𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐜𝐜𝐜𝐜𝐂𝐂𝐂𝐂𝐂𝐂 𝐜𝐜𝐬𝐬𝐂𝐂𝐂𝐂𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬 = 𝑷𝑷
𝑨𝑨
  . . . . . . . . . . . . .(iii) 
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4.4.10 Swelling behaviour of GCH scaffold 
Water uptake of the scaffolds were measured using the method described by Thein and Misra 
[207]. A sample with 5 mm diameter and 12 mm height was immersed in distilled water for 
30 h. Then the sample was gently removed and placed on a wire rack for 1 min. The weight 
of the sample was averaged from triplicate measurements for each group of samples. The 
water uptake of the scaffolds was calculated using the following equation [208]. 
 
 
Where, 
 
 
4.4.11 Mineralization behaviour of Gelatin/HAp-Chi scaffold  
The ability to form apatite when immersed into simulated body fluid (SBF) is an index of 
biocompatibility exhibited by the GCH 30 scaffold [209]. The SBF solution is known to be a 
metastable buffer solution and even a small, undesired variance in both of the preparation 
steps and the storage temperature may drastically affect the final nucleation of apatite phase. 
SBF solution was prepared in accordance with the chemical ion concentrations nearly equal 
to those of the inorganic constituents of human blood plasma and were used by A. Cuneyt 
Tas et al. [209]. Analytical grade pure NaCl (99.5%), NaHCO3 (99.5%), KCl (99.0%), 
Na2HPO4 2H2O (99.5%), MgCl2 6H2O, (99.0%), Na2SO4, (CH2OH)3CNH2 (99.5%), 
CaCl2,.H2O (99.0%) and HCl (37 vol.%) were used in the preparation of SBF solution for 
this study. Fresh 1000 ml SBF solution was prepared by dissolving the required amount 
chemical reagents into a 2000 ml polystyrene (Tarson) beaker as mentioned in Table 4.2. In 
the beginning, reagents were added to 700 ml deionised water continuously one by one in 
sequence only after the previous reagent has completely dissolved. During the preparation of 
SBF solution, pH ~7 was maintained by addition of 1M HCl in each step and temperature 
33 oC. Finally, volume of the solution was adjusted up to 1000 ml by deionised water to 
maintain solution pH~7.4 at 37 oC. The resulting solution was stored in air tight polystyrene 
(Tarson) container at 5oC. Porous scaffold with 5 mm in diameter and 12 mm in height was 
placed in 50 ml of simulated body fluid (SBF) solution and kept in an incubator at 37oC for 7 
days. After every 3-day interval, old SBF solution was replaced by freshly prepared SBF 
𝐜𝐜𝐬𝐬𝐂𝐂𝐬𝐬𝐬𝐬𝐂𝐂𝐬𝐬𝐬𝐬 % = 𝐖𝐖𝐜𝐜−𝐖𝐖𝐖𝐖
𝐖𝐖𝐖𝐖
  × 100 . . . . . . . . . . . . . .(iv)  
Ws = wet weight  
Wd = Dry weight 
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solution. After 7 days, the scaffold was removed from SBF, repeatedly washed with 
deionized water for three times and freeze dried at -20oC for 24 h. The SBF treated dried 
scaffold was sputter coated with gold and examined using FESEM. 
 
Table.4.2. Chemical composition of SBF. 
Order Reagent Amount (gpl) 
1 NaCl 6.547 
2 NaHCO3 2.268 
3 KCl 0.373 
4 Na2HPO4, 2H2O 0.178 
5 MgCl2,6H2O 0.305 
6 CaCl2,2H2O 0.368 
7 Na2SO4 0.071 
8 (CH2OH)3CNH2 6.057 
4.4.12 Biodegradation of GCH scaffold 
In vitro biodegradation was carried out in PBS buffer solution at 37 oC and pH ~ 7.4. GCH 
scaffolds were taken in a sealed polystyrene (Tarson) Petridis followed by soaked in PBS 
buffer solution for different time interval inside an incubator at 37 oC and pH ~ 7.4. Samples 
soaked in PBS were repeatedly washed with deionised water and dried at 100 oC. The final 
weight of the sample was taken through digital weighing balance. The weight loss was 
correlated with biodegradability of scaffold. The percentage of weight loss was estimated as: 
 
 
 
Where, 
 
 4.4.13 In-vitro cell culture study 
4.4.13.1 Isolation and culture of MSCs  
Human Umbilical cord (UCB) derived MSCs were used for in vitro cell culture. The UCB 
MSCs were collected from Ispat General Hospital, Rourkela, India with prior consent from 
patient and kindly provided by the Department of Biotechnology and Medical Engineering of 
𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤ℎ𝑡𝑡 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙% = 𝑊𝑊0−𝑊𝑊1𝑊𝑊0   × 100 . . . . . . . . . . . . . .(vi) 
W0 = Initial weight  
W1 = Final weight 
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NIT Rourkela, India after getting required approval by institutional ethical board. The details 
of isolation and characterization can be obtained from the earlier research work in the 
Department of Biotechnology and Medical Engineering, NIT, Rourkela, India [210]. 
4.4.13.2 Cell seeding and culture  
Scaffolds were sterilized prior to cell seeding by soaking in 70% ethanol and 10 U/ml 
penicillin solution for 2 hrs followed by sterile PBS wash. Cells from 4th passage were 
seeded on sterilized scaffolds with a seeding density of 5 × 106 cells/ml by static method 
[211]. The cell seeded GCH scaffolds were incubated in DMEM culture medium with a 
media change for every 3 days [212]. 
4.4.13.3 Cell morphology and cell attachment  
Human mesenchymal stem cell (hMSCs) seeded composite GCH scaffolds were cross-linked 
with 4% paraformaldehyde in phosphate buffered saline (PBS). 2% (v/v) gluteraldehyde was 
used for fixing the cells and the samples were rinsed with wash buffer. Osmium 
tetroxide(OsO4) (1%) was added to the samples and kept aside for 30 min. Then the samples 
were rinsed with phosphate buffer for five times and dehydrated with series of ethanol 
gradations (50, 70, 80, 95 and 100%) for 10 min each [213]. Finally, the samples were air 
dried at 37°C and sputter coated with gold, platinum for 30 sec prior to imaging. 
(Quorumtech, Q150RES, Czech Republic). Images were taken by SEM [JEOL-JSM 6480 
LV], and Field Emission Scanning Electron Microscopy (FE-SEM) [Nova SEM-Nederland] 
in high vacuum at 30 kV. 
4.4.13.4 Cytotoxicity assay  
To estimate the number of viable cells onto GCH composite scaffolds a colorimetric assay 
i.e. MTT assay was used, which quantities the ability of mitochondrial dehydrogenases to 
metabolize 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide to an insoluble 
formazan [28]. Fresh media was supplemented to the cells consisting of 100μl MTT solution 
(diluted in 1:10 PBS). Then the cells were incubated at 37°C for 4 hrs. 0.5 ml DMSO was 
added followed by centrifugation at 1000 rpm for 5 min. The optical density (O.D) of intense 
pink colored formazan derivative was measured using a spectrophotometric plate reader 
(2030 multi label reader Victor X3, Perklin Elmer, USA) at 595 nm. 
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4.4.13.5 Immunofluorescent imaging of Osteogenic cell marker: Osteocalcin and 
RUNX2 
We also measured the expression of osteogenesis-related genes with the help of confocal 
microscopy. Expression of osteoblast markers, the transcription factor RUN-X2 and the bone-
specific protein, osteocalcin coding gene (OCN) were observed in hMSC-seeded GCH 
scaffolds cultured in osteogenic medium. For immunostaining the scaffolds were cut into 
slice using sharpe blade and then placed in PBS solution. Then the immunostaining was 
carried out using standard protocols. On one side staining for osteocalcin was achieved using 
rabbit antimouse osteocalcin (1/100, Abcam) and Alexa 488 antimouse (1:400, Invitrogen) as 
a secondary antibody. On the other hand, staining of RUN-X2 was achieved using antirabbit 
RUN-X2 antibody (1:200, Abcam) and using Alexa 647 antirabbit (1:400, Invitrogen) as 
secondary antibody. Finally, the samples were mounted with Fluorsave Vectashield mounting 
medium with DAPI (Atom). All the specimens were examined using a confocal microscope 
[214]. 
4.5 Statistical Analysis of Experimental Data 
Three samples were used for repeated experiments to get mean value on each time point. All 
data are expressed as mean ± standard deviation. The data were compared using Student’s t-
test and differences were considered significant when *p < 0.05. A p-value more than 0.05 (p 
> 0.05) was taken as indicating no significant difference. 
4.6. Results and Discussion  
4.6.1 XRD analysis HAp-Chi composite powder 
Phase analysis of the HAp-Chi nanopowder was performed using XRD. The characteristic 
diffraction peaks for both chitosan and HAp were observed in the synthesized nanopowder. 
The sharp peaks of (002) and (112) plane in HAp (Figure. 4.4) confirmed that the synthesized 
powder was well crystallized. No other calcium phosphate phase was detected in XRD 
pattern in Figure 4.1 that indicated the presence of phase pure hydroxyapatite- chitosan in the 
synthesize nanopowders.  
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Figure.4.4. XRD pattern of chitosan/HAp composite nanopowders. 
4.6.2 FTIR analysis HAp/Chitosan composite powder 
Figure4.5 shows the FT-IR spectrum of pure chitosan and HAp-chitosan composite 
nanopowder. The characteristic bands for different functional groups present in the scaffold 
are shown in Table 4.3. Two bands were observed at 3570 and 622 cm-1 due to the stretching 
of hydrogen bond in OH ions present in HAp and liberation mode of hydrogen-bonded OH 
ions respectively. The band at 1024 cm-1 arises from ѵ3 PO4, whereas the band at 603 and 
555 cm-1 suggest the presence of ѵ4 PO4. The absorptions bands observed at 2887, 1631, 
1595, and 1543 cm-1 were 
 
Figure.4.5. IR spectra of Chitosan and HAp-Chitosan composite powder. 
assigned to methylene (-CH2), amide І(C=O), amino (-NH2), and amide ІІ (-NH) groups in 
chitosan respectively. Carbonate bands at 1382, and 852 cm-1 appeared because of the 
carbonate incorporation in HAp from CO2 in air. The FT-IR spectra also indicated the 
shifting of characteristic bands of amine (1655 cm-1) and amide (1599 cm-1) in chitosan to 
lower wavenumber in the HAp- chitosan composite nanopowder, as a result of interaction 
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between chitosan and HAp, through hydrogen bonds between –NH2 and –OH as well as 
chelation between –NH2 and Ca+2.[215, 216]  
Table.4.3.Peaks of infrared spectra assigned to synthesized HAp-chitosan nanopowders. 
 
 
 
 
 
 
 
 
 
 
4.6.3 TEM analysis of HAp/Chitosan composite powder 
The synthesized HAp-chitosan composite powder showed a particle size distribution between 
90 -100 nm (Figure 4.6) with aspect ratio of 1.7±0.18 and found to be well dispersed as in 
TEM micrographs in Figure 4.7(a). The electron diffraction pattern of HAp-chi crystals 
exhibited diffused ring pattern. The SAED pattern of pure HAp-Chi composite powder 
reveals the formation of spherical particles near to 50 nm diameter with a consistent strong 
concentric ring pattern for (120) of chitosan and (002), (211), (112) and (310) plane of 
polycrystalline HAp [217]. Elemental distribution data of both the samples confirmed the 
presence of HAp with a Ca/P ratio of nearly equal to 1.67. 
 
Figure.4.6. DLS measurement of particle size distribution of HA–Chi 40:60 nanopowder. 
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(a) (a1) 
 
 
 
 
 
 
 
 
 
 
Figure.4.7. TEM micrograph of HAp-chitosan composite nanopowders. 
4.6.4 Thermogravimetric analysis of HAp/Chitosan composite powder  
Figure 4.8 shows the TG thermogram of the synthesized HA–chitosan nanopowders. The 
observed weight loss of 7 wt% between 70 and 150 °C was attributed to the loss of adsorbed 
water molecules in HAp and chitosan. Thermal decomposition of chitosan accounted for 
another 21–35 wt% weight loss between 310 and 600 °C. Almost all the organic 
macromolecules and carbonate were decomposed by 620 °C as negligible or no weight loss 
occurred after 620 °C. The calculated composition of HA–chitosan composite nanopowders 
from TG data closely resembled the theoretical composition of the powder as in Table 4 4. 
 
 
 
 
 
 
 
 
Figure.4.8. Thermo gravimetric analysis of pure HAp, pure chitosan and HAp- chi nanopowders. 
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Table 4.4. Theoretical and actual compositions of Chitosan/n-HAp nanopowder as determined by TG 
analysis at 1000˚C. 
Sample Theoretical chitosan/n-Hap composition Actual Chitosan/n-Hap 
composition 
HAp-Chitosan wt% Chitosan Wt % -HAp wt% Chitosan wt% -HAp 
40 60 37.68 62.31 
 60 40 62.19 37.81 
 80 20 77.92 22.08 
4.6.5 FTIR analysis of HAp-chitosan/gelatin composite scaffold 
Figure 4.9 shows the FTIR spectrum of scaffold and different IR bands or peaks are shown in 
Table 4.5. Apart from PO4 3- (1027, 562 cm-1), CO32- (875 cm-1), OH- (3406, 605 cm-1) bands 
in HAp and amide I (1662 cm-1), amide II (1232 cm-1) and carboxylate (1446 cm-1) bands in 
gelatin, a distinct band at 1552 cm-1 was detected, which signifies the formation of C=N- 
bond due to intergelatin and chitosan gelatin crosslinking to develop 3D interconnected 
network in the scaffold. The band at 1330 cm-1 is attributed to the interaction between 
carboxylate group in gelatin and Ca+2 ion in HAp to bind the particulate reinforced composite 
scaffold together, a fact that is well established in the earlier studies also [218, 219].  
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Figure.4.9. IR spectra of gel-chi and HAp / Chitosan-Gelatin composite scaffold. 
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Table.4.5. Peaks of infrared spectra assigned to fabricated GCH30 scaffold. 
Compound Assignment Infrared frequency  (cm-1) Ref 
HAp -PO4 bending 602 (weak) 16 
stretching 1027(weak) 
-CO32- 1480,876 
Gel-Chi C=N 1552 17 
Amide I 1539  to   1662 
COO- 1446 
Gel-Chi-HAp Ca+2-----COO- 1330 53 
Amide A, N-H stretching 3140 ,2878 
4.6.6 Analysis of microstructure, porosity and mechanical strength of prepared 
scaffolds with variation in HAp and gelatin content 
The total porosity of the Gel:Chi:HAp -based scaffold was measured using Archimedes’
principle as described earlier while pore size distribution in the scaffold was determined from 
Hg porosimetry data using Hg intrusion in the porous scaffold. Table 4.6 indicates the total 
porosity values and compressive strength exhibited by all the prepared scaffolds with varying 
composition. One interesting fact is that the mean porosity in the prepared scaffolds varied 
between 70 to 79% reflecting that compositional variation did not affect total porosity in the 
scaffold in a significant manner (all p values > 0.05).  The scaffold having 30 wt% gelatin 
and prepared from HAp–Chi nanoparticle with 40:60 composition showed the highest 
average porosity of 78% and compressive strength of 3.46 MPa. The variation in compressive 
strength of all the prepared scaffolds with variation in gelatin content from 10 to 50 wt% is 
shown in Figure.4.11 (a). Irrespective of HAp and chitosan content, all the prepared scaffolds 
showed higher compressive strength value at 30 wt% gelatin content. With variation in 
gelatin content from 10 to 30 wt% the compressive strength in the scaffolds gradually 
increased and beyond 30 wt% gelatin content it decreased. The increase in compressive 
strength with increasing gelatin content can be explained by enhanced HAp–gelatin 
interaction in the pore wall of scaffold with higher degree of interconnected covalent 
networks. 
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The excess amount of gelatin beyond 30 wt% might present some uncrosslinked separated 
phase instead of forming crosslinked interconnected network which served as the weakest 
link in the matrix to lower down compressive strength value in the scaffold. Further the 
compressive strength value exhibited by the scaffold was gradually increased as HAp content 
in the prepared scaffold increased from 14 wt% to 28 wt%. Figure 4.10(b) represents the 
variation in average pore diameter with varying amount of HAp content in polymer matrix. 
With increasing HAp content beyond 30 wt% in the scaffold, the most frequent pore size in 
the scaffold was decreased as evident from Figure 4.10(b). This was due to clogging of pores 
in the scaffolds by excess HAp agglomerates instead of going into the pore wall formed by 
gelatin and chitosan matrix. With an increase in net amount of HAp beyond 28 wt% in the 
scaffold, the excess amount of HAp–Chi system formed a separate phase of HA agglomerate 
in the scaffold that initiated the weakest link in the scaffold and caused failure at lower 
compressive strength. Both from FESEM micrographs and pore size distribution data in 
Figure.4.10(b), it is clear that maximum amount of pores possessed a pore size below 35 μm 
with very narrow pore size distribution in GCH36 scaffold containing HAp 36 wt%. On this 
account, our subsequent study was focused on measuring properties of the scaffold 
containing ≤30 wt% HAp with gelatin content fixed at 30 wt%.  
Table.4.6. Physiological characterization of prepared GCH scaffold. 
HAP/Cht(%) Sample id Gel/Cht/HAp 
Most 
frequent 
pore dia 
(µm) 
Porosity Compressive mechanical property (MPa) 
20/80 
GCH18 10/72/18 165±6.4 73.76±2.1 0.5 
GCH16 20/64/16 133±5.2 75.23±3.2 1 
GCH14 30/56/14 120±5.3 76.14±3.2 1.2 
30/70 
GCH27 10/63/27 135±9.6 72.15±5.2 1.45 
GCH24 20/56/24 121±7.3 69.87±4.6 1.8 
GCH21 30/49/21 110±11.8 73.89±5.4 3.2 
40/60 
GCH36 10/54/36 111±5.8 70.12±4.4 2.1 
GCH32 20/48/32 105±7.3 75.33±3.6 2.3 
GCH28 30/42/28 94±6.9 78.12±3.2 3.46 
70/30 
GCH63 10/27/63 59±9.5 78.13±3.1 0.5 
GCH56 20/24/56 51±7.1 76.32±3.2 1.16 
GCH49 30/21/49 43±6.8 75.13±4.7 1.25 
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Figure.4.10. (a) Variation of mechanical strength with varying amount gelatin.(b)Variation of most 
frequent pore diameter with increasing amount of HAp in the GCH scaffold. 
4.6.7 FESEM microstructure of fabricated GCH scaffold 
Figure 4.11(a), (b), (c) show FESEM micrographs of the cross section of the scaffolds 
prepared after varying HAp content from 10 to 30 wt% keeping gelatin fixed at 30 wt% in 
GCH14, GCH20 and GCH30 scaffold. The reason for optimization of scaffold composition 
with ≤ 28 wt% of HAp content and 30 wt% gelatin in the prepared scaffold was discussed 
earlier in section 4.6.6 on the basis of physicochemical and mechanical properties of the 
corresponding GCH scaffold. All the FESEM micrographs in Figure.4.11, show an 
interconnected porous network of the prepared GCH14, GCH20 and GCH30 scaffolds, which 
is ideal for tissue ingrowth and osteoinduction. As it is evident from Figure 4.12(a) the pores 
were interconnected with irregular shapes with average pore size of 120 µm for GCH14 
scaffold (Figure 4.11 (a)), where HAp-Chi particle distribution in pore wall of the scaffold is 
shown in Figure 4.11(d). Similarly, from figure 4.11(b), the microstructure of GCH20 
scaffold exhibited open macroporous morphology with average pore diameter 110 µm and 
corresponding distribution of HAp-Chi particles in pore wall of the scaffold is shown in 
Figure 4.11(e). Nearly round shaped interconnected pores with average pore diameter of 94 
µm was found in GCH28 scaffold as shown in Figure 4.11(c) and corresponding HAp-Chi 
particle distribution inside pore wall of GCH28 scaffold is presented in Figure 4.11(f). HAp-
Chi nanoparticles were found to be randomly dispersed in gelatin matrix which suggests 
gelatin’s role as a good binder for anchoring HAp- chitosan particulate together.  
The average pore size of the prepared GCH scaffold was decreased with increasing HAp 
content from 14 to 28 wt% due to the presence of higher amount of hydrophilic HAp particles 
(a
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in the slurry of prepared scaffold that hindered the growth of ice crystals during freezing. 
GCH30 exhibited smaller average pore diameter of 94 µm than that exhibited by GCH10 and 
GCH20 as shown in Table 4.7, but that is sufficient for attachment and ingrowth of osteoblast 
cell and exhibiting osteoinduction.  
 
Figure.4.11. Microstructural observation HAp-chitosan/gelatin composite Scaffold fabricated from 
different amount of HAp content (a) GCH14, (b) GCH20, (c) GCH30 and their particle distribution in 
pore wall is (d), (e) and (f) respectively. 
 
Table.4.7 Average pore diameter of GCH composite scaffold (FESEM data) 
Sample name Average Pore 
Diameter(µm) 
Porosity 
GCH 14 120 ± 5.3 76 ± 4.0 
GCH 20 110±11.8 73.89±5.4 
GCH 30 94 ±6.9 78.12±3.2 
 
It can be inferred from this study that the pore size and its distribution in the prepared 
scaffold can be controlled by modifying the freezing rate, solids loading and composition of 
the slurry [220].  
500 µm 500 µm 500 µm 
10 µm 10 µm 10 µm 
(d) (f) (e) 
(c) (b) (a) 
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4.6.8 Mercury pore size distribution of GCH scaffold 
In all the fabricated scaffolds some micropores were observed in the range of 0.5-5 µm. The 
pore size distribution data measured through mercury intrusion porosimetry, as shown in 
Figure 4.12 also revealed the fact that most frequent pore diameter was decreased from 150 
µm to 80 µm on going from 10 to 30 wt% gelatin content in the scaffold. Also, scaffold 
containing 30 wt% gelatin showed the narrowest interconnected pore size distribution as 
evident from Figure 4.11 (c), which is ideal for bone tissue ingrowth and also exhibiting 
osteoinduction and osteointegration by the scaffold. 
 
Figure.4.12. Mercury pore size distribution of freeze dried scaffold (a) GCH10,(b)GCH20, (c)GCH30. 
4.6.9 Mechanical behaviours of GCH scaffold 
The stress-strain behaviours of GCH scaffolds having HAp content varying between 14-49 
wt% are presented in Figure 4.13. In all cases, the stress strain plot exhibits three regimes of 
 
Figure.4.13. Stress strain plot of prepared GCH composite scaffold. 
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behaviour, namely linear elastic, a plastic collapse-plateau and densification regime. GCH30 
scaffold exhibited the highest compressive strength of 3.46 MPa, which is close to the lower 
limit of compressive strength in human spongy bone [221]. The dispersed HAp-Chi particles 
in gelatin matrix inhibited the propagation of crack during compression and enhanced the 
resistance of the scaffold under compressive load. This explains why with the increase in 
HAp content in the prepared scaffold from 14 wt% to 28 wt%, the compressive strength of 
the scaffold gradually increased. The decrease in compressive strength in GCH 49 scaffold as 
compared to that exhibited by GCH 30 (Table 4.8) was due to the presence of HAp 
agglomerates in the former leading to the weakest link in the scaffold as discussed earlier.  A 
further study on the interfacial bonding between organic and inorganic phase can highlight 
the origin of mechanical behaviour exhibited by the composite scaffold. 
Table 4.8 Chemical composition and mechanical property of prepared GCB scaffold. 
Sample Id Gel:Chi:HAp(wt 
ratio) 
Mechanical 
property 
(MPa) 
GCH 14 30:56:14 1.2 
GCH 20 30:49: 21 3.2 
GCH 30 30:42: 28 3.45 
GCH 49 30:21: 49 1.25 
Here, we choose GCH30 scaffold having 30% gelatin and 28% HAp with an average pore 
diameter of 94 µm and compressive strength of 3.46 MPa for further biological 
characterization. 
4.6.10 In vitro study 
4.6.10.1 Mineralization ability of HAp-Chitosan-Gelatin composite scaffold 
Mineralization ability of scaffold in SBF has been regarded as one of the key evidences of 
bioactivity for bone scaffold. It has been reported scaffold which supports osteoblast cell 
growth, proliferation and differentiation in vitro and in vivo, exhibits good mineralization 
behaviour in physiological environment [222, 223] . Highly dense bone-like carbonated 
apatite layer formation on SBF treated GCH30 scaffold (Figure. 4.14) indicates that the 
prepared scaffolds are not only biocompatible, but also bioactive. 
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Figure.4.14. SEM micrographs of carbonated apatite layer formed on the surface of GCH30 scaffold 
immersed in SBF for 7 days. 
4.6.10.2 In vitro biodegradability of GCH scaffold 
Figure 4.15 illustrates the biodegradation of GCH scaffold in PBS buffer solution at 37oC and 
pH~ 7.4, where a weight loss to the extent of 26 wt% in GCH14, 18 wt% in GCH 20 and 14 
wt% in GCH30 was recorded after 18 days of incubation. Figure 4.15 follows an initial 
increase in degradation upto 12 days and steady state behaviour afterwards. It is reasonable to 
think that the strong interaction between gelatin macromolecular chains and HAp consumed 
some hydrophilic groups and depressed the solvent uptake, which protected the 
macromolecules from hydrolysing. Zheng et al [224] revealed a weight loss of 40 wt% of gel-
chi-montmorillonite based scaffold for an incubation time of 6 days in tris-buffer solution of 
pH~ 7.4. The results showed that degradation of GCH scaffold can be modified by changing 
the concentration of HAp. 
 
Figure.4.15 In vitro degradation behaviour of GCH scaffolds with varying HAp content. 
4.6.10.3 Swelling studies of the GCH scaffold 
Swelling study is an important index to the scaffold in relations to its pore size, 
interconnected porosity, to facilitate nutrients for cell adhesion and attachment. Figure 4.16 
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illustrates the result of swelling ratio exhibited by GCH14, GCH20 and GCH 30 scaffold. 
The HAp content influenced the swelling ratio of the prepared GCH scaffolds. The swelling 
ratio decreased as the HAp content increased from 14-30 % in the GCH scaffold. Since some 
of the NH2+ and Ca+2 bound together in gelatin matrix, the –OH group could not form 
hydrogen bond, hence decrease in swelling ration was observed [225]. 
 
Figure.4.16. Swelling behaviour of GCH scaffolds with varying HAp content in PBS at 37oC. 
4.6.11 In-vitro cell culture study 
4.6.11.1 Cell attachment onto scaffolds 
The scaffold having composition of GCH30 was chosen on the basis of its pore size and 
mechanical strength as an ideal scaffold to study the MSC–scaffold interaction in this work. 
The MSC and scaffold interactions after different days of cell culture are shown in the 
FESEM micrographs in Figure 4.17 that clearly exhibit that MSCs were attached, spread, and 
then proliferated with increasing cell culture time in the scaffold. The increasing numbers of 
lamellipodia and filopodia extensions from the cytoskeleton of MSCs were evident with 
progress in cell culture time as in Figure 4.17.(b) and (c). A separate image of a healthy MSC 
after 14 days culture on the scaffold is shown in inset of Figure 4.17(c). The attached cell 
exhibited numerous lamellipodia and filopodia from its cytoskeleton and spreading behaviour 
on to the scaffold. The fluorescent images in Figure 4.17 (d-f) also showed the increasing 
intensity of living cell on the scaffold with progress in cell culture time. 
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Figure.4.17. FESEM image showing MSCs attached on the HA:Chi:Gel (28:42:30) composite scaffold 
after (a) 3 days, (b) 7 days, (c) 14 days of cell culture. Dapi staining showing the distribution of cells on 
GCH28 scaffold (d) 3days, (e) 7 days (f) 14 days. 
4.6.11.2 Metabolic activity of cells 
After culturing it on the scaffold upto 7 days, MSC’s viability in scaffold was studied using 
MTT assay, with MSCs cultured on tissue culture plate without Triton X100 and with Triton 
X100 in cell culture media were treated as positive control and negative control, respectively. 
Keeping up with the same trend as exhibited by the positive control, the scaffold material 
showed higher and higher number of a viable cell with progress in cell culture time as shown 
in Figure 4.18. The cell density on 5 days was significantly higher (p value ˂ 0.001) from that 
on 3 days, and subsequently, viable cell density after 7 days of culture was significantly 
higher (p value = 0.015) as compared to that on day 5. This showed that the selected scaffold 
was conducive to cell attachment and proliferation [226]. 
 
30 µm 50 µm 50 µm 
200 µm 200 µm 200 µm 
(a) (b) (c) 
(d) (e) (f) 
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Figure.4.18. MTT assay for cell proliferation study in positive control, negative control GCT 30 scaffold 
using human Mesenchymal stem cell on days 3, 5, and 7. * indicates significant difference at p ≤ 0.05. 
4.6.11.3 Study of MSC’s differentiation into osteoblast 
Figure 4.19 shows the confocal images of RUNX2 and osteocalcin expressions after culturing 
MSCs for 7 and 14 days on control and sample group, respectively. RUNX2 expression 
appeared significantly higher in the Gel: Chi: HAp (30:42: 28) scaffold compared to pure 
gelatin-chitosan scaffold after 7 days (Figure 4.20(a, b)  and 14 days (Figure 4.19 (c,d) ) of 
cell culture study, supporting the differentiation of MSCs into osteoblast. The expression of 
the RUNX2 was only enhanced during early differentiation of osteogenic lineage and 
maintained at steady levels after initial commitment [227] as evident from Figure 4.19(a) and 
(b). Osteocalcin is a primary non-collagenous protein produced by osteoblasts, which signals 
the termination of osteogenic differentiation and is commonly used to measure new bone 
formation [228]. Osteocalcin expression for osteogenesis was much more pronounced in 
composite scaffold as compared to very negligible or no osteocalcin expression observed in 
control (pure gelatin-chitosan scaffold) (Figure 4.19 (c, d)) that suggests bone lineage and 
bonding osteogenesis on the scaffold within 14 days of cell culture. This study showed that 
scaffold prepared from 30 wt% gelatin, 42 wt% chitosan, and 28 wt % HAp promoted MSCs 
differentiation into osteoblast cell and then to osteogenic lineage. 
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Figure.4.19. Confocal images of RUNX2 and osteocalcin (a, b) control (gelatin-chitosan) after culturing 
MSCs for 7- and 14-days culture and (c, d) HA–Chi/Gel (28:49:30) after culturing MSCs for 7- and 14-
days culture. 
4.7 Conclusions 
In this study composite scaffold of nano HAp-chi and gelatin was prepared and characterized. 
HAp-chi composite nanopowders in the size range between 40-70 nm were synthesized using 
in situ co-precipitation method. The porous composite scaffold with varying weight per cent 
of hydroxyapatite (HAp), chitosan and gelatin was fabricated using freeze drying method. 
The FTIR spectrum indicated the ability of glutardaldehyde to form effective crosslinked 
network in the polymer matrix of the scaffold. The GCH30 scaffold exhibited the highest 
compressive strength and a pore size distribution ideal for bone tissue ingrowth and eliciting 
osteoinductive property. With increase HAp content upto 30 wt%, the compressive strength 
in the prepared GCH scaffold increased. Nanosize HAp-chi particles were found to be 
uniformly dispersed in gelatin network, leading to higher compressive strength. The prepared 
GCH 30 scaffold exhibited conducive and bioactive environment for MSC’s attachment, 
spreading, proliferation, and differentiation into bone cells. In vivo evaluation of bioactivity 
of the scaffold using rabbit model is the next step to prove its high efficacy as a bone 
scaffold.
(a) (b) 
(c) (d) 
       100 µm 100 µm 
500 µm 500 µm 
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Abstract 
The aim of the present study was to prepare and characterize bioactive-gelatin-chitosan based 
composite scaffold and evaluate its bone regeneration ability at orthopaedic defect site. 
Bioactive 58s glass nanoparticles having composition SiO2:CaO:P2O5 equals to 58:33:9 in 
mol.% was synthesized using the sol-gel method in the size between 80 to 100 nm. Porous 
scaffolds with varying bioglass composition from 10-30 wt% in chitosan, gelatin matrix were 
processed using the method of freeze-drying of slurry containing 40 wt% solids loading. 
Polymer matrix was crosslinked with glutaraldehyde to improve scaffold’s mechanical 
strength with microstructure having interconnected porosity. The prepared scaffolds exhibited 
high (>80%) porosity with a mean pore size varying between 100-300 micron. With increase 
in bioactive glass amount up to 30 wt%, the compressive strength of the scaffold increased 
and showed a maximum of 2.2 ± 0.1 MPa for GCB30. Swelling and degradation studies 
showed that the scaffold possessed excellent hydrophilicity and controlled biodegradability. 
GCB30 scaffold was shown to be non-cytotoxic and supported mesenchymal stem cell 
attachment, proliferation and differentiation as indicated by MTT assay and RUNX-2 
expression by the cultured MSC’s. Higher cellular activity was observed in GCB 30 scaffold 
as compared to GCB 0 scaffold suggesting the fact that 58S bioactive glass nanoparticles 
addition into the prepared scaffold promoted better cell adhesion, proliferation and 
differentiation. Strongly positive osteocalcin signalling within 14 days of cell culture 
supported the fact that the prepared scaffolds stimulated new bone tissue regeneration. Thus, 
the study showed that the developed composite scaffolds are potential candidates for 
regenerating damaged bone tissue and could be useful in orthopaedic applications. 
5.1 Introduction 
Designing new biomaterials that can mimic the micro/nano-structure and chemical 
composition of the native extracellular matrix (ECM) is one of the most attractive and 
important research areas in the field of tissue engineering. ECM governs cell attachment, 
growth, migration and differentiation, as well as the formation of new tissues[229]. Scaffolds 
that mimics ECM of bone should ideally be processed from biomaterials with adequate 
properties such as biocompatibility, osteoconduction, bioactivity, osteoinduction, and 
biodegradatio [230]. Three dimensional (3D) porous structure of scaffolds provides necessary 
support for cells to proliferate and differentiate, and its architecture ultimately governs the 
shape of a new bone[231, 232]. Moreover, scaffolds for bone regeneration should mimic 
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bone morphology, structure, and function. Bone is composed of calcium phosphate (69–80 wt 
%, mainly hydroxyapatite), collagen (17–20 wt %), and other components (water, proteins, 
etc.).[232] For this reason, composites based on apatite crystals and natural biopolymers have 
received increasing attention in bone tissue engineering applications [233, 234]. 
Biocomposites based on biodegradable polymers and bioactive ceramics have been 
developed for applications in bone repair and reconstruction. Several polymers such as 
polylactic acid (PLA), polyglycolic acid (PGA), polylactic-coglycolic acid (PLGA), gelatin, 
alginate and chitosan (CH) are widely used for this purpose because of their proven 
biocompatibility and complete bioresorbability [180, 235-239]. 
Chitosan (CS) is a natural biopolymer extracted from crustacean. CS is a polysaccharide-type 
biological polymer possessing reactive amine and hydroxyl groups that promote osteoblast 
growth and in vivo bone formation [240-243]. Chitosan plays an important role in the 
attachment, differentiation and morphogenesis of osteoblasts, the bone forming cells, because 
of its structural similarities with glycosaminoglycans, a major component of bone and 
cartilage.[244-246]. Despite its tremendous promise in bone tissue engineering application, 
the poor mechanical properties of chitosan limits its clinical application in weight bearing 
bones, which has been addressed by the addition of bioceramics in chitosan scaffolds [247]. 
Gelatin, a non expensive and commercially available biomaterial that has gained interest 
in biomedical engineering, mainly because of its biocompatibility and biodegradability. Since 
it contains Arg–Gly–Asp (RGD)-like sequences that promote cell adhesion and migration, it 
has been blended with chitosan to improve biological activities of composite scaffold [248, 
249]. Gelatin–chitosan scaffold has been tested for the regeneration of various tissues 
including skin [250], cartilage [251], and bone [252]. 
Bioactive glasses are a group of bioactive ceramic materials with good bioresorbility. When 
immersed in physiological solution, these bioactive materials can form hydroxyl carbonate 
apatite (HCA) layer that is chemically and compositionally similar to the mineral phase of 
human bone. The formation of apatite layer triggers chemical bonding between implant 
biomaterials and bone tissues [53, 253-255]. Shalumon et al.[256] investigated the effect of 
nanoscale bioactive glass and hydroxyapatite incorporation in PCL/chitosan nanofiber for 
bone and periodontal tissue engineering. Piergiorgio et al, Gentile et al.[257] in their study 
found that SiO2-P2O5-CaO-MgO-Na2O-K2O containing bioglass in 70 wt% amount in 
chitosan –gelatin composite exhibit excellent bioactivity. Bioactivity and mechanical 
properties of composite scaffold comprising chitosan (CS) and 55S bioactive glass ceramic 
nanoparticles was reported by Mathew Peter et al.[258]. In another study, Mathew Peter et al 
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[219] investigated the effect of 55S bioglass nanoparticle addition on physio-chemical 
properties of  chitosan-gelatin scaffold. The effect of 45S5 BG in Chi-Gel based scaffold on 
mesenchymal stem cell activity was reported elsewhere [259]. Previous reports demonstrated 
that 58S BG containing 58 mol% SiO2– 33 mol% CaO–9 mol% P2O5 is suitable for bone 
repair due to its excellent biocompatibility, bioactivity and biodegradability[260, 261]. 
Despite none of the studies was focused on investigating the effect of addition of 58S 
bioglass nanoparticles into chitosan- gelatin based scaffold on mechanical properties and 
mesenchymal stem cell activity onto the scaffold. 
Here we report the effect of compositional variation amongst chitosan, gelatin and 
synthesized 58S bioglass nanoparticles on physicochemical properties, microstructure, 
mechanical properties and bioactivity of the prepared scaffold. Optimization of the 
composition of the prepared scaffold was performed evaluating the pore size and its 
distribution, biodegradation kinetics and mechanical properties. In detail scaffold-MSCs in- 
vitro interaction was investigated on scaffolds using SEM, MTT assay and 
immunocytochemistry. 
5.2 Materials and Methods 
5.2.1 Materials  
Chitosan (medium molecular weight , degree of deacetylation=85%) and gelatin (Type B 
extracted from bovine skin) were purchased from Sigma Aldrich (USA). Tetra Ethyl Ortho 
Silicate (TEOS: C8H20O4Si), Triethyl Phosphate (TEP:C6H15O4P) and calcium nitrate tetra 
hydrate (Ca(NO3)2,4H2O) were purchased from Merck (India). Glacial acetic acid (96%) and 
ammonia solution (NH4OH) were procured from LOBA chemical (India). Glutaraldehyde 
(GA)(C5H8O2) and 0.1M nitric acid (HNO3) were purchased from Merck Inc (India).  
5.2.2 Sol-Gel preparation of 58S bioactive glass  
Figure 5.1 shows a schematic diagram of 58S bioactive glass nanopowder synthesis using 
sol-gel method through one step acid catalyzing process.The composition of the synthesized 
bioactive glass was 58% SiO2 , 33% CaO and 9% P2O5 in molar percentages and 
composition was chosen based on the ternary phase diagram of CaO–SiO2–P2O5 [262, 263]. 
In brief, 14.8 g of tetraethoxysilane (TEOS) was added to 30 ml of 0.1 M nitric acid, and the 
mixture was allowed to react for 30 min for maximum completion of acid hydrolysis of 
TEOS. Distilled water was added to the solution and allowed to mix until the solution became 
clear. The H2O: (TEOS) molar ratio was 12:1. After 30 minutes, 0.85 gm of Triethyl 
Phosphate (TEP) was added to the stirred solution followed by the addition of 7.75 gm of 
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calcium nitrate after another 20 minutes. The solution was then stirred for an hour. The 
mixture was cast in a cylindrical teflon container and kept sealed for a week at room 
temperature to allow hydrolysis and a polycondensation reaction occurs in course of gelation 
of the sol. The gel was dried at 120∘C for two days in an oven. The dried powder was heated 
for 24 h at 600∘C for nitrate elimination and stabilization of gel. Subsequently, the powders 
were ball milled by planetary milling (Fritsch Company, Germany) at 400 rpm for six hr. 
 
 
Figure5.1. A schematic diagram of bioactive glass powder production via acidic catalysed sol-gel process. 
5.2.3 Preparation of porous Gelatin-Chitosan/Bioglass(GCB) composite scaffold  
The GCB scaffolds were prepared with varying amount of synthesized 58S-BG nanopowder 
keeping the amount of gelatin constant at 30 wt% as listed in Table 5.1. Our previous work 
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indicated that increase in nanoceramic phase content beyond 30 wt% in gelatin-chitosan 
matrix resulted in <50 µm pore size in the prepared scaffold, rendered it not ideal for cell 
ingrowth and hence exhibiting osteoinduction. Similarly, scaffold’s average pore size 
decreased below 40 µm on increasing gelatin content higher than 30 wt% with nanoceramic 
phase content varying between 10-30 wt% in the scaffold. As we found that 30 wt% gelatin 
content scaffold exhibited the highest compressive strength, our objective in this study was to 
evaluate the physicochemical and mechanical properties of the prepared scaffold on varying 
bioglass content from 10 wt%-30 wt% keeping gelatin content fixed at 30 wt%.   
 
Figure 5.2 illustrates the preparation processes of GCB scaffolds. First, chitosan (Chi) 
solution was prepared by dissolving required amount of medium molecular weight chitosan 
in a solution containing 4 ml of acetic acid and 96 ml of deionized water with stirring for 5 h 
to get a perfectly transparent solution. A glutaraldehyde solution was prepared by dissolving 
0.5 mL (50%) glutaraldehyde in 100 mL deionized water. Then, required amount of gelatin 
was dissolved in deionized water with continuous stirring at 40oC for four hour. This solution 
was then added to the two wt% chitosan solution. Different weight percentages (10%, 20%, 
30%) of 58S-BG was then added into the gelatin-chitosan solution and stirred for 4 hours. 
The resulting slurry (gelatin-chitosan-bioglass) was put in PTFE cylindrical mould and then 
rapidly prefreezed at -20˚C to solidify the water and kept overnight. Next, the frozen samples 
were lyophilized using a freeze-dryer (Labconco, US) at -52˚C for 24 hrs. Finally, samples 
were soaked in 1 wt% GA solution for 24 h and then carefully washed with de-ionized water 
to remove the remaining amount of GA. The crosslinked scaffold was further treated with 
sodium borohydride aqueous solution to block residual aldehyde groups, and then washed 
with ethanol-NaOH followed by deionized water. The washed porous scaffold was again 
freeze-dried to obtain the hybrid network of gelatin -chitosan- bioactiveglass. The schematic 
flow diagram is presented in Figure.5.3. 
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Figure.5.2. Fabrication procedure for the GCB scaffolds. 
 
Figure.5.3. Schematic flow diagram of fabrication of GCB scaffolds. 
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Table.5.1. Composition of GCB scaffolds. 
Specimen 
name 
Gel 
concentration 
(w/w)% 
Chitosan 
Concentration 
(w/w %) 
CS-Gel/BG 
Ratio 
(w/w)% 
Solid Loading 
(%) 
GCB-0 30 70 100/0 40 
GCB-10 30 60 90/10 40 
GCB-20 30 50 80/20 40 
GCB-30 30 40 70/30 40 
5.2.4 Characterization 
5.2.4.1 X-Ray Diffraction (XRD) analysis  
The phases of composite scaffolds were characterized by X-ray diffraction (XRD) using fully 
automated X- ray diffractometer (Panalytical, USA) fitted with Ni filter. The detailed 
procedure was mentioned in Chapter4 in section 4.4.1. 
5.2.4.2 Particle size analysis using dynamic light scattering (DLS) 
 Particle size of synthesized bioglass nano powder was measured using (DLS) technique by 
Malvern zetasizer (ZEN3690, USA). The detailed procedure was mentioned in Chapter4 in 
section 4.4.4. 
5.2.4.3 Fourier Transform Infrared Spectroscopy (FTIR) analysis 
The characteristic peaks of the composite scaffold were analysed using Fourier transform 
infrared (FTIR) (Perkin Elmer, USA) spectroscopy. The detailed procedure was mentioned in 
Chapter4 in section 4.4.2. 
5.2.4.4 Transmission Electron Microscopy (TEM) of 58s bioactiveglass nanoparticles 
The particle size, morphology and crystallinity of as synthesized 58s bioactive glass powder 
was studied by TEM (FEI, Nederland), SAED (Selected Area Electron Diffraction) pattern. 
The detailed procedure was mentioned in chapter 4 in section 4.4.4. 
5.2.4.5 Scanning Electron Microscope (SEM) analysis 
 The composition of prepared bioactive glass powder was studied using energy dispersion X-
ray (EDX) analysis. The morphology and microstructure of the scaffolds have been observed 
using field emission scanning electron microscopy (FESEM) (Novanano 450, FEI, 
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Netherland) operated at 78 µA, 15KV. The detailed procedure was mentioned in Chapter4 in 
section 4.4.6. 
5.2.4.6 Mechanical behaviour (Compression test) 
 The mechanical properties of the composite scaffolds were determined using a Universal 
Testing Machine (Tinius Olsen, UK) with a crosshead velocity of 1 mm min-1 and a 1000N 
load cell. The detailed procedure was mentioned in Chapter4 in section 4.4.9. 
5.2.4.7 Porosity of scaffold 
 The porosity of composite scaffold (diamter 5 mm, height 12 mm) was measured using 
Archimedes principle with xylene as liquid medium . The detailed procedure was mentioned 
in Chapter4 in section 4.4.7. 
5.2.4.8 Swelling behaviour of GCB scaffold  
The swelling properties of the chitosan–gelatin- bioactive glass scaffolds were investigated 
using PBS solution for 24 days. The detailed procedure was mentioned in Chapter4 in section 
4.4.10. 
5.2.4.9 Mineralization behaviour of GCB scaffold  
The ability to form apatite when immersed into simulated body fluid (SBF) is an index of 
biocompatibility exhibited by the GCB scaffold. The detailed procedure was mentioned in 
Chapter4 in section 4.4.11. 
5.2.4.10 In vitro biodegradability of GCB scaffold 
 The scaffolds were immersed into the phosphate buffer solution. and degradation assessment 
by monitoring the weight loss. The detailed procedure was mentioned in Chapter4 in section 
4.4.12. 
5.2.4.11 Cell Culture Study 
5.2.4.11.1 Attachment and morphology of cell on GCB composite scaffolds 
 Human Umbelical Chord Mesehenchymal stem cells (MSCs) were grown in a Dulbecco's 
modified Eagle's medium (DMEM; Sigma-Aldrich, UK) supplemented with 10% fetal bovine 
serum (FBS; Sigma-Aldrich, UK) and 100 U/mL penicillin–streptomycin. The detailed 
procedure was mentioned in Chapter4 in section 4.4.13.3. 
 
 
76 
 
 
Chapter 5 GCB Composite Scaffold 
5.2.4.11.2 Analysis of viability differentiation of MSc cultured onto the scaffolds  
Cell viability of MSCs cultured onto the scaffolds were determined after performing [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. The detailed procedure 
was mentioned in Chapter4 in section 4.4.13.4. 
5.2.4.11.3 Inmunofluorescent imaging of cell markers: osteocalcin and RUN-X2 
The expression of RunX2 and Osteocalcin, an osteogenic marker was examined using 
immunocytochemistry. The detailed procedure was mentioned in Chapter4 in section 
4.4.13.5. 
5.3 Statistical Analysis 
All data are expressed as mean ± standard deviation. The data were compared using Student’s 
t-test and differences were considered significant when *p < 0.05. A p-value more than 0.05 
(p > 0.05) was taken as indicating no significant difference. 
 
5.4 Results and Discussion 
5.4.1 XRD and FTIR analysis 
Figure.5.4 (a) shows the FT-IR spectrum of synthesized bioactive glass powder. The 
characteristic bands for different functional groups present in the powder are shown in 
Table.5.2. The band at 1638 cm-1 corresponds  to carbonate (CO3-) coming from atmospheric 
CO2 and attached to Ca2+. The band at 1022 cm-1 arises from ѵ3 PO4, whereas the band at 
653 cm-1 suggests the presence of ѵ4 PO4. The band at 836 cm-1 was assigned to the 
stretching vibration of Si-O- groups in bioglass. The abs option bands observed at 1076 cm-1 
and 540 cm-1were assigned to stretching vibration of Si-O-Si respectively and bending of Si-
O-Si [264]. Typical absorption band at 1786 cm-1, 1431 cm-1 are attributed to the deformation 
mode of adsorbed molecular water in the pores. Phase analysis of the composite nanopowder 
was performed using XRD. Figure.5.4 (b) clearly indicates the amorphous nature of the 
synthesized bioactive glass powder [257]. 
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Figure.5.4. FTIR and XRD pattern of 58SBioglass powder prepared via sol-gel process. 
Table.5.2. Peaks of infrared spectra assigned to synthesized bioactiveglass powder. 
Bond Infrared Frequency (cm-1) 
Si-O-Si  bending 540,1076 cm-1 
P-O  bending vibration 1022,653 cm-1 
-OH 3456 cm-1 
CO3- 1638 cm-1 
Adsorbed molecular water 1786,1431 cm-1 
5.4.2 Particle size, morphology and composition of nano-bioactiveglass powder 
Figure.5.5 represents DLS particle size mesurement data of synthesized 58s bioactiveglass 
nanopowder. An average particle size of 85± 9.5 nm was obtained from the DLS mesurement 
which is little bit higher as compared to the particle size shown in the FESEM image in 
Figure 5.6(a). Particle size mesurement by DLS technique gives the hydrodynamic diameter 
of the particle and also bioglass particles were to some extent in agglomerated state in the 
suspension that suggest higher average particle size value in the DLS mesurement. From 
FESEM micrograph in Figure.5.6 (a) it is evident that the bioglass particles were spherical in 
morpology and agglomerated in course of drying. EDS analysis in Figure.5.6 (b) suggests that 
the synthesized powder with a molar composition of Si:Ca:P=56:30:9 closely resembled the 
theoritical composition as shown in Table.5.3.It can be seen from TEM analysis in Figure.5.6 
(c,d) that bioactive glass powred exhibited an amorphous phase with a particle size less than 
100 nm. 
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Figure.5.5. The particle size distribution of NBG measured by DLS. 
 
 
 
 
 
 
 
Figure.5.6.(a) FESSEM micrograph of synthesized bioglass nanopowders  (b) Elemental composition 
analysis of the synthesized bioglass nanoparticles.(c) TEM image of 58 bioactive glass nanoparticle.(d) 
SAED pattern of bioactive glass particle. 
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Table.5.3. EDS analysis of 58s Bioglass powder. 
Elements Bioactive glass  
Atomic percent  
Si 56.14 
Ca 30.88 
P 9.02 
O 3.96 
5.4.3 XRD analysis of composite scaffold 
 Phase analysis of the composite scaffolds was performed using XRD. The characteristic 
diffraction peaks for both chitosan and gelatin were suppressed by the huge amorphous peak 
of bioglass observed in the range between 2θ equals to 20o-40o. The broad amorphous peaks 
of bioglass confirmed that the prepared scaffolds were predominantly amorphous as shown in 
Figure.5.7. 
 
Figure.5.7. XRD analysis of GCB composite scaffold with varying amount of bioglass powder. 
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Figure.5.8. Possible chemical interaction between Bioactiveglass and Gelatin-Chitosan (a) Gelatin-
Bioglass, (b) Chitosan-Bioglass, (c) Gelatin-Chi crosslinking, (d) Gelatin-Chi-BG complex. 
5.4.4 Chemical structure study of composite scaffold 
Chemical structure of composite scaffolds was investigated by FTIR, in order to examine the 
chemical interactions between the gelatin, chitosan and bioglass phases, as shown in 
Figure.5.9. Apart from corresponding peaks of PO4 3- at 1026 and 651 cm-1, Si-O-Si in 
bioactive glass at 1076 cm-1, bands for amide I at 1662 cm-1, amide III at 1232 cm-1 and 
carboxylate at 1446 cm-1 in gelatin, a distinct band at 1552 cm-1 was detected. This 
absorption band signifies the formation of –C=N- bond due to inter-gelatin and chitosan -
gelatin cross linking to develop 3D interconnected network in the scaffold [265]. appearance 
of band at 1661 cm-1 indicates amide I of gelatin which suggested the predominantly alpha- 
helical protein configuration of gelatin in prepared GCB30 scaffolds [157], and this was 
further confirmed by the appearance of amide II mode at 1552 cm-1. The band at 1330 cm-1 is 
attributed to the chemical bond formation between carboxylate group in gelatin and Ca+2 ion 
in bioactive glass to bind the particulate reinforced composite scaffold together [266, 267]. 
These interactions between the gelatin, chitosan and silica phases would enhance the stability 
of the composite gelatin–chitosan-bioactive glass hybrid scaffolds in a water-based 
environment as shown in Figure 5.8. 
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Figure.5.9. FTIR spectra of Gelatin/Chitosan/Bioglass (GCB 30) composite scaffold. 
5.4.5 FESEM microstructure of fabricated GCB scaffold 
The physical characteristic of a scaffold can be described by its average pore size, pore 
interconnectivity and pore shape. Pores are necessary for the bone tissue formation because 
they allow migration and proliferation of osteoblast and mesenchymal stem cells, as well as 
the proper vasculariztion of the implant [268]. The morphology of BCG scaffolds before and 
after bioactiveglass incorporation is shown in Figure.5.10. FESEM micrograph of composite 
scaffolds (Figure 5.10) showed that scaffolds were macro porous in nature. The porosity was 
found to vary from 81 to 89% depending on the percent addition of bioactive glass powder. 
The average pore sizes of GCB scaffolds with 10wt% bioactive glass were varied between 
200–250 µm. As the bioactive glass content increased to 30wt%, the average pore sizes of the 
scaffold was reduced to 115 µm and pore shape became irregular. With the augmentation of 
bioglass content in GCB slurry, the interactions between bioactiveglass particles and gelatin 
increased with consequent increase in solution’s viscosity. Thus as we go from 10 – 30 wt% 
bioactiveglass content in scaffold, a higher and higher force was necessary for GCB slurry to 
be expelled by water molecules, so the ice crystals growth was hindered during freezing of 
slurry resulting in reduced size of inter trapped ice blocks and scaffolds with smaller pores 
were formed during subsequent sublimation[269]. A top view (Fig.5.10 (a-d)) and side 
view(Figure 5.10 (al-dl)) representation of the scaffold are shown in Figure.5.10 that were 
used to calculate the average pore size. In particular, with an increase in bioactive glass 
content, increasing amount of bioactive glass particles were deposited onto the chitosan-
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gelatin based pore walls (Figure 5.10all-dll) as confirmed subsequently by FESEM 
examination. All results demonstrate that the prepared scaffolds exhibited a porous 
distribution with pore size varying between 94-250 micron with rough pore wall, crucial for 
protein and cell adhesion. 
 
Figure.5.10. FESEM microstructure of GCB composite scaffolds. crossection (a-d), longitudinal  (al-dl), 
pore wall distribution (all-dll). 
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5.4.6 Analysis of Pore size and its distribution in the scaffold  
Table.5.4 indicates the total porosity and mean pore diameter values of different scaffolds 
with varying composition. The mean porosity value varied between 81%-89% suggesting that 
compositional variation did not affect the total porosity in a significant manner (all p values > 
0.05). Pore size distribution data in Figure.5.11 also shows the unimodal pore size 
distribution for all the prepared scaffolds. The most frequent pore diameter in the scaffold 
was decreased from 250 µm to nearly 100 µm as we increase bioactive glass content from 
10%-30% in GCB slurry. All the scaffolds showed the ideal pore size distribution for 
exhibiting osteoinductivity and osteoblast or stem cell ingrowth into the scaffold as the pore 
size distribution in the scaffold falls within 100-400 µm. 
 
Figure.5.11. Pore size distribution data of Gelatin-chitosan-bioglass scaffold(a)GCB 10,(b) GCB 20, 
(c)GCB30 
Table.5.4. Pore diameter and porosity of prepared GCB scaffold. 
Sample name Average Pore 
Diameter( m) 
Porosity 
BCG 0 400 ± 13.6 89.3 ± 7.8 
BCG 10 250 ± 26.3 82.4 ± 5.0 
BCG 20 160±17.8 80.8 ± 3.3 
BCG 30 100 ±25.9 81.3 ± 6.1 
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5.4.7 Compressive mechanical Properties of GCB scaffold 
 Figure.5.12 describes the stress-strain behaviour of GCB composite scaffolds under 
compression. The stress- strain curve can be decomposed in two stages. The first is the elastic 
region before yield point and second are the post yield stage i.e. deformation region and then 
densifying region where the pore wall collapses. In this case, compressive strength of the 
scaffold is denoted by the point that denotes the end of first linear region. With increase in 
bioactive glass concentration from 10%-30% wt% compressive strength continued to enhance 
significantly as in Table 5.5. The compressive strength of pure gelatin-chitosan scaffold are 
only 0.8 ± 0.16 MPa. After incorporating 30 wt% bioactive glass particles in gelatin-chitosan 
matrix, the compressive strength increased to 2.2 ± 0.02MPa. The composite scaffold was 
elastic up to yield point but after yield point some micro crack occurred. The interactions 
between bioactive glass particles and polymer network bridged the cracks in the scaffold that 
resulted in postponed final fracture. It is noteworthy that the slope of the deformation region 
in 30 wt% bioactive glass loaded scaffold was the maximum due to enhanced resistance from 
the ceramic particle to crack propagation. 
  
Figure.5.12. Stress-strain behaviour of GCB scaffolds prepared at different bioactive glass 
concentrations. 
 
 
 
85 
 
 
Chapter 5 GCB Composite Scaffold 
Table.5.5. Summary of mechanical properties of GCB scaffolds prepared from solutions of different 
bioactiveglass concentrations (wt%).  
Bioactiveglass scaffolds 
specimens 
Porosity (%) 
Mechanical Properties 
Compressive Strength* (MPa)  
 
BG 0% 
 
89.3 ± 7.8 
 
0.8 ± 0.16 
BG 10% 82.4 ± 5.0 1.2 ± 0.01 
BG 20% 80.8 ± 3.3 1.6 ± 0.01 
BG 30% 81.3 ± 6.1 2.2 ± 0.02 
*P˂0.05, by student’s t-test, n=3, all values in each mechanical property category 
were found to be significantly different from each other. 
 
5.4.8 Mineralization ability of Gelatin Chitosan-bioactive glass composite scaffold 
Mineralization ability of scaffold in SBF has been regarded as one of the key evidences of 
bioactivity for bone scaffold. It has been reported scaffold which support osteoblast cell 
growth, proliferation and differentiation in vitro and in vivo exhibits good mineralization 
behaviour in physiological environment. Highly dense bone-like carbonated apatite layer 
formation on SBF treated GCB30 scaffold (Figure.5.13) indicates that the prepared scaffolds 
are not only biocompatible, but also bioactive. 
 
Figure.5.13. SEM micrographs of carbonated apatite layer formed on the surface of GCB30 composite 
scaffold immersed in SBF for 7 days. 
5.4.9 Biodegradation study 
Scaffold materials are expected to be biodegradable and bioresorbable with a proper rate to 
match the speed of new bone tissues formation. The controlled, and steady degradation 
behaviour of bone scaffold in physiological environments plays an important role in the 
regeneration of new bone tissues. The in vitro degradation of GCB scaffold in phosphate 
buffer solution (PBS) at 37°C is an important study to assess its resorbability under 
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physiologically relevant conditions. For long term mechanical stability and reliability, 
scaffold material should exhibit slow and controlled degradation behaviour. Figure.5.14 
demonstrates the effect of bioactive glass contents on the degradation rate of the scaffold. 
With an increase in the bioactive glass content, the degradation rate in PBS solution at 37oC 
decreased significantly. The bioactive glass particulate interacted through ionic and hydrogen 
bonding with the water molecules and weakened the interaction between the gelatin 
macromolecule and water. Bioactive glass also acted as a physical crosslinking sites to 
enhance the stability of the chitosan-gelatin network. Thus, the degradation rate and as a 
result strength retention in the physiological environment may be controlled by adjusting the 
bioactive glass contents in the scaffold.  
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Figure.5.14. In vitro degradation of the GCB scaffold with different bioactive glass contents in PBS. 
5.4.10 Swelling studies 
The ability of the scaffold to swell plays an important role during the in vitro cell culture 
studies. Swelling of scaffold allows absorption of body fluid and transfer of cell nutrients and 
metabolites inside the scaffold. Swelling also increases the pore size and total porosity, thus 
maximizing the internal surface area of the scaffolds for cell infusion and attachment. 
However, swelling under physiological condition must be controlled otherwise it may cause 
weakening and rapid degradation of the bone scaffold. 
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Figure.5.15. Swelling behaviour of GCB composite scaffolds with different bioactive glass contents in 
PBS. 
Figure.5.15 shows that swelling in the GCB scaffold increased initially and gradually attained 
saturation after 10 hours of soaking in PBS at 37 oC. The degree of swelling was found to 
decrease with increasing bioactiveglass amount in the scaffold that may be attributed to the 
lower hydrophilicity of the inorganic phase as compared to the polymeric matrix having 
caroboxylate, amine and amide end groups: Thus the increase in predominantly covalent 
bonded bioglass content in the scaffold resulted in a decreased water sorption. Also, the 
enhanced polymer-bioactive glass interaction with increasing concentration of bioactive glass 
resulted in higher elasticity and slower relaxation of polymer chains and also accounted for 
decrease in swelling ratio. 
5.4.11 Cell attachment study on GCB 30 scaffolds  
Figure.5.16 shows cell density and morphology after culturing MSCs on GCB 30 for 
different days of culture time. Cell density, as well as number of lamellipodia and filopodia 
extensions from the cytoskeleton of MSCs, was increased with progress in cell culture time 
on composite scaffold. The cell presented a round shape initially [Figure5.16 (a)] and became 
elongated with increasing time of culture. After 14 days, MSCs cells adopted a polygonal 
morphology and spread well on the scaffolds [Figure5.16 (c)]. These results clearly indicate 
that MSCs were attached, proliferated and spread well with increasing cell culture time. 
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Figure.5.16. FESEM image of MSCs on gelatin-chitosan-bioactive glass (GCB 30) for (a) 1d (b) 3d (c) 14d 
of cell culture. 
Figure.5.16 (a1-c1) shows confocal micrographs of MSC’s on the GCB 30 scaffolds after 1, 3 
and 14 days of culture. Confocal images revealed that a higher number of cells were attached 
to the scaffold on increasing days of cell culture time. Figures 5.16 (b1,c1) show a uniform 
interconnecting cytoskeleton of MSC’s on the GCB 30 scaffolds after culturing cells for 3 
and 14 days. The increasing numbers of lamellipodia and filopodia extensions from the 
cytoskeleton of MSC’s were evident with progress in cell culture time as in Figure.5.16 (a1-
c1). Extensive networks of polymerized β-tubulin and F-actin filaments as well as multiple 
cell–cell contacts indicate a higher degree of active cell spreading, movement, and signalling 
events with progress in cell culture. All the results revealed higher proliferation of MSCs on 
GCB 30 scaffolds after 14 days of cell culture.   
5.4.12 Cell proliferation/MTT assay study 
After culturing it on the GCB scaffold, MSCs viability study for 3-7 day was performed using 
MTT assay with cell culture media as negative control and MSCs cultured on tissue culture 
plate as a positive control. Keeping up with the same trend as exhibited by the positive 
control, the scaffold material showed higher and higher number of the viable cell with 
progress in cell culture time as in Figure.5.17. The cell density on five days’ cell cultured 
GCB 30 sample was significantly higher (p value = 0.018) from that on three days sample. 
Again seven days’ cell cultured GCB 30 sample showed significantly higher (p < 0.001) 
(a) (b) 
(a1) (b1) (c1) 
(c) 
100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 
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viable cell density as compared to that on day 5 sample. For all incubation periods, GCB 30 
presented significantly higher (p = 0.026) cell viability than that on GCB 0 scaffold which 
suggests that addition of 58S bioactive glass nanoparticles in the scaffold promoted better cell 
adhesion and proliferation. 58S nanoparticles helped in apatite mineralization onto the 
scaffold in the presence of cell culture media and acted as sites for cell adhesion through 
integrin mediated interactions from the MSCs. This showed that the selected scaffold was 
conducive to cell attachment and proliferation. 
 
 
Figure.5.17. MTT assay for cell proliferation study in positive control, negative control, GCB0 and GCB 
30 scaffold using human Mesenchymal stem cell on days 3, 5, and 7. * indicates significant difference 
at p ≤ 0.05. # indicates significant difference at p ≤ 0.05. 
5.4.13 Study of MSC’s differentiation into osteoblast 
In order to assess the effect of material composition on cell differentiation, expression of 
osteoblastic transcription factor RUN-X2 and bone non-collagenous protein osteocalcin (OC) 
were studied using immunefluorescent markers. As can be seen in Figure.5.18(a-a1) no 
RUNX2 marker was visible from 1-day cell cultured sample indicating nascent and 
premature stage of osteoprecursor cells. There was several fold decrease in the level of 
expression of most of the osteogenic genes on GCB 0 scaffold (Figure.5.18 (b-c)) as 
compared to the GCB 30 (Figure 5.18 (b1-c1 )) at different stages of differentiation, which 
supports the  fact that bioglass addition actually increased the bioactivity of the overall 
scaffold. RUNX2 expression appeared strongly positive in the GCB30 scaffold cultured for 7 
days, supporting the differentiation of MSCs into osteoblast. RUNX2 is a marker for 
osteoblast differentiation, and an increase in the specific activity of RUNX2 with progress in 
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cell culture time in a population of mesenchymal stem cell indicates a corresponding shift to 
a more differentiated state (Figure5.18b1-c1). 
  
Figure.5.18. Confocal image of RUNX2 and osteocalcin after culturing MSCs on GCB 30 scaffolds on (a) 
1 day, (b) 7 day (c) 14 day. In fluroscenes images, osteocalcin is stained green, RUNX2 stained red and 
nuclei stained blue. 
Osteocalcin is a primary non-collagenous protein produced by osteoblasts, which signals 
termination of osteogenic differentiation and is commonly used to measure bone cell lineage 
and new bone formation [269]. Greater osteocalcin (green) deposits were seen in scaffolds of 
14 days cell culture indicating a higher amount of new bone formation with progress in cell 
culture time (Figure.5.18(c)). Thus, our result suggests that MSCs in GCB30 scaffold were 
well committed to osteogenic lineage.  
5.5 Conclusions 
In summary, we have successfully fabricated GCB nanocomposite scaffolds by using freeze 
drying method. The scaffolds were highly porous with total porosity of about 80% and 
average pore size in the scaffold fell to nearly 95 µm from 250 µm with increase in bioactive 
glass content from 10 wt% to 30 wt% in the gelatin–chitosan matrix. The bioactive glass 
particles (BG) were well distributed in gelatin-chitosan matrix, significantly improving the 
compressive strength of the scaffolds. Thus, GCB 30 scaffold showed a compressive strength 
value comparative to that of natural cancellous bone. It was found that the swelling behaviour 
(a) (b) (c) 
(a1) (b1) (c1) 
100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 
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of the scaffolds was reduced with the increase in 58S-BG nanopowder content in the scaffold. 
Biodegradation test in PBS showed that the increase in 58S-BG content resisted the 
biodegradability of the scaffold. Preliminary results on cell culture using MSCs suggested 
that cells could adhere, spread, proliferate and differentiate very well onto GCB 30 scaffolds. 
MSCs were also found to transform into the new bone cell within 14 days of cell culture on 
the GCB 30 scaffold making it promising artificial bone grafts. 
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Abstract 
Bio-engineered bone scaffolds prepared imitating the extracellular matrix (ECM) of the 
native bone is an attractive area of research mainly because it can meet the essential demands 
and current challenges in bone replacement therapies. The primary aim of this study was to 
fabricate the gelatin/chitosan/β-tricalcium phosphate (GCT) composite scaffold to improve its 
compressive mechanical behaviour and in-vivo biocompatibility with predictable degradation 
rate. The β-TCP powder was synthesized in size range between 70-100 nm using aqueous 
precipitation route at a fixed Ca/P molar ratio of 1.5:1 at pH 10 and after subsequent heat 
treatment of the as precipitated powder at 800o C for 4 hours. The composite scaffolds were 
fabricated using the solid-liquid phase separation of the slurry containing gelatin, chitosan, β-
tricalcium phosphate in varying proportion and subsequent lyophilisation of the phase 
separated mixture. The phases, functional groups, and chemical bonds present in the GCT 
scaffolds were evaluated using X-ray diffraction and Fourier transform infrared (FTIR) 
spectroscopy respectively. The prepared scaffold exhibited high porosity of 86% with pore 
sizes ranging between 100-300 µm as determined using Hg-porosimetry. SEM result revealed 
that incorporation of β-TCP upto 30 wt% resulted in well-shaped and uniformly distributed 
interconnected pores of average pore size 100 µm in the scaffold. Compressive strength of 
the scaffolds was increased from 0.8 MPa to 2.45 MPa on increase in β-TCP content from 10 
wt%-30 wt% in the scaffold. Human Umbilical Cord derived Mesenchymal stem cells were 
used to assess the biocompatibility of GCT30 scaffold after culturing them for 3, 7 and 14 
days onto the scaffold. Higher degree of lamellopodia and phillopodia extensions and better 
spreading behaviour of MSC’s were observed in FESEM micrograph of MSC cultured GCT 
30 scaffold. MTT assay and immunocytochemistry studies with cultured MSC’s revealed that 
GCT 30 scaffolds were more conducive to MSC’s proliferation and differentiation into 
osteoblast lineage. In vivo implantation of GCT 30 scaffold subcuteneously into mice did not 
indicate any significant inflammatory reaction, and ongoing vascularization and scaffold 
degradation could be observed after four weeks of implantation into mice subcuteneously.  
6.1 Introduction 
Autograft and allograft bone substitute have been clinically performed worldwide for the 
treatment of large size uneven bone defects. However, autograft face problems due to 
limitation of donor supply and chances of infection during healing process [270]. On the 
other hand, allografts are associated with reduced bioactivity and potential for disease 
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transmission. To address these problems, bone tissue engineering is emerging as a novel 
solution that can regenerate the bone tissue on interaction with 3D scaffold that mimics 
closely to bone extra cellular matrix [271]. Bioceramic have attracted a great deal of attention 
as a way to mimic the structure of natural extracellular matrix by means of providing 
temporary support for self or implanted cells. The ECM of bone tissue typically form a 
nanoscale organized composite between the inorganic and organic ingredients. While calcium 
phosphate nanocrystals are the major constituents of the composite inorganic material, the 
organic part is composed of collagen protein network [32, 272, 273]. Mechanically, the 
organic network provides resilience, while the inorganic crystal hardened the matrix, 
contributing to a strong and tough ECM. Much research effort has been directed at 
combination of biopolymer and bioceramics based composite scaffold with improved 
mechanical and bone regeneration property [184, 274]. 
Chitosan as a biopolymer receives much attention due to its biocompatibility and 
biodegradability and its structural similarity with glycosaminoglycan’s. Moreover, chitosan 
can interact with growth factors, receptors, and adhesion proteins. [275, 276]. Ding et al in 
2006 investigated chitosan/ calcium phosphate composites for studying the effect of chitosan 
on the crystal phase of CaP [277]. Zhang et al. in 2009 investigated the two bone matrices 
(Col-CS-HA and Col-HA) and found that chitosan helped in osteoblast adhesion and 
proliferation in vivo by altering the surface chemistry, which in turn would accelerate the 
process of bone regeneration [278]. The unique features of chitosan have also been 
appreciated in tissue engineering [150, 279]. Gelatin is a potential candidate material for bone 
tissue engineering because of its biological origin, biodegradability, hydrogel properties and 
commercial availability at a relatively low cost [16]. Gelatin protein, derived from partial 
hydrolysis of collagen, has been extensively used in the orthopaedic field. It contains free 
carboxyl groups on its backbone and has the potential to blend with chitosan to form a 
network by hydrogen bonding [205, 280]. 
Calcium phosphate ceramics has been extensively studied as scaffold material for bone tissue 
engineering during last 30 years, because of possessing excellent biocompatibility and 
bioactivity. Beta-tricalcium phosphate (β-TCP), compared with hydroxyapatite, is more 
osteoconductive having excellent biodegradation properties and characterized by rapid 
absorption and replacement by new bone matrix [281, 282]. Because of its bioresorbability , 
it can induce an interface mechanism that leads to a release of calcium and phosphate ions. 
Ca is known to influence osteoblastic cells in vitro. Moreover, extracellular Ca plays an 
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important role in bone remodelling by directly activating intracellular mechanisms after 
controlling Ca-sensing receptors in osteoblastic cells. For example, Ca increases the 
expression of Insulin like growth factors IGF-I or IGFII, which regulate human osteoblast 
proliferation. These findings have been recently reviewed in the literature [283]. Inorganic 
Phosphate (P) was recently shown to stimulate expression of matrix Gla protein (MGP), a 
key regulator for bone formation, in osteoblastic cells when added (10 mmol) to cell culture 
medium [284].  
Gelatin/chitosan/β-TCP (GCT) formulations must be bioactive, bioresorbable and possess 
favourable mechanical properties to be useful for tissue regeneration and clinical 
applications. Limited studies have investigated the efficacy of GCT scaffolds in the bone 
regeneration. MM Islam et al investigated the effect of γ-radiation on GCT composite 
scaffold. Khan et al successfully developed a bioactive, biocompatible scaffold using gelatin, 
chitosan, PEO and TCP. There have been many studies confirming the proliferative and 
osteoconductive properties of β-TCP particles but few with regard to effect of its particle 
size, and concentration over microstructure and mechanical properties of biopolymer based 
scaffold that is reported elsewhere [285, 286]. The goal of this work is to study the effect of 
compositional variation on mechanical and biological properties of fabricated composite 
scaffold to consolidate our understanding on the impact of nanoparticle incorporation into 
composite scaffold for bone tissue regeneration. 
To the best of our knowledge, no study has been previously reported on the use of nanosized 
β-TCP particle for reinforcing gelatin-chitosan scaffolds. However, the commercialize micro 
β-TCP with a average particle size <85 nm) to reinforce freeze-dried or gelatin-collagen 
scaffolds has been reported [287]. Our objective here is to develop novel gelatin chitosan-
based composite scaffolds with nano β-TCP as the reinforcement. In the present study, 
extensive research has been carried out to optimize the processing parameters that can retain 
interconnected 3D porous structure in bone scaffold. Porous gelatin/chitosan/β-TCP scaffold 
was prepared via thermally induced phase separation and lyophilisation and post crosslinking 
with glutaraldehyde a common synthetic crosslinking reagent, for intermolecular crosslinking 
between protein molecules [288]. Here we report the effect of compositional variation 
amongst chitosan, gelatin and synthesized β-TCP nanoparticles on physicochemical, 
microstructural, mechanical properties and bioactivity of the prepared scaffold. The in vivo 
study was designed to evaluate the preliminary biocompatibility of GCT composite scaffold 
after implanting this scaffold subcutaneously on mouse. The investigation represents a 
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successful contribution toward the development of superior porous structures for bone tissue 
engineering. 
6.2 Materials and Methods 
6.2.1 Materials 
Chitosan [85%percentage deacetylated, medium molecular weight ] and gelatin (pH- 4.4-
5.4, Bloom Number 240) were purchased from Sigma Aldrich (USA). and calcium nitrate 
tetra hydrate [Ca(NO3)2,4H2O] and Di-ammonium hydrogen phosphate [(NH4)2HPO4] 
were procured from Merk (India). Glacial acetic acid and ammonia solution (NH4OH) were 
obtained from LOBA chemical (India). Glutaraldehyde (GA) and all other chemicals were 
of analytical grade and were used as received from the manufacturer. 
6.2.2 β−TCP powder synthesis 
Calcium nitrate was dissolved in deionized water to form calcium nitrate solution. 
Ammonium di-hydrogen phosphate (NH4)2HPO4) solution was added drop wise to the 
calcium nitrate solution to maintain Ca/P molar ratio of 1.5 in the reaction mixture. The pH of 
the reaction mixture was maintained at 9 by the addition of ammonium hydroxide (NH4OH). 
The reaction solution was aged for 24 h, filtered, washed thoroughly for 5 times, and dried 
overnight at 60˚C. Finally, the dried powder was calcined at 900 ˚C for 3 hr to obtain β-TCP 
nano powder. 
6.2.3 Fabrication of Gelatin /Chitosan /TCP hybrid scaffolds  
The process of scaffold fabrication is shown in Figure.6.1. Chitosan solution was prepared by 
dissolving 2 gm chitosan in 1% acetic acid solution and stirring continuously for 6 hr. 
Aqueous slurry of   gelatin solution was prepared at 40˚C and mix with chitosan solution. The 
β-TCP nanoparticles were added into the gelatin-chitosan solution to maintain a specific 
composition of gelatin-chitosan-β-TCP as shown in Table.6.1. The mixed slurry was 
dispersed ultrasonically for 30 min and dispensed into glass vials with 2 ml of slurry per vial. 
The glass vials were rapidly transferred into a freezer at -50˚C and frozen overnight. The 
samples were lyophilized in a freeze-dryer (Freeze Dryer (LABCONCO, KOREA) LTFD 5505) 
under vacuum lower than 50 Pa for 3 days.  
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Figure.6.1. Schematic representation of fabrication of GCT scaffold. 
Table.6.1. Composition of the scaffold prepared via Freeze drying. 
Sample 
abbreviation 
Gelatin/Chitosan β-TCP Freeze drying 
temp(˚C) 
Crosslinking 
agent(%) 
GCT 0  30/70 0 -50 0.25 
GCT 10 30/60 10 -50 0.25 
GCT 20 30/50 20 -50 0.25 
GCT 30 30/40 30 -50 0.25 
GCT 40 30/30 40 -50 0.25 
 
6.2.4 Characterization 
6.2.4.1 Studies on microstructure and chemical composition 
X-ray diffraction analysis of β-TCP powder and GCT scaffold were performed with a 
Panalytical (USA) model operated at 40Kv and 40 mA using Cu Kα radiation. The detailed 
procedure was mentioned in Chapter4 in section 4.4.1. 
Microstructure of the fabricated gel/chitosan/β-TCP scaffolds was observed by a Field 
emission scanning electron microscope (FEI Nova Nano, Nederland) operated at an 
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accelerating voltage of 15 kV. The detailed procedure was mentioned in Chapter4 in section 
4.4.6. 
6.2.4.2 Porosity measurement of the scaffold 
The porosity value of the prepared composite scaffolds was measured by using Archimedes 
principle, using xylene as liquid media. The detailed procedure was mentioned in Chapter4 in 
section 4.4.7. The characteristic pore size distribution was evaluated using mercury (Hg) 
porosimetry. The detailed procedure was mentioned in Chapter4 in section 4.4.8. 
6.2.4.3 Mechanical Properties of Gelatin /Chitosan /TCP Hybrid Scaffolds 
Compressive strength of the GCT composite scaffolds (sample with 22 mm in hight and 5mm 
in diameter) was measured using a Universal Testing Machine (Tinius Olsen, UK) equipped 
with a load cell of 1 KN at a constant rate of 1 mm min-1 [28]. The detailed procedure was 
mentioned in Chapter4 in section 4.4.9. 
6.2.4.4 Mineralization behaviour of GCT scaffold  
The ability to form apatite when immersed into simulated body fluid (SBF) is an index of 
biocompatibility exhibited by the GCT scaffold. The detailed procedure was mentioned in 
Chapter4 in section 4.4.11.  
6.2.4.5 Degradation of scaffolds 
The degradation of the scaffolds was studied by placing them in phosphate buffer saline 
(PBS) at 37˚C for up to 28 days. The detailed procedure was mentioned in Chapter4 in 
section 4.4.12. 
6.2.4.6 In vitro cell culture 
6.2.4.6.1 Attachment and morphology of cell on GCB composite scaffolds 
Human Umbelical Chord Mesehenchymal stem cells (MSCs) were grown in a Dulbecco's 
modified Eagle's medium (DMEM; Sigma-Aldrich, UK) supplemented with 10% fetal bovine 
serum (FBS; Sigma-Aldrich, UK) and 100 U/mL penicillin–streptomycin. The detailed 
procedure was mentioned in Chapter4 in section 4.4.13.3. 
 6.2.4.6.2 Proliferation Assays 
Cell viability of MSCs cultured onto the GCT scaffolds were determined after performing [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. The detailed 
procedure was mentioned in Chapter4 in section 4.4.13.4. 
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6.2.4.6.3 Inmunofluorescent imaging of cell markers: osteocalcin and RUN-X2 
The expression of RunX2 and Osteocalcin, an osteogenic marker on GCT scaffold was 
examined using immunocytochemistry. The detailed procedure was mentioned in Chapter4 in 
section 4.4.13.5. 
6.2.4.7 In vivo experiment 
6.2.4.7.1 Animal used in the experiment 
In this study we aimed to assess preliminary biocompatibility in vivo using a skin defect 
model in the back skin of Albino white mouse (2-2.5kg) over a 8 week period. The study was 
in compliance with the standards of the Institutional Animal Ethics Committee of the West 
Bengal University of Animal and Fishery Sciences, India. Each implant scaffold had the 
dimensions of 1cm diameter and 3mm in hight , prepared of 30 wt.%  TCP  in cross-linked 
gelatin-chitosan matrix(GCT30). Scaffolds contained pores in the range of 100–200 μm. 
Before implantation, the cylindrical GCT composite scaffolds were cut into 6-mm-length 
sections and sterilized by exposure to 15 KGy of γ radiation and kept in a vaccum desiccator 
until use.  
6.2.4.7.2 Surgical procedure and implant retrieval 
The animal experiments were performed following an ethical committee approved 
protocol in West Bengal University of Animal and Fishery Sciences (WBUAFS), West 
Bengal, India. Mouse were anesthetized with isoflurane (20mg/kg body weight) in O2, their 
backs shaved with an electric hair trimmer, injected with 100 μL bupivicaine (0.25% in 
sterile saline), and cleaned with an antiseptic lotion. Implant scaffolds were washed in sterile 
saline then inserted into 1 cm longitudinal incisions and then the wound was closed with 3–4 
skin clips. After surgery, animals were postoperatively cared for in an oxygen-rich chamber 
until fully conscious then returned to their single-housing cages. At the end of each 
experiment (2,4,8 weeks), mouse were anesthetized with isofluorane in O2 and euthanized 
with increasing CO2. Each scaffold was removed, trimmed of connective tissue, washed in 
PBS, and fixed for 1 hour in 10% formalin.  
 
6.2.4.7.3 Histological assessment 
Hematoxylin and eosin stain (H&E stain or HE stain) is one of the principal stains in 
histology. It is the most widely used stain in medical diagnosis and is often the gold standard. 
The staining method involves application of hemalum, a complex formed from aluminium 
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ions and hematein (an oxidation product of haematoxylin). Hemalum colours nuclei of cells 
(and a few other objects, such as keratohyalin granules and calcified material) blue. The 
nuclear staining is followed by counterstaining with an aqueous or alcoholic solution of eosin 
Y, which colours eosinophilic structures in various shades of red, pink and orange. For 
histological analysis, scaffold specimens from the bottom of the original skin defect were 
collected, washed thoroughly with normal saline and were immediately fixed in 10% 
formalin for 7 days, followed by fixation with 4% paraformaldehyde. Finally, the samples 
were embedded in paraffin wax. 4 mm sections were prepared and stained with haematoxylin 
and eosin to assess the cellular response of the host skin to the implants.  
6.3 Statistical Analysis 
Quantitative data were presented as mean ± standard deviation (SD). The two-tailed 
Student’s T-test (T-test) was employed to obtain p values, which determined the level of 
significance of the data. Difference between groups were statistically significant if p < 0.05 
and highly significant if p < 0.01. 
 
6.4. Results and Discussion 
6.4.1 Particle size and phase analysis of β−TCP powder 
The XRD patterns of β-TCP powders matched the JCPDS card no. 09-0169, with two intense 
diffraction peaks detected between 2ϴ = 25º-35º, corresponding to the (214) and (0210) 
crystal planes, respectively [289]. Only characteristic peaks of pure β-TCP powder were 
indexed in Figure.6.2, suggesting that the synthesized powder was pure β-TCP with hardly 
presence of any other secondary phase. SEM examination clearly revealed the morphology of 
β-TCP powder (Figure.6.3 (a)), having spherical shape with an average particle size varying 
between 70-100 nm, which is corroborated well with the particle size data obtained from 
DLS measurement (Figure 6.3 (c)). The Ca/P ratio of as synthesized β-TCP powder was 1.5, 
as determined using EDX analysis (Figure.6.3 (b)).  
Figure.6.3 (d) shows the crystal structure of synthesized β-TCP nanoparticle. Particle size 
measurement using FESEM and DLS was little bit higher compared to TEM measurement, 
which was the result of agglomeration of nano-particle Figure 6.3 (e) shows the HRTEM 
image of crystal planes of (0210) of crystallized β-TCP nanopowders. 
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Figure.6.2. XRD plot of synthesized β-TCP powder (JCPDS file # 09-0169).  
 
 
 
 
 
 
 
 
Figure.6.3. β-TCP nanoparticles prepared using co-precipitation method (a) FESEM image. (b) EDX 
analysis (c) DLS measurement (d) Bright field TEM image (e) HRTEM analysis. 
6.4.2 XRD analysis of GCT composite scaffold  
Figure.6.4 shows the XRD diffraction patterns of pure Chitosan, Gelatin, β-TCP, and GCT 
nanocomposites scaffold. Chitosan was identified with a characteristic peak at 2θ= 19.5. 
Gelatin showed a large amorphous hump between 2θ= 20-25 [290]. In nano-composites, the 
chitosan and gelatin peaks were subdued as compared to much highly crystalline β-TCP 
peaks. The slightly less crystalline nature of GCT 30 composite scaffold as compared to β - 
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TCP nanoparticle was due to the presence of amorphous gelatin-chitosan phase in the 
scaffold as in Figure. 4 (d). 
 
 
 
 
 
 
 
 
Figure.6.4. XRD pattern of GCT scaffold (a) β-TCP, (b) gelatin, (c) Chitosan, (d) gelatin/chitosan/β-TCP. 
6.4.3 FTIR study of composite scaffold 
The chemical structure of β-TCP, chitosan, Gel-CS, and Gel-CS-β-TCP composite scaffold 
was investigated using FTIR spectroscopy, as shown in Figure.6.5. Apart from peaks at 1045, 
972, and 606 cm-1corresponding to phosphate group , the absorption band observed at 553 
and 1119 cm-1 were due to characteristic peaks of PO4- in β-TCP [291]. The characteristic 
peaks of chitosan observed at 1647 and 1597 cm-1, assigned to amide I(C=O) and -NH2 
deformation, respectively [35]. Amino band at 1541 cm-1 and carbonyl peak at 1647 cm-1 
correspond to the characteristic peaks of ampholytic gelatin [36]. The appearance of 1552 and 
1655 cm-1 in scaffold attributed to the characteristics of imine C=N group, indicate the 
crosslinking reactions between amino groups of chitosan and gelatin with aldehyde groups of 
glutaraldehyde. The spectrum of chitosan– gelatin hybrid polymer network (CS–Gel HPN) in 
the composite scaffold was confirmed by the existence of the peak at 1552 and 1655 cm-1. 
These peaks were also significant even when β-TCP fraction reached up to 30 wt%. The band 
at 1330 cm-1 confirmed the chemical interaction between Ca+ ion in β-TCP and COO- group 
in gelatin. This reaction can be observed in Figure.6.1. Further, the gelatin-chitosan network 
not only serves as a matrix, but also anchoring site for β-TCP particles which in turn 
enhances the stability of the composite scaffold in the water based environment [292]. 
10 20 30 40 50 60
  
(a)TCP
 
(c)Chitosan
 
(b)gelatin
 
2θ
(d) gelatin/chitosan/TCP
Inte
nsi
ty (
a.u
)
103 
 
 
Chapter 6 GCT Composite Scaffold 
 
 
 
 
 
 
 
Figure.6.5. FTIR spectra of β-TCP, Chitosan, Gelatin-chitosan and (GCT 10) composite scaffold. 
6.4.4 SEM observation of composite scaffold morphology 
For successful diffusion of nutrients and oxygen a scaffold must have interconnected micro 
amd macroporosity [293]. Furthermore, recent studies show that multi-scale porosities in 
scaffold can perform better than only macro porosity [293]. Figure.6.6 shows a representative 
cross-sectional structure of Gel-CS-TCP composite scaffolds with varying concentrations of 
the composite slurry. We have demonstrated that composition of the scaffold had a 
significant effect (P < 0.05) on its mean pore size in the microstructure, and smaller pore 
structures resulted with an increase in β-TCP content (Table.6.2). The freeze dried porous 
scaffolds incorporating β-TCP up to 30 wt% showed to be well-shaped with a relatively 
uniform distribution of macropores, which was severely hampered with the incorporation of 
β-TCP above 30 wt%. The viscosity of composite slurry significantly affects the pore 
structure during the freeze drying process [294]. As we go upto 30 wt% of β-TCP content in 
the composite slurry, a higher force was necessary for migration of water molecules. This 
high viscosity resulting in reduced size of inters trapped ice blocks and smaller pores were 
formed during freeze drying in the composite scaffold. The mean pore size decreased from > 
200 µm in Figure.6.6 (b) to 120μm Figure.6.6 (e). This content of β-TCP scaffold was 
considered to be the optimum for the fabrication of GCT nano-composite scaffolds. All 
scaffolds contained a high amount of total porosity of greater than 82%, which is known to be 
beneficial for cell infiltration and survival [295]. Keeping this in view, the average pore size 
of the GCT30 scaffold in the range of 120 µm was considered to be beneficial for bone tissue 
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engineering. Furthermore, it was reported that calcium from TCP has the ability to induce 
MSC’s differentiation toward osteogenesis [296]. 
 
 Figure.6.6. FESEM image of GCT composite scaffolds with different fraction of β-TCP (a) 0 wet% (b)  
10 wt% (c) 20 wt% (d) 30% . scale bar designated as 500 µm. 
Table.6.2. Pore diameter and porosity of GCT composite scaffold. 
Sample  
abbreviation 
β-TCP 
(%) 
Avg Pore Diameter  
Porosity(%) 
GCT 0 0 300 ± 10.2 88 ± 5.6 
GCT 10 10 197.87 ± 12.4 85 ± 7.3 
GCT 20 20 168.38 ± 11.2 83 ± 8.4 
GCT 30 30 120 ± 18.6 80 ± 7.3 
 
6.4.5 Mechanical properties of scaffolds 
The mechanical properties obtained from compression tests of both gelatin-chitosan and 
gelatin-chitosan-TCP composite scaffold are shown in Figure.6.7. The result shows that a 
maximum average compressive strength of 2.45 MPa registered by GCT 30 scaffold as 
compared to a paltry of 1 MPa of average compressive strength in non-βTCP based polymer 
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scaffold (Figure.6.7). However, any attempt to increase the β-TCP nano-particle content to 
higher values than 30 wt% cause a decrease in strength. In fact, compressive strength of 
spongy bone fall in the range between  1-7 MPa [297]. All of the scaffolds showed average 
porosity between 80 to 88% .GCT0 showed the highest average porosity of 88% and the 
lowest average porosity of 80% was exhibited by GCT 30. There is an inverse relationship 
between the nano powder content and percentage of porosity in scaffold. As it is summarized 
in Table.6.3, GCT 30 scaffold having a lower porosity and pore size exhibited the highest 
compressive strength. β- TCP reinforcement makes a significant improvement in 
compressive mechanical properties of the scaffolds. From the results it is clear that the 
mechanical property improved significantly with β-TCP nanoparticles loading upto 30 wt% 
in the scaffold. Addition of β-TCP particles in the composite slurry by more than 30 wt% 
caused enormous nanoparticle agglomeration and caused inhomogeneity in the scaffold 
matrix. Though, agglomerated particles broke down under application of compressive load to 
scaffold, broken agglomerates acted as stress-concentrating points leading to formation of 
macro cracks, reflected in an enormous decrease in the mechanical properties of the nano-
composite scaffold (Figure.6.6 (f)). In terms of compressive strength, GCT 30 scaffold 
appeared to be the best among the prepared scaffolds for meeting the criteria of adequate 
compressive strength for bone tissue regeneration. 
 
 
 
 
Figure.6.7. Compressive strength of composite scaffold with variation in TCP content. 
Table.6.3. Summary of porosity and mechanical property of GCT scaffold. 
Sample Compressive strength 
(MPa) 
Porosity (%) 
 
GCT0 1±4.3 88 ± 5.6 
GCT10 1.8±2.25 85 ± 7.3 
GCT20 1.96±2.1 82 ± 8.4 
GCT30 2.45±1.95 83 ± 7.3 
GCT40 1.3±2.35           82 ± 9.2 
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6.4.6. Mineralization ability of GCT 30 composite scaffold 
Mineralization ability of scaffold in SBF has been regarded as one of the key evidences of 
bioactivity for bone scaffold. It has been reported scaffold which support osteoblast cell 
growth, proliferation and differentiation in vitro and in vivo exhibits good mineralization 
behaviour in physiological environment. Highly dense bone-like carbonated apatite layer 
formation on SBF treated GCT30 scaffold (Figure.6.8) indicates that the prepared scaffolds 
are not only biocompatible, but also bioactive. 
Figure.6.8. SEM micrographs of carbonated apatite layer formed on the surface of GCT30composite 
scaffold immersed in SBF for 7 days. 
6.4.7 Biodegradation behaviour 
As the tissue engineering aims at the regeneration of new tissues, the scaffolds has to be 
degraded with the formation of new bone tissues. The degradation behaviour of biomaterials 
in physiological environments plays an important role in the engineering process of a new 
tissue. In our work, the in vitro biodegradation performance of GCT scaffolds in PBS 
containing lysozyme was investigated. The degradation procedure involves hydrolyzation of 
gelatin and enzymatic degradation of chitosan. The lysozyme present in internal body fluids 
can hydrolyse the β-1, 4 N-acetyl-glucosamine groups of chitosan macromolecule[298]. The 
large quantity of hydrophilic amino and carboxyl groups exist in gelatin, makes it degrade 
quickly.  
The scaffold degradation provided a progressive weight loss with a degradation rate almost 
constant over time, up to day 24. Figure.6.9 shows the effect of β-TCP addition on GCT 
scaffold after in-vitro degradation in PBS at 37oC for 4 weeks. The degradation percentage 
dramatically decreased with addition β-TCP upto 30 wt%. It is reasonable to think that the 
strong interaction between gelatin macromolecular chains and β-TCP consumed some 
hydrophilic groups and decreased the solvent uptake, which protects the macromolecules 
from hydrolyzing. Moreover, the presence of β-TCP also serves as physical crosslinking 
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sites, which enhanced the stability of the network. All of the above results reveal that the 
degradation rate may be controlled by adjusting the β-TCP contents in the scaffold. 
 
 
 
 
 
 
Figure.6.9. Gelatin-Chitosan–β-TCP scaffold degradation with varying percentage of β-TCP 
(0%,10%,20%,30%). The experiments were carried out for 30 days. Data were expressed as mean of 
three experiments ± SD (∗P < 0.05). 
6.4.8 Cell morphology on GCT scaffold 
It is well known that surface characteristic of materials play a crucial part for bone 
regeneration by supporting adhesion, proliferation and differentiation of bone cells [51]. We 
hypothesized that β-TCP particle with Gelatin-Chitosan scaffold would encourage the 
osteogenic capacity of MSC pre-osteoblast cells [299]. Such verification was performed 
based on GCT scaffolds prepared under Freeze drying process with 30% TCP loading, in 
comparison with the neat Gelatin-chitosan scaffold. Figure.6.10(a) shows pre-osteoblast 
morphology and bone cell– material interactions for cell adhesion, growth, and differentiation 
on a neat GC scaffold after 14 days  and GCT 30 scaffold (Figure.6.10 (b) to (d)) after 3, 7, 
and 14 days of culture respectively. Cell attachment through small micro extensions onto the 
GC surface was evident after 14 days of the MSC culture (Figure.6.10 (a)). After day 7, cell 
density was higher on the surface of GCT 30 scaffold (Figure.6.10 (c)) as compared to that on 
day 3 [Figure 6.10 (b)]. After day 14, the cells displayed elongated morphology with 
numerous lamellipodia and filopodia extensions to attach and migrate onto the GCT 30 
surface as shown in [Figure.6.10 (d)]. The cells in β-TCP embedded matrix appeared to cover 
and spread on the GCT 30 surface better than those in GC surface [Figure.6.10 (a, d)]. Some 
researchers stated the significant role of Ca2+ in the extracellular signalling by membrane 
mediated ionic transfer [300]. These facts implied that composite scaffolds would regulate 
osteoblastic differentiation in part triggered by bioresorbable β-TCP that releases Ca2+ in cell 
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culture medium. All the results suggest that MSC cells were able to grow and proliferate well 
on GCT 30 scaffold as compared to GC scaffold, which is a good sign for exhibiting 
enhanced bioactivity. 
 
Figure.6.10. FESEM images showing MSCs attached on (a) GC control for 14 days and on GCT 30 
scaffold for (b) 3 day, (c) 7 days, and (d) 14 days of cell culture. 
6.4.9 Cell Proliferation/MTT assay 
MSC’s proliferation on GCT 0 and GCT 30 scaffolds up to 14 days of culture was studied 
through MTT assay treating cultured MSC’s on sole tissue culture plate as a positive control. 
Compared with MSCs cultured onto GCT0, viable cell density on GCT30 was higher at all 
periods of cell culture, as shown in Figure.6.11. The cell density on GCT30 scaffold was 
significantly higher on day 1 (# p < 0.05) and on day 7 (# p < 0.05) than GCT0. Furthermore, 
a significant level of increase in proliferation (# p < 0.05) was seen in GCT 30 on day 14, 
(a) (b) 
(c) (d) 
     20 µm      20 µm 
     20 µm      20 µm 
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showing that the β-TCP with Gelatin-chitosan assisted in increased proliferation of the 
cultured MSCs. 
 
Figure.6.11. MTT assay for cell proliferation study in positive control, GCT0 and GCT 30 scaffold using 
human Mesenchymal stem cell on days 1, 7, and 14. * indicates significant difference at p ≤ 0.05. # 
indicates significant difference at p ≤ 0.05. 
6.4.10 Study of MSC’s differentiation into osteoblast onto GCT30 scaffold 
The differentiation of MSCs toward the osteogenic lineage was ultimately demonstrated by 
the expression of genes that are usually associated with the mineralization during 
osteogenesis, such as transcription factor Runx2, and the matrix protein osteocalcin (OCN).  
Figure 6.12 shows the confocal microscopic images of expression of osteocalcin from MSCs 
cultured on GCT0 and GCT 30 scaffolds after 7 and 14 days of cell culture. Osetocalcin 
expression became gradually higher on both GCT0 and GCT 30 scaffolds with progress in 
cell culture periods from 7 to 14 days as suggesting the fact that both the scaffolds supported 
differentiation of MSCs into osteoblast and mineralization of extracellular matrix for 
osteogenesis. OCN expression was found to be higher on GCT 30 as compared to GCT 0 
[Figure 6.12 (a), (c)]. With increase in cell culture period upto 14 days. Osteocalcin 
expression became even higher on GCT 30 as compared to GCT0 as shown in Figure 6.12 
[(b), (d)]. Our results showed that differentiated MSCs produced higher OCN expression on 
GCT 30 than cells on GCT 0. The explanation for these phenomena lay in increasing ability 
of protein adsorption and continuous release of Ca2+ into medium from GCT30 composite 
scaffold as compared to GCT0. The protein affinity and bioresorbability of β-TCP 
nanoparticles present in GCT 30 helped in better mineralization of bone extracellular matrix 
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and hence triggered differentiation of MSCs into osteoblast to higher degree. Our result 
suggests that MSC’s cultured onto GCT30 scaffold were well committed to osteogenic 
lineage. 
 
Figure.6.12. Representative immunofluorescent images for osteocalcin expression of MSCs in the GCT0 
scaffolds after (a) 7 days (b) 14 days of cell culture and cells in the GCT-30 scaffolds after (c) 7 days (d) 14 
days of cell culture. Cell nucleus stained with DAPI (blue), and Osteocalcin (Green) . 
6.4.11 In vivo animal experiment 
Histologically, after 2 weeks of implantation into mouse skin, the open pore morphology of 
the GCT 30 scaffold was maintained, but the scaffold integrity was worse [Figure.6.13 (a)]. 
The infiltrating cells began to change into lymphocytes and plasma cells, which was the 
indication of first phase of wound healing (Figure.6.13 (a1)). This is also reported as the 
initiation of minimal chronic inflammation [53]. 
At 4th week [Figure.6.13 (b)] cellular infiltration had clearly decreased with formation of 
ECM throughout the composite scaffold. Blood capillaries began to appear in between almost 
disintegrated scaffold structure and scaffold interspaces were fully filled with ECM of 
fibroblast [Figure.6.13 (b1)]. 
(a) (b) 
(c) (d) 
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As can be seen in Figure.6.13 (c), at 8th week after implantation, cellular infiltration had 
gradually decreased as the vascular structure was prominent inside composite scaffold 
[Figure.6.13 (c1)]. The scaffold structure was completely disintegrated and scaffold remnants 
were scattered in the surroundings. In addition, fibroblast can be seen in the interspace region 
throughout the composite scaffold. These findings indicate that GCT30 composite scaffolds 
showed excellent biocompatibility, tissue repair ability, and controlled biodegradability, 
which is a good sign of exhibiting its efficacy in bone tissue regeneration. 
 
Figure.6.13. Histological images (× 10) of material degradation (a) 2 week (b) 4 week (c) 8 week after 
implantation. Magnification of image(×100) shown tissue response (a1) 2 week (b1) 4 week (c1) 8 week 
after implantation. M-material, v- blood vessel, F- fibroblast cells, +- Inflamatory cells. 
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6.5 Conclusions 
In this study, Gelatin/Chitosan/β-TCP nano-composite scaffolds were successfully fabricated 
using the thermally induced phase separation method. Both pore size and mechanical 
properties of the nano-composite scaffold could be tailored by changing the β-TCP content in 
the scaffold. Increasing β-TCP content into the chitosan/Gelatin(CG) matrix significantly 
improved mechanical properties and upto 30 wt% addition of β-TCP resulted in a higher 
compressive strength in scaffolds. The GCT30 scaffolds showed 1.5 times higher 
compressive yield strength than those exhibited by GC scaffolds and eventually match with 
the lower range mechanical properties of cancellous bone. Furthermore, GCT30 scaffolds 
exhibited good biocompatibility and promoted better cell proliferation and MSC’s 
differentiation into osteoblast than only neat Gelatin-chitosan scaffold up to 14 days of cell 
culture. Also, GCT30 composite scaffold was found to promote new blood vessels formation 
and skin tissue regeneration in-vivo. From the experiment it was found that GCT30 scaffold 
was highly biocompatible and non-toxic that rendered hardly any justification to carry out 
same test with other compositions of the prepared scaffolds. The scarcity of animals to 
perform in vivo test and limited resources of scaffold material also compelled us to restrict 
the number of such tests. 
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Chapter 7 Comparative Study 
Abstract 
The aim of this work is to compare the effect of hydroxyapatite-chitosan (HAp), β-TCP and 
58sbioactiveglass nanoparticles in a gelatin-chitosan based composite scaffold aimed to 
regenerate bone at defect site. Gelatin-chitosan based scaffolds made of gelatin-chitosan(GC) 
and GC composites containing 30 wt% HAp, β-TCP and 58s bioactiveglass nanoparticles 
were fabricated using freeze drying technique. The porosity, protein absorption capacity, 
biodegradation and compressive strength of the all the prepared scaffolds were evaluated. 
The average pore pore size of all the prepared composite scaffolds was in the range between 
90-125 µm. Most frequent pore size in GCT 30 scaffold was the highest of 120 µm whereas 
that for GCH 30 was the lowest of 96 µm as suggested by Hg porosimetry analysis. GCH30 
scaffolds showed the highest average compressive strength of 3.45 MPa with high degree 
interconnected porosity appropriate for cellular colonization. Biodegradation ability of all the 
composite scaffold did not vary too much, but certainly lower than neat gelatin-chitosan(GC) 
scaffold. BSA protein adsorption was found to be the maximum of 24 mg/cc onto GCB 30 
scaffold whereas a lowest of 13 mg/cc adsorption was shown by neat gelatin-chitosan 
scaffold. To study the effect of different bioceramics phases on MSCs differentiation, 
scaffolds were cell cultured for up to 14 days in osteogenic medium. GCB 30 scaffold 
showed higher capacity to proliferate MSCs cultured onto it as compared to other composite 
scaffolds. Degree of differentiation of MSCs into osteoblast was higher in GCB 30 scaffolds 
than in the GCH 30 and GCT 30 composite scaffold as evident from higher amount of 
RUNX2 and Osteocalcin expression in the former upto 14 days of cell culture. Inclusion of 
58s bioactive glass particles showed positive effects on cell differentiation. In coherence with 
the in vitro appearance, histomorphometric analysis and flurochrome study in a rabbit tibia 
model showed a significantly greater amount of new bone formation in GCB30 compared to 
other composite scaffolds. The results demonstrated that the prepared GCB30 scaffold could 
be a better candidate as bone substitute material for its higher bioactivity in bone tissue 
regeneration. 
7.1 Introduction 
Bone is a tissue with a high regeneration capacity. In most cases fractures and small defects 
heal alone without any surgical intervention. But in the case of osteopenia or osteoporosis 
replacement and regeneration of large defect bone is a major challenge in orthopaedic 
surgery. The preferred clinical option like autograft (patient own tissue) and allografts (tissue 
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from another patient) suffer from many drawbacks including limited supply and risk of 
disease transmission [270]. For these reasons bone substitutes have been developed out of 
synthetic biomaterials. The final objective is the design of a product that induces 
differentiation and the integration of the construct into the surrounding bone with sufficient 
mechanical strength which can be used as bone graft materials. The successful engineering of 
damaged tissue depends on the control of interactions between cells and scaffold, and 
therefore it is critical to develop an ideal scaffold to direct desirable cell response. Bone 
tissue engineering has focused mainly on bioceramics and polymers to reach these aims. 
Bone substitutes based on bioceramics use a wide range of inorganic materials with 
composition similar to bone [274].  
Hydroxyapatite, a bioceramics from synthetic or natural origin, has been reported to induce 
osteoblast differentiation [69]. The synthetic hydroxyapatite has a stoichiometric composition 
(Ca10(PO4)6(OH)2) and high crystallinity, in contrast to the biological apatites, having very 
low crystal size with variable composition and generally calcium-deficient in nature [301]. 
As a result, in vivo resorption rate for synthetic HAp is longer than many other calcium 
phosphates [302].  
Tricalcium phosphate implants have been used for two decades as synthetic bone void fillers 
in orthopaedic and dental applications [303]. The small particle size and interconnected 
microporosity are believed to improve osteoconductive properties and promote timely 
resorption combined with the process of remodelling [304]. The 58Sbioactiveglass (58% 
SiO2, 33%CaO, and 9% P2O5) is a bioactive glass based on the three dimensional silica 
network. Through degradation reactions on the surface of bioactive glass, ions are released to 
the medium. These ions have been seen to mediate positive effects on osteoblast proliferation 
and collagen secretion [305]. The biopolymers used in bone tissue engineering can be either 
of natural origin (such as proteins as collagen, or polysaccharides as hyaluronic acid, chitosan 
and others) or synthetic origin (biodegradable polyesters, polyfumarates or poly-a-
hydroxyesters and others). The principal deficiency of synthetic polymers for tissue 
engineering is their low intrinsic bioactivity[306]. On the other hand, the principal advantage 
of natural polymers is their good biological properties, close to those of natural tissues. Using 
composite scaffolds is a great approach for designing bone substitutes because composites 
combine the advantages of two biomaterials classes [307]. As a matter of fact, bone is a 
composite, and its outstanding biological and mechanical properties are due to its composite 
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nature formed by an organic protein phase (collagen and other bone proteins) in which 
nanometric particles of mineral phase (apatite) are embedded [308].  
In this work, we use chitosan because of its natural nature (obtained by alkaline deacetylation 
of chitin), non-toxicity, biocompatibility, and biodegradability. Due to its desired properties, 
chitosan-based materials are widely considered to fabricate scaffolds for tissue engineering 
and regenerative medicine[309]. Many composites of HAp and Bioactive glass mixed with 
either natural or synthetic polymers have been studied [186]. Osteoconductivity of HAp is 
implicated in its direct interaction with natural bone tissues. In the comparative study 
between porous HAp, β-TCP ceramics, former showed greater potential for promoting the 
differentiation of osteoblasts than β-TCP [310]. Other studies show that for scaffold having 
5% bioactive glass reinforced PCL enhances the cell adhesion compared to pure PCL 
scaffold [311]. 
To the authors’ knowledge no study has yet been carried out to investigate mechanical 
mechanical and biological performance of GC scaffold containing either HAp or β-TCP or 
BG as reinforced nano particulate in macroporous structure of scaffolds. The objective of this 
study was to develop three series of GC composite scaffolds with 30% (w/w) 
hydroxyapatite/58s Bioglass/β-TCP using a mixed technique of  thermal induced phase 
Separation (TIPS) followed by freeze drying. Physicochemical, mechanical, in vitro and in 
vivo bioactivities of compositionally different three composite scaffolds were compared in a 
sequential manner to understand their efficacies in bone tissue engineering. 
7.2 Methods 
7.2.1 Physicochemical Characterization 
7.2.1.1 Studies on microstructure and chemical composition 
X-ray diffraction analysis of GCH30, GCΒ30 and GCT30 scaffold were performed with a 
Panalytical (USA) model operated at 40Kv and 40 mA using Cu Kα radiation. The detailed 
procedure was mentioned in Chapter4 in section 4.4.1. 
Microstructure of the fabricated GCH30, GCΒ30 and GCT30scaffolds was observed by a 
Field emission scanning electron microscope (FEI Nova Nano, Nederland) operated at an 
accelerating voltage of 15 kV. The detailed procedure was mentioned in Chapter4 in section 
4.4.6.  
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7.2.1.2 Porosity measurement of the scaffold 
The porosity value of the prepared GCH 30, GCΒ 30 and GCT 30 composite scaffolds was 
measured by using Archimedes principle, using xylene as liquid media. The detailed 
procedure was mentioned in Chapter4 in section 4.4.7. 
7.2.1.3 Mechanical Properties of Gelatin /Chitosan /TCP hybrid Scaffolds 
Compressive strength of the GCH30, GCΒ30 and GCT30 composite scaffolds (sample with 
22 mm in hight and 5mm in diameter) was measured using a Universal Testing Machine 
(Tinius Olsen, UK) equipped with a load cell of 1 KN at a constant rate of 1 mm min-1 [28]. 
The detailed procedure was mentioned in Chapter4 in section 4.4.9. 
7.2.1.4 Degradation of scaffolds 
The degradation of the GCH30, GCΒ30 and GCT30 scaffolds was studied by placing them in 
phosphate buffer saline (PBS) at 37˚C for up to 28 days. The detailed procedure was 
mentioned in Chapter4 in section 4.4.12. 
7.2.1.5. In vitro cell culture 
7.2.1.5.1 Attachment and morphology of cell on GCB composite scaffolds 
Human Umbelical Chord Mesehenchymal stem cells (MSCs) were grown in a Dulbecco's 
modified Eagle's medium (DMEM; Sigma-Aldrich, UK) supplemented with 10% fetal bovine 
serum (FBS; Sigma-Aldrich, UK) and 100 U/mL penicillin–streptomycin. The detailed 
procedure was mentioned in Chapter4 in section 4.4.13.3. 
 7.2.1.5.2 Proliferation Assays 
Cell viability of MSCs cultured onto the GCH 30, GCΒ 30 and GCT 30 scaffolds were 
determined after performing [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
(MTT) assay. The detailed procedure was mentioned in Chapter4 in section 4.4.13.4. 
7.2.1.5.3 Inmunofluorescent imaging of cell markers: osteocalcin and RUN-X2 
The expression of RunX2 and Osteocalcin, an osteogenic marker on GCH30, GCΒ30 and 
GCT30 scaffold was examined using immunocytochemistry. The detailed procedure was 
mentioned in Chapter4 in section 4.4.13.5. 
7.2.2 BSA protein adsorption on GCH 30, GCΒ 30 and GCT 30 composite scaffold  
 Bovine serum albumin (BSA) was selected for the protein adsorption study. Bicinchoninic 
acid (BCA) assay was used to determine the amount of adsorbed protein on the scaffold. The 
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three different small pieces of composite scaffolds of 12 mm in height and 5 mm in diameter 
was sliced down by steel blade and immersed in 10 ml BSA solution of 5 mg/ml initial 
concentration and kept in an incubator at 37 oC for different time duration from 6 h to 144 
hour. The supernatant solutions were collected from individual solution through centrifuge at 
100 rpm for 10min. The adsorbed BSA protein amount was quantified by taking 0.1 ml of 
supernatant from each specimen and mixed it with 2 ml of bicinchoninic acid solution 
(Thermo Pierce, Bicinchoninic acid protein assay kit). UV-vis spectrophotometer (Perkin 
Elmer, Lambada 35) at 562 nm was used to obtain absorbance peaks and to estimate BSA 
concentration with the help of a predetermined standard BSA concentration vs intensity 
calibration curve. The estimated concentrations of protein were the average of protein 
concentration from three wells. The adsorbed amount of protein on the 3-D porous scaffolds 
was determined by subtracting the amount of proteins left in the supernatant solution after 
adsorption from the amount of protein in starting BSA solution under the same condition. 
7.2.3 Micro-architectural analysis of composite scaffold 
 X-ray microtomographic (µ-CT) systems have been widely used as a non-destructive 
technique to study or characterize microstructural morphology of various biomaterials [312, 
313]. For tomography experiment the detector was placed at 450 mm away from the sample 
stage. The sample was rotated in steps of (0.2˚) and was exposed to a beam energy (E = 28 
keV) for a duration of 5 sec for all the samples. Dark field and flat field corrections were 
performed to limit CCD and beam related artifacts during reconstruction.  The maximum size 
of the sample was 12mm. The 2-D images generated by X-ray were recorded from a slice to 
another slice with a rotation of 0.4° by rotating the sample through 180°. The scanned images 
were acquired at a pixel size of 11.4 μm. Total acquisition time was approximately 20 min 
and more than 900 2-D images were recorded for each sample. The images of 3-D 
microstructures were produced with suitable software [314]. Interconnectivity was calculated 
as follows: 
 
Interconnectivity = 100(V − Vshrink−wrap)(V − Vm)−1 
 
where V is the total volume of the VOI, Vshrink−wrap is the VOI volume after shrink-wrap 
processing, and Vm is the volume of the material.[319] 
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7.2.4 Expression of osteogenic specific genes  
Semi-quantitative RT-PCR was performed to assess the expression of osteoblast related 
markers at mRNA level for cells cultured upto 14 days. Primer sequences used for the study 
are shown in Table 7.1. For RT-PCR analysis, the total cellular RNA from osteoblasts 
(differentiated from hMSCs) was extracted by TRIzol. Synthesis of cDNA was carried out 
using first strand cDNA synthesis kit following the manufacturer’s protocol. The synthesized 
cDNA was used as a template for the semi-quantitative RT-PCR following the procedure 
followed elsewhere [315]. The GAPDH gene was used as a housekeeping gene for 
normalizing mRNA level of Col-1, RUNX2, OCN, OPN gene. The PCR reaction mixture 
consists of 1X PCR buffer, 50 mM mgCl2, 10 mM dNTPs, 0.2 μM of each primer, 1U Taq 
polymerase and autoclaved water. PCR chain reactions were performed at 94°C for 2 min, 35 
cycles at 96°C for 30s, 55–63°C for 45s, and 72°C for 45s and 72°C for 10 min. Finally, the 
amplified DNA fragments (PCR products) were subjected to electrophoresis on 1.5% agarose 
gel and the band intensity was analysed using Image J software for evaluating the relative 
expression of selected genes (BioRad, USA). 
Table.7.1. RT-PCR Primers used for expression of osteogenic specific genes. 
Gene Direction Primer Sequence 
Osteocalcin 
Forward 51- CCC AGG CGC TAC CTGTAT CAA-31 
Reverse 51- GGT CAG CCA ACT CGTCAC AGTC-31 
Osteopontin 
Forward 51-CATCTCAGAAGCAGAATCTCC-31 
Reverse 51-CCATAAACCACACTATCACCTC-31 
RUNX2 
Forward 51-TGGTTACTGTCATGGCGGGTA-31 
Reverse 51-TCTCAGATCGTTGAACCTTGCTA-31 
Col1 
Forward 51- GGCAATAGCAGGTTCACGTACA -31 
Reverse 51- CGATAACAGTCTTGCCCCACTT-31 
7.2.5 In-vivo animal study 
7.2.5.1. Animal experimentation 
 Animal experimentation was carried out following the procedures confirming to the 
standards of the institutions Animal ethical committee of the West Bengal University of 
Animal and Fishery Sciences, India. Eighteen clinically healthy adult Newzeland white 
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rabbits (12-15 months) of either sex, weighing 2.5-3 kg, were used in this study. They were 
randomly distributed into three groups of six animal each: Control (Group I) i.e gelatin-
chitosan(GC) scaffold, gelatin-chitosan-HAp (GCH 30) scaffold (Group II), gelatin-chitosan- 
TCP (GCT 30) scaffold (Group III) and gelatin-chitosan-bioactive glass (GCB 30) scaffold 
(Group IV).Prior to surgery, the rabbits were housed in individual cages in a humidity control 
room, given water ad libitum and were without restriction of movement. All surgeries were 
performed under standard anaesthesia. This 90 days study evaluated early stage in vivo 
osteogenesis and bone remodelling using a bone defect model in the proximal tibia of 
Newzeland white rabbit. 
7.2.5.2 Surgical procedure 
The animal experiments were performed following an ethical committee approved 
protocol in West Bengal University of Animal and Fishery Sciences (WBUAFS), West 
Bengal, India (E.C/180). Sixteen adult New Zealand White rabbits (1.5–2 kg) were 
randomized into four groups (n = 4), control group I (GC) and the test animals, group II 
(GCH 30), group III (GCT 30) and group IV (GCB 30) with bilateral implantation 
(Figure.7.1 (e)). 
Surgeries were performed under aseptic conditions and sedation by intramuscular injection of 
xylazine hydrochloride (5mg/kg) and ketamine hydrochloride at 25mg/kg body weight. A 
motorize drill was used to create 2×2×5 mm3 (Figure7.1 a-d) in the medial aspect of 
proximal Tibia (Figure.7.1.a) The implants were inserted in the defects and secured a position 
by suturing the muscle, subcutaneous tissue and skin in layers (Figure.7.1 c-d). Treated 
animals were daily administered with cefotaxime sodium (Mapra, India) at 20mg/kg body 
weight intramuscularly for 5 days at 12-hour interval and meloxicam at 0.2mL/kg body 
weight. Surgical wounds were inspected daily and appropriate wound care was taken. The 
operated animals were observed carefully upto 3 months postoperatively, to note any 
associated sign of local inflammatory reactions, fracture by visual or manual examinations. 
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Figure.7.1. Surgical placement of porous scaffold into Rabbit tibia. Digital image of sample used in in vivo 
experiment. 
7.2.5.3 Radiological study 
Sequential radiographs of the femur bone were recorded at regular intervals (days 0,1,2,3 
months postoperatively) in a medical diagnostic X ray machine (300 mA, M.E, X-Ray, India) 
to study the status of the implant and the degree of host bone –material interaction. 
 
7.2.5.4 Histology analysis 
The radiological results were further verified histological investigations of the operated sites 
in order to understand distribution and development of osseous tissue in-growth at the defect 
site. After sacrificing the animals at the end of 1,2 and 3 months post operatively, the bone 
specimen were collected , washed with normal saline, cut into thin sections containing the 
implant and preserved in 10% formalin. For histological analysis, decalcccified tissues(using 
Goodling and Stewart’s fluid) were stained with hematoxylene and eosin to observe the 
matrix formation in optical microscope. 
 
7.2.5.5 Fluorochrome labelling study  
Fluorochrome labelling analysis of the implanted bony sections was carried out using an 
Orthoplan microscope (Excitation filter, BP-400range, Leitz,,USA)to understand the new 
bone formation as well as the mineralization process. For this study oxytetracycline 
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dehydrate (OTC) (Pfizer India, India),a bone forming marker, was administered to each 
animal (intramuscularly at25mg/kg body weight) 25days before the sacrifice of 2 month 
samples i.e., on days35,36 and after a gap of 6 days on day43,44(2-6-2)post-operatively for 
double toning of the new bone. Again on days 65 and 66 and then on 71, 72 days, OTC was 
administered to each animal for 3 months’ sample. For the analysis, thin and un-decalcified 
sections were prepared from the implanted bone specimens which were observed under UV 
light. Data obtained was further taken in LeicaDM2000 Bright light phase contrast and 
fluorescence microscope including Leica Qwin software. In the said microscope, area of bone 
formation (golden yellow fluorescence) has been measured in mm2 and subsequently 
converted to percentage of bone formation and finally statistical analysis was carried out. 
 
7.2.5.6 ESEM analysis of implant material 
The radiological results were further verified by microscopic evidences using Environmental 
scanning electron microscope (ESEM, Quanta FEG 250, Nederland) investigations of the 
operated sites in order to understand the distribution and development of the osseous tissue 
in-growth at the defect site. For ESEM analysis, the wet samples were directly put into the 
ESEM chamber before imaging. 
 
7.3 Statistical Analysis 
Quantitative data were presented as mean ± standard deviation (SD). The two-tailed 
Student’s T-test (T-test) was employed to obtain p values, which determined the level of 
significance of the data. Difference between groups were statistically significant if p < 0.05 
and highly significant if p < 0.01. 
7.4 Results and Discussion 
7.4.1 X-Ray diffraction analysis 
Phase analysis of the prepared scaffolds was performed using XRD analysis as shown in 
Figure 7.2. Only characteristic peaks of GCT30 were indexed in Figure.7.2 (a), suggesting 
that the synthesized powder was β-TCP with hardly presence of any other secondary phase. 
The sharp peaks of (002) and (112) plane in GCH30 [Figure.7.2 (b)] confirmed that presence 
of phase pure hydroxyapatite in the fabricated GCH30 scaffold. The broad amorphous peaks 
of 58s bioactive glass confirmed that the synthesized scaffolds were predominantly 
amorphous [Figure.7.2(c)]. The characteristic diffraction peaks for both chitosan and gelatin 
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were suppressed by the huge amorphous peak of bioactive glass observed in the range 
between 2𝜃𝜃 equal to 20∘–40∘. It is clearly evident from figure.7.2 that composite scaffolds 
contain sharp peak of HAp in GCH30, β-TCP phase in GCT30 and a big amorphous hump of 
bioactive glass in GCB30, demonstrating the presence of respective bioceramics component 
in the scaffold. 
 
 
Figure.7.2. XRD pattern of composite scaffold (a) GCT30, (b) GCH30, (c) GCB30.prepared using freeze 
drying technique. 
7.4.2 FTIR analysis 
Figure7.3 shows the FTIR spectra of GCH 30, GCT 30, GCB 30 composite scaffolds to 
determine that the blended scaffolds were fabricated successfully. GCH 30 composite shows 
that the N-H bending vibration of chitosan band shifted from 1556 cm-1 to 1544 cm-1, this 
bond shift was result from the interaction between HAp with Gelatin-Chitosan matrix 
respectively [316]. The spectra of GCB 30 composite scaffold showed 1300 cm-1 band due to 
the interaction between Ca+2 of bioactive glass and COO- of gelatin molecule. The shift of N-
H vibration band to 1555 cm-1 suggest the interaction between β-TCP with gelatin-chitosan 
matrix in GCT 30 scaffold[225]. The peak near 1552(inset graph) in all composite scaffold 
corresponds to the C=N bond of cross linked gelatin-chitosan in all composite scaffold on 
reacting with glutaraldehyde solution.  
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Figure.7.3. FTIR-ATR analysis of (a) GCH30 scaffold (b) GCT30 scaffold, (c) GCB30 scaffold, analysed 
in the 500 cm−1 ~4000 cm−1 regions. 
 
Table7 2. Characteristic band of fabricated composite scaffold [317]. 
Wavenumber (cm-
1) 
Assignment Material 
~1652 Amide I(C=O stretch) Characteristic bond of Chitosan and Gelatin 
~1550 Amide II (N-H bend and C-H 
stretch) 
Characteristic bond  of Chitosan and Gelatin 
~975-480 v2 stretching vibration Characteristic vibration modes of PO4-3 in GCH 
and GCT. 
~1090, 1035, 607, 
550 
v3 and v4 vibration modes Characteristic vibration modes of PO4-3 in GCH 
and GCT  
~448, 1410, 1640 to carbonate ions (CO32_) Carbonate ion of ceramic phase 
~1300 Ca+-Coo- Interaction between organic and inorganic phase 
1552 -C-N- crosslinking of chitosan and gelatin via 
glutaraldehyde 
~463 Si-O-Si bending Characteristic of silicate network in Bioglass 
~1029 Si-O-Si stretching (asymmetric) Stretching vibration bond in Bioglass 
 
7.4.3 SEM analysis of GCH 30, GCB 30 and GCT 30 composite scaffold 
Scanning electron microscope was used to observe porous microstructure of the 
glutaraldehyde cross-linked composite scaffolds. As shown in Figure.7.4 (a,b,c) the pores in 
the composite scaffolds were interconnected in the size range between 90-120 µm, which is 
ideal for exhibiting osteoinduction. From SEM images (Figure 7.4 (a-d), it is clear that 
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bioceramic reinforced scaffolds possessed lower pore sizes as compared to neat gelatin-
chitosan based (GC) scaffold. GCH 30 exhibited the lowest average pore size of 94±5.2 µm, 
whereas the average pore size of GCT 30 was the highest of 120±6.4 µm amongst the 
composite scaffolds as evident from Table7.3. EDX analysis in Figure.7.4a1-c1 confirmed the 
presence of Calcium (Ca), Phosphorous (P) in GCH30, GCT30 and Silicon(Si), Calcium 
(Ca), Phosphorous (P) in GCB30 scaffold prepared using freeze drying technique. GCT 30 
exhibited the highest value of most frequent pore diameter of 118 µm whereas that for GCH 
30 is the lowest of 96 µm as evident from Hg porosimetry data in Figure 7.4 (a2, c2). The 
most frequent pore size of GCB 30 scaffold was close to an intermediate value of 100 µm 
(Figure 7.4 b2).Figure 7.4 (d). 
 
Figure.7.4. SEM micrographs of cross-section of scaffolds (a) GCH30 (b) GCB30 (c) GCT30 (d) GC. EDX 
analysis and pore size distribution of (a1,a2) GCH30, (b1,b2) GCB30, (c1,c2) GCT30 scaffold. 
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(a) (b) 
7.4.4 Mechanical characterization of the scaffold: compression resistance 
 
 
 
 
 
 
 
 
 
 
Figure.7.5.(a) Average compressive strength of the prepared scaffolds (b). Typical stress strain plot of 
GCH 30, GCT 30, GCB 30 and GC scaffold. 
 
Average compressive strengths of GCB 30, GCH 30 and GCT 30 scaffolds are shown in 
Figure.7.5a. The compressive strengths of three types of scaffolds were in the range between 
1–4 MPa [Figure.7.5(a)]. It is clear that bioceramics reinforced scaffolds have a significantly 
higher compressive strength (∼4 MPa) than pure gelatin-chitosan scaffolds (∼0.97 MPa) 
while the scaffolds porosity varied very little between 78–83% as shown in Table.7.3. GCH 
30 scaffold showed the highest compressive strength due to effective anchoring of 
nanoparticulate with gelatin-chitosan matrix. Higher surface area and higher number of 
unsaturated ionic bonding sites of HAp- chitosan nanopowders were mainly responsible for 
better bonding interaction with gelatin matrix in GCH 30 scaffolds and accounted for it’s 
lower average pore diameter and highest compressive strength among all the prepared 
scaffolds. Stress-strain behaviours of all the prepared scaffolds are represented in Figure 7.5 
(b). All the scaffolds showed similar stress–strain behaviour: the stress increased linearly 
upto elastic deformation zone, then reduced in slope in plastic deformation zone, followed by 
an abrupt stress increase at high strain in densification zone [318]. Owing to the high 
flexibility of gelatin, no final fracture was observed. Average maximum compressive strength 
of 3.45 MPa was exhibited by GCH 30, whereas the other composite scaffolds showed a 
lower compressive strength of 2.47 MPa by GCT 30 and 2.24 MPa by GCB 30.  
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Table.7.3. Porosity,pore size and compressive strength of composite scaffold. 
Sample ID Porosity (%) Compressive 
Strength(MPa) 
Pore Size (µm) 
(SEM) 
GCB30 81.08±6 2.24±0.01 100±8.6 
GCH30 78.12±3.2 
 
3.45±0.04 94±6.9 
GCT30 83.11±8 2.47±0.02 120±6.4 
 
7.4.5 Micro CT scanning of GCH 30, GCΒ 30 and GCT 30 composite scaffold 
Micro-CT scanning on the prepared scaffold was conducted to quantify the pore size, 
porosity and interconnected porosity. Figure 7.6 depicts 2D cross-sectional and 3D 
reconstructional images of the scaffolds. All GCH 30, GCT 30 and GCB 30 scaffolds 
presented roughly homogenous porous structures, with high degree of interconnected and 
open porosity (Table 7.4). The measured interconnected porosities of GCH 30, GC T30 and 
GCB 30 were 63 ± 1.37%, 67 ± 2.65, 72 ± 3.24% respectively, indicating that the 
interconnected porosities of the prepared composite scaffolds could be well controlled and 
GCB 30 showed the highest interconnected porosity in the prepared scaffolds.. This study 
confirms that scaffolds were prepared with sufficient degree of interconnected porosity which 
is important for in vivo osteogenesis. The average pore size values obtained from micro CT 
and as well as from SEM investigation of microstructures of prepared scaffolds were found in 
good proximity. 
 
 
128 
 
 
Chapter 7 Comparative Study 
 
Figure.7.6. 2D and 3D images of GCH 30, GCB30 and GCT30 scaffolds acquired from micro-CT 
scanning. 
 
Table.7.4. Measurement of porosities in the prepared scaffolds by Micro-CT scan. 
 Unit GCH 30 GCB 30 GCT 30 
Pore size Micrometre (µm) 96 ± 2.41 102 ± 3.01 118 ± 2.84 
Total porosity Percent (%) 79 ± 3.41 81 ± 4.01 83 ± 3.29 
Open Porosity Percent (%) 79 ± 3.41 81 ± 4.01 83 ± 3.29 
Interconnected  Porosity Percent (%) 63 ± 1.37 72 ± 3.24 67 ± 2.65 
All data shown as average ± standard deviation 
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7.4.6 BSA protein adsorption study by composite scaffold 
 
Figure.7.7. (a) BSA protein uptake by different composite scaffold (b) UV visible spectrum of BSA in 
supernatant solution after its adsorption onto different composite scaffold after 36h of study. 
BSA adsorption on three composite scaffolds was evaluated for different time intervals from 
10 to 144 hours as shown in Figure 7.7(a). BSA concentration in supernatant at solution was 
measured in the wavelength region of ~560-570 nm using UV-visible spectrophotometer 
after adsorption of protein onto scaffolds from a standard BSA solution. In all the scaffolds 
the amount of protein adsorption was the highest up to 36 hours and then became more or 
less saturated. After 36 hours of incubation in BSA solution, protein adsorption was found to 
be maximum of 24 mg/cm3 in GCB 30 scaffold and minimum of 13 mg/cm3 in GC scaffold. 
Report says that, incorporation of ΗΑp into PLLA scaffold improved protein adsorption 
capacity of the composite scaffold by forming a microenvironment on the scaffold surface 
favourable for protein adsorption [320]. In composite scaffold higher protein adsorption was 
evident because of higher surface area due to the presence of hydrophilic bioceramic 
nanoparticulate that interacted with the hydrophilic parts of the protein to bind more amount 
of protein on the surface as compared to the neat gelatin-chitosan (GC) scaffolds. Figure 
7.7(b) shows lower amount of BSA concentration in supernatant solution from GCB 30 
scaffold as compared to neat gelatin-chitosan(GC) scaffolds because of higher amount of 
protein adsorption onto GCB 30 surface from standard BSA solution after 36 hours of 
incubation. It appeared that GCB 30 scaffold had the maximum protein adsorption capacity 
among all the scaffold tested here after 36 hour of incubation in protein solution. The ability 
of surface protein adsorption is considered as an important factor contributing to the 
biocompatibility of materials, as it could influence cell adhesion, proliferation, differentiation 
[321]. 
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7.4.7 Degradation Study of GCH30, GCΒ30 and GCT30 composite scaffold 
Degradability of the prepared scaffold was measured after immersing them in PBS solution 
having pH 7.4 for 25 days. Figure.7.8 represents the percent weight loss of GC and composite 
scaffolds after immersing them for upto 25 days in SBF. All the composite scaffolds showed 
lower rate of degradation as compared to neat GC scaffold upto 25 days of immersion in 
PBS. The nanoparticulate ceramic phase addition into GC matrix resisted the rate of 
degradation due to stronger bonds between Ca2+ and COO- or PO43- and NH3+ present in 
bioceramic and gelatin- chitosan matrix. 
 
Figure.7.8 Degradation kinetics of GC, GCT30, GCB30 and GCH30 scaffolds. Data represent mean value 
of three independent experiments. 
The average weight loss of GCH 30 and GCB 30 scaffold was found to be 16% and 17% 
respectively after 25 days of immersion in PBS, whereas GCT 30 scaffold exhibited higher 
weight loss of 20% for same period of immersion in PBS. All the composite scaffolds 
showed a similar trend in degradation rate in PBS upto 25 days, which supports the fact that 
there exists no significant difference (p>0.05) in degradation capability among the prepared 
scaffolds. That means the nature of existed bioceramics phase did not exert any significant 
influence on the degradation capability of the prepared composite scaffolds. 
7.4.8 Cell attachment on GCH30, GCΒ30 and GCT30 composite scaffold 
Cell attachment and migration within the scaffold are essential for exhibiting osteoconduction 
and osteoinduction. MSCs were seeded and cultured onto GC, GCH 30, GCT 30 and GCB 30 
scaffolds for 7 and 14 days taking GC scaffold as control. As observed from SEM images in 
Figure 7.9 (a), though MSCs were sparsly distributed on the surface of composite scaffolds 
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after 7 days of culture, densities of attached MSCs were higher on composite scaffolds as 
compared to neat GC scaffold. 
 
 
 
Figure.7.9. Scanning electron microscope (SEM) images of human mesenchymal stem cells (hMSCs) 
grown on (a)GC, (b)GCH30, (c)GCT30 and (d)GCB30 scaffolds after 7 days and 14 days. 
The cells maintained round shapes on the surface of GCH30 and GCT30 scaffold, whereas 
the morphology of cells was little bit flattened on GCB30 scaffold after 7 days of culture. In 
contrast to 7 days’ culture scaffold, 14 days cultured sample showed higher cell density and 
flattened morphology. As compared to other scaffolds, the MSCs cultured on GCB30 
attached fully to cover the whole surface with numerous lamellipodia and filopodia 
(b) 14 days 
(d) 14 days 
(c) 14 days 
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extensions exhibiting better attachment and excellent spreading behaviour. The cells cultured 
onto GCH 30 and GCT 30 scaffold after 14 days were rather round shape and clingged 
together as compared to the GCB 30. MSCs showed better attachment, spreading and growth 
onto composite scaffolds as compared to neat gelatin-chitosan scaffold. 
7.4.9 Cell proliferation on GCH 30, GCΒ 30 and GCT 30 composite scaffold 
Proliferation ability of MSCs cultured in osteogenic medium and onto composite scaffolds 
was studied using MTT assay after 1, 3, 5 and 7 days. With progress in cell culture time the 
cell density in all the scaffold increased as shown in Figure.7.10.  
 
Figure.7.10. MTT assay for proliferation of MSCs cultured in osteogenic medium at various periods of 
cell culture at 1,3,5 and 7 days, onto GC, GCH30,GCT30 and GCB30 scaffold. Error bars represent 
means ±SD for n = 3. *p<0.05, #p < 0.01 (compared to MSCs cultured in osteogenic medium). 
The cell densities in composite scaffolds were significantly higher (*p <0.05) as compared to control 
during all periods of cell culture. Moreover, GCB 30 scaffold exhibited better proliferation ability of 
MSCs compared to GCT 30 scaffold as suggested by p values (# <0.01) for all the periods of cell 
culture. This reflects the fact that MSCs proliferation tendency was enhanced after addition of 
bioactive glass nanoparticles into gelatin-chitosan matrix of GCB 30. 
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7.4.10 Differentiation of MSCs in contact with Scaffolds 
Treating GAPDH as a control, the expression levels of RUNX2, COL-1, OCN and OPN were 
detected with the help of rt-PCR at two different time points of cell culture onto each type of 
composite scaffold. The band intensities obtained after gel electrophoresis of respective 
proteins are shown in Figure.7.11. It is evident from Figure.7.11 that RUNX2 expressions 
were more prominent at 7 days of cell culture compared to later time point of 14 days, which 
is consistent with MSC’s differentiation into preosteoblast and then bone lineage at later time 
points. 
 
 
 
 
 
 
 
 
Figure.7.11. Images of amplified cDNA products using GAPDH as control for hMSCs cultured on GC, 
GCH30, GCT30 and GCB30 composite scaffolds in osteogenic media for 7 days and 14 days. 
On the other hand, expression levels of COL-1, OPN and OCN were higher on later time 
point (14 days) of cell culture compared to earlier time point (7 days). Higher expression of 
COL-1, OCN and OPN at later time point of cell culture is consistent with the higher degree 
of bone matrix mineralization and mature osteoblast formation in each group of scaffold. 
7.4.11 Osteogenic Gene expression study 
Figure.7.12 shows osteogenic gene expression profile of MSCs cultured onto GCH 30, GCT 
30 and GCB 30 scaffold. Semi quantitative result showed that relative expression of RUNX2 
in GCB 30 scaffold was higher (# p< 0.05) on 7 days than that is on 14 days as in Figure 7.12 
(a). At the same time GCB 30 showed higher (**p<0.01) expression of RUN X-2 as 
compared to GCT 30 on earlier time point of 7 days reflecting its better capacity to 
differentiate MSCs into preosteoblast.  
7days   14days    
Osteocalcin 
Osteopontin 
Runx2 
COL 
GAPDH 
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Figure.7.12. Quantitative analysis of osteogenic markers upto 14 days on composite scaffold of (a) 
RUNX2, (b) COL I (c) Osteocalcin (d) OPN expression of MSCs cultured on scaffolds by Q-PCR. 
*Represents statistically significant difference (P < 0.05). 
Expression of COL-1, OCN, OPN found to be higher on all the scaffolds particularly on GCB 
30 (# all p values < 0.05) at later time point of 14 days as compared to 7 days which is 
corroborated well with MSCs commitment to matured osteoblast, bone lineage and bone 
matrix mineralization. Moreover, gene expressions of COL-1, OPN, OCN appeared to be 
significantly higher (** p values< 0.01) on GCB 30 as compared to GCT 30 and GCH 30 
after 14 days of culture of MSCs [Figure 7.12 (b), (c), (d)]. The reason behind the increasing 
osteoblastic gene expressions may be attributed to the synergic effect between Ca2+ and Si4+ 
ion released from GCB30 scaffold in cell culture media that helps in enhanced differentiation 
of MSCs seeded onto GCB30 scaffold as compared to other composite scaffold. This clearly 
reflects higher efficiency of GCB 30 scaffold to regenerate bone tissue in vitro as compared 
to other composite scaffolds. 
7.4.12 Confocal microscopic analysis of GCH 30, GCB30 and GCT30 composite scaffold  
The confocal images for expression of osteogenic marker RUNX2 and Osteocalcin by MSCs 
cultured onto GC, GCH30, GCT30 and GCB30 scaffold for 14 days are shown in 
Figure.7.13. The cultured MSCs differentiated into osteogenic lineage to elicit dual 
expression of RUNX2 and osteocalcin after 14 days of culture onto prepared scaffolds as 
shown in Figure.7.13. 
(a) 
(C) 
(d) 
(b) 
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Figure.7.13. Dual immunocytochemical analysis for the expression of RUNX2 and osteocalcin, 
differentiation marker of MScs into osteoblast, on (a) control GC, (b) GCH30, (c) GCT30 and (d) GCB30 
at 100× magnification after 14 days of cell culture. Nucleus (blue) stained with DAPI. 
RUNX2 is an enzyme expressed by MSCs during osteogenesis and well defined marker of 
osteoblastic lineage [30]. Osteocalcin is an enzyme expressed during matrix mineralization. 
Previous studies reported that extracellular Ca2+ and inorganic phosphorous released by CaP 
biomaterials, favour MSCs differentiation into osteoblast and matrix mineralization through 
activating calcium sensing receptor in osteoblast cells [16-48]. All the composite scaffolds 
contained Ca2+ and PO43- which were released during cell culture period to promote better 
differentiation of MSCs into osteoblast and bone matrix mineralization as indicated by higher 
degree of RUNX2 and osteocalcin expression in the composite scaffold as compared 
(a) RUNX2 
(b) RUNX2 
(c) RUNX2 
(d) RUNX2 
(a) Osteocalcin 
(a) Merge 
(b) Osteocalcin 
(b) Osteocalcin 
(b) Osteocalcin 
(b) Merge 
(c) Merge 
(d) Merge 
100 µm 
100 µm 100 µm 
100 µm 
100 µm 
100 µm 100 µm 
100 µm 100 µm 100 µm 
100 µm 100 µm 
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to neat GC scaffold. Furthermore, GCB30 appeared to have higher ability to promote MSCs 
differentiation into osteoblast and matrix mineralization as compared to other composite 
scaffold as evident from higher degree of RUNX2 and osteocalcin expression on GCB30 [ 
Figure 7.13(d)] among the all prepared scaffolds studied here. Apart from calcium and 
phosphate, Si4+ released from bioactive glass in GCB30 scaffold helped in better stimulation 
of MSCs into osteoblast and higher degree of bone matrix mineralization. 
7.4.13 In vivo study 
7.4.13.1 Radiological analysis 
In GC scaffold, radiological plate showed partial radio dense implant placed in created defect 
of distal end of femur bone at 0 day. After 1 month, the material was observed within the 
defect with slightly reduced radio density. There was minute amount of gap between material 
and host bone in the created defect. At 2 and 3 months, implant was still visible with reduced 
radio density and negligible gap between bone and implant indicating initiation of bone 
formation.as shown in Figure.7.14 (a). 
In GCH 30 scaffold on “0” day, the radio dense implant was visible in the distal part of 
femur. On 1 month, the material was observed in defect but with reduced radio density 
indicating initiation of new bone formation. The radiograph taken on 2 months showed 
further reduced radio density of implant material in substantial quantity in defect indicating 
in-growth of new bony tissue at the defect site. At 3 months, the implant’s radio density was 
comparable with the host bone indicating satisfactory healing under progress as evident from 
Figure.7.14 (b). 
Implanted GCT 30 scaffold on “0” day showed a radio dense part as placed in the created 
defect of distal metaphysis of femur. At 1 month, the bony defect was observed filled with 
the implant material though the radio density of implant decreased subsequently than what it 
was on “0” day. The radiograph taken on 2 month showed reduced size and shape of implant 
material in defect site indicating better in-growth of new bony tissue. At 3 months, an 
impression of implant was visible with further reduced shape, size and radio density 
indicating better healing in progress, as indicated by Figure.7.14 (c). 
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Figure.7.14. Radiograph observations at defect site, taken after 0,1,2 and 3 months post operatively 
(a)GC, (b)GCH 30, (c)GCB 30 and (d)GCT 30 implant. 
The “0” day radiograph of bony defect of epiphyseal area implanted with GCB 30 scaffold 
showed round shape area packed with radio dense implant material. At 1-month radiograph 
showed narrowing of bony defect as well as substantially reduced radio density of implant. 
Subsequent radiograph was taken on 2 months showed negligible impression of implant and 
bony defect. The radio density in targeted area was almost comparable to the adjacent of the 
healthy bone indicating good stage of remodelling. At 3 months, implant was not visible 
indicating degradation of material vis-a-vis in-growth of satisfactory amount of new osseous 
tissue in the defect site as shown in Figure 7.14 (d). 
7.4.13.2 Histological assessment 
Figure.7.15 demonstrated the histological evaluation of implanted bony specimens after 1 
month postoperatively, to figure out the cellular response at the host-implant interface. After 
1 month, osteogenesis was not visible at GC sample and angiogenesis was lesser in amount in 
GC sample as compared to composite scaffold as shown in Figure.7.15 (a-d). The section of 
138 
 
 
Chapter 7 Comparative Study 
GCH 30 sample in Figure 7.15 (b) showed well-formed bony matrix surrounded by few 
osteocytes, osteoblast and fibrin network with little bit of angiogenesis observed at the centre 
of specimen after 1 month of implantation. The angiogenesis at the certain points was well 
marked specially at the trabecular margin of GCT 30 sample (Figure 7.15 (c)) after 1 month. 
GCB 30 sample in Figure 7.15 (d) was composed of osteoblast, osteocytes, few RBC and 
slight masses of fibrin and angiogenesis was visible at certain points after 1 month of 
implantation. 
After 2 months’ (Figure.7.15 a-d), mild angiogenesis was observed in GC sample. The bony 
trabeculae and periosteum were lined by dense fibrous tissue and mononuclear cells in 
GCH30 sample. GCT30 sample depicted a well formed bony structure containing numerous 
Haversian canals, medullary cavities and number of angiogenic points. On the other hand, 
GCB30 sample showed a well organised pattern of bony structure consisting of numerous 
bony medulla, Haversian system and bony lacunae. Moreover, the trabaculae around bony 
structure consisted of collagenous matrix of osseous tissue and fibrocytes. 
As shown in Figure.7.15(a-d), 3 months GC sample showed a trabecular structure with 
proportionate amount of osteoblast, osteocyte and marginal fibrous tissue and medulla 
consisted of large amount of RBC, osteoblast, and fibrinous deposits. Angiogenesis was well 
marked almost throughout the section in GCH3 0 sample, although some medullary cavities 
were relatively avascular. Sufficient proliferation of osteoblast was seen in GCT 30 and GCB 
30. However, in GCB 30, the peri-osseous tissues were highly vascular and composed of 
large masses of RBC, mononuclear cells, osteocytes and fibrinous network. The presence of 
osteoblastic and osteoclastic activity indicated remodelling of bone at the implanted site of 
GCB 30. In comparison to other samples, GCB 30 exhibited visibly higher angio 
proliferation with numerous Haversian system and lacunae and canalicuilar space after 3 
months of in vivo study in rabbit tibia. 
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Figure.7.15. Histological sections taken after 1,2 and 3 months post-operatively implanted with (a) 
Control(GC), (b) GCH 30, (c) GCT 30 and (d) GCB 30 scaffolds. 
 
 
 
140 
 
 
Chapter 7 Comparative Study 
7.4.13.3 Flurochrome labelling study 
Under UV radiations, the oxytetracycline (OTC) labelled new bone gives characteristic bright 
golden yellow fluorescence while the old bone areas give deep sea green fluorescence. 
Figure.7.16 (a, b, c, d) exhibited the OTC labelled implanted specimens, collected after 
sacrificing the animals at 1,2 and 3 months. At 1 month, GCB 30 scaffold showed more. 
 
Intense golden yellow fluorescence, compared to other three samples. As evident from 
Figure.7.16 (a-d) the amount of new bone formation was also higher for 2 months as 
compared to 1 month in all the samples. In control and GCH30 sample, the golden yellow 
fluorescence was observed in the centre but few patches of new bone formations could be 
seen in different regions of the section, both on endosteal and periosteal side after 2 months. 
GCT 30 and GCB 30 samples showed greater area of golden yellow fluorescence indicating 
more new bone formation after 2 months of implantation. 
At three months, the golden yellow fluorescence in control sample was visible on few 
concentrated patches as in Figure.7.16 (a) that reflected the mild activity for new bone 
formation at the implant site. In GCH30 sample, fluorescence micrograph imparted a golden 
yellow fluorescence in wider zone, suggesting new bone formation was more as compared to 
control (GC) sample (Figure.7.16 (b)). In contrast, the implanted site of GCT 30, showed 
even wider regions of golden yellow fluorescence indicating rapid new bone regeneration in a 
particular region as shown in Figure.7.16(c). In GCB 30 sample [Figure.7.16 (d)], intensity of 
new bone formation was the highest as compared to other three samples although 
fluorescence was little patchy in nature, but throughout the section demonstrating their higher 
effectiveness in bone regeneration. Based on the calculation, percentage of bone 
formation through fluorochrome labelling images at three-time points of 1,2 and 3 
months was performed and is given in Table 7.4 and compared in Figure.7.17. It is 
evident from Table 7.4 and Figure 7.17 that percent new bone formations at the GCB 30 
implanted site was higher (*p value <0.05, ** p value < 0.05) as compared to the sites of 
other implanted scaffolds which is well corroborated with the in vitro bioactivity of GCB 30 
scaffold in terms of MSCs attachment, proliferation and differentiation. 
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Table.7.5. Percentage bone formation onto composite scaffold after 1,2 and 3 months of implantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 month(%) 2 month(%) 3 month(%) 
GC  16.215 ± 2.43 20.389 ± 2.72 29.643 ± 1.58 
GCH 30 19.095 ± 2.61 21.351 ± 1.06 37.542 ± 3.62 
GCT 30 20.895 ± 3.42 39.031 ± 3.42 62.177 ± 2.92 
GCB 30 33.209 ± 2.43 43.333 ± 2.61 70.450 ± 2.63 
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Figure.7.16. Flurochrome labelling images taken after 1,2 and 3 months post-operatively implanted in (a) 
GC (b) GCH 30 (c) GCT 30 (d) GCB 30 showing the golden yellow new bone and the deep sea green old 
bone zone. 
 
 
 
 
 
 
 
 
(d) 1 month (d) 2 month (d) 3 month 
(a) 1 month 
(b) 1 month 
(c) 1 month 
(a) 2 month (a) 3 month 
(b) 2 month (b) 3 month 
(c) 2 month (c) 3 month 
NB 
OB OB 
OB 
OB 
OB 
OB 
OB 
OB 
OB 
OB 
OB 
OB 
NB 
NB 
NB 
NB 
NB 
NB 
NB 
NB 
NB 
NB 
NB 
143 
 
 
Chapter 7 Comparative Study 
 
Figure.7.17. Bone ingrowth in GC, GCH 30, GCT 30 and GCB 30 composite scaffolds after 1,2 and 3 
months of implantation  
7.4.13.4 ESEM investigation on the implanted site of scaffolds 
Figure.7.18 (a-d) exhibited ESEM micrographs of the host implant interface postoperative at 
1 month and 3 months, respectively, for investigation of osseous ingrowth processes inside 
the scaffolds and across the interfacial regions. Figure 7.18 shows that osseous tissue growth 
was much higher in 3 months’ samples as compared to 1-month sample irrespective of the 
nature of scaffold indicating good osteogenesis in all scaffolds tested here. While comparing 
the ESEM images of respective scaffold- bone tissue interfaces, substantial interfacial gap 
with little tissue growth was observed at the host–graft interface of GC implanted site in 
Figure.7.18 (a). In case of composite scaffolds such as GCH 30, GCT 30, GCB 30 
[Figure.7.18 (b-d)], there was considerable reduction in the interfacial gap with substantial 
osseous ingrowth indicating superior bone mineralization and ECM formation. New bone 
regions were clearly observed at the interfacial zone of the implanted sites of GCH3 0, GCT 
30, GCB 30 both after 1 month and 3 months postoperatively. Interfacial zone was almost 
collapsed in GCT 30 and GCB 30 scaffolds after 3 months of implantation indicating better 
osteointegration between bone and scaffolds. In figure.7.18 (d), the GCB 30 implanted site 
both after 1 month and 3 months postoperatively, showed densification of extra cellular bone 
matrix leading to strengthening of the scaffold –bone tissue interface. 
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(b) 3 month 
GCH30 (C) 3 month GCT30 
 
Figure.7.18. ESEM image of  host implant interface in (a) GC, (b) GCH 30, (c) GCT 30 and (d) GCB 30 
scaffolds post operatively after 1 month ( above) and 3 months (below). 
7.5 Conclusions 
Gelatin and chitosan based composite scaffolds reinforced with 30 wt% HAp, β-TCP and 58s 
bioactive glass nanoparticles were prepared using freeze drying technique. The prepared 
composite scaffolds possessed high porosity varying between 75 to 83% where GCT 30 
exhibited the highest average pore size of 120 µm. The protein adsorption capacity onto GCB 
30 was found to be the highest. Cultured MSCs proliferated to a better extent onto GCB 30 
scaffold as compared to other scaffolds. Expression of osteogenic genes was significantly 
enhanced on the composite scaffold as compared to neat GC scaffold. On the other hand, 
MSCs differentiation into osteoblast was much faster and more pronounced on GCB 30 
scaffolds than on other composite scaffolds. In in vivo study, GCB 30 showed significantly 
improved bone-forming efficiency as compared to GC scaffold as well as other composite 
scaffolds. Bioactive 58s glass reinforced gelatin -chitosan scaffold offers a new dimension in 
3D porous bioactive scaffolds with synergistically improved physicochemical and biological 
properties for improved bone tissue engineering. 
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CHAPTER # 8 
Effect of Cryogenic Treatment on the Strength Retention and Biological 
property in GCB 30 scaffold under physiological condition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There's a way to do it better - find it.  
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Abstract 
The highly porous GCB 30 scaffold was prepared through freeze drying technique. 
Mechanical property such as compressive strength was improved after curing it in liquid 
nitrogen. The compressive strength of GCB 30 scaffold was increased up to 5.5 MPa on 5 h 
of cryogenic treatment but decreased beyond that because of abrupt excessive internal stress 
and micro-cracking. From CD and FTIR analysis of amide bond in gelatin present in GCB30 
scaffold, it is evident that there was no significant change in the relative content of secondary 
structures after cryogenic treatment, which supports insignificant denaturisation of protein 
structures after 5 hours of treatment in liquid nitrogen. MTT assay confirmed excellent cell 
attachment and growth on 5 hours cryo treated GCB 30 scaffold as compared to untreated 
scaffold.  
8.1 Introduction 
One of the main limitations of gelatin based scaffold is its strength retardation in contact with 
physiological fluid, primarily because of considerable solubility of gelatin in water based 
solution. This imparts a serious concern for gelatin based scaffold in its handling in 
moderately load bearing site. Though being a dehydrated derivative of collagen, gelatin 
shows excellent bioactivity, its poor mechanical strength under physiological condition 
seriously limits its application in orthopaedic sites. 
 Earlier there was report on enhanced crystallinity of epoxy based resin on cryogenic 
treatment . On this ground we may hypothized that cryo treatment of gelatin based scaffold 
might have an effect on increasing its crystallinity. This increase in crystallinity should have 
an effect in lowering the rate of dissolution of gelatin based scaffold under physiological 
environment, and to enhance its strength retention capability on exposure to physiological 
fluid. In the present work, we have performed cryogenic treatment on GCB30 after 
immersing it for 1h,2h,5h and 8h in liquid nitrogen chamber (Table.8.1), and studied a 
comparative compressive strength analysis of cryo treated and untreated GCB30 scaffold 
with a subsequent investigation on its degradation in PBS solution of pH 7.4 at room 
temperature. We have also tried to analyse the changes in conformation of gelatin secondary 
structure in cryo treated and untreated scaffold using FTIR and Circular dichromism study. 
 
 
147 
 
 Chapter 8- cryo treated GCB 30 scaffold 
 
Table.8.1. Sample identification of GCB 30 scaffold for different treatment time with liquid nitrogen. 
Sample id Liquid N2 treatment time 
(hours) 
GCB030 0 hour 
GCB230 2 hour 
GCB530 5 hour 
GCB830 8 hour 
 
8.2 Materials and Methods 
Cryogenic treatment of scaffold 
The freeze dried GCB 30 scaffold sample of 12 mm in height and 5 mm in diameter  was 
treated in liquid nitrogen at 77 K for different time duration of 2, 5, and 8 hours inside a cryo 
chamber. Original GCB 30 scaffold as well as liquid nitrogen treated scaffolds was further 
characterized using XRD, FT-IR and compressive strength analysis. 
 
8.2.1 XRD analysis of GCB0 30 and GCB5 30 scaffold 
X-ray diffraction analysis of GCB0 30 and GCB5 30 scaffold were performed with a 
Panalytical (USA) model operated at 40Kv and 40 mA using Cu Kα radiation. The detailed 
procedure was mentioned in Chapter4 in section 4.4.1. 
8.2.2 FTIR analysis of GCB0 30 and GCB5 30 scaffold 
The characteristic peaks of pure GCB0 30 and GCB5 30 were analysed using Fourier 
transform infrared (FTIR) (PerkinElmer, USA) spectroscopy. The detailed procedure was 
mentioned in Chapter4 in section 4.4.2. 
8.2.3 Mechanical Strength analysis 
Compressive strength analysis of the scaffold was performed using an universal mechanical 
testing machine (Instron, Tinius Olsen,UK). Cylindrical specimens with dimensions of 12 
mm in height and 5 mm in diameter were used for the tests at both “Cryo treated” and 
“Untreated” states. Compressive strength analysis of both treated and untreated samples was 
performed in a dry state at 25°C. For testing mechanical behaviour of GCB5 30 scaffold in 
physiological environment, the specimens were submerged in PBS for 2 days and were tested 
under compression in situ in PBS using Universal Testing Machine (UTM) at the rate of 1 
mm min-1 at 37oC. 
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8.2.4 CD analysis 
Circular Dichroism (CD) spectroscopy is the most widespread technique used for estimating 
the secondary structures of proteins and polypeptides in solution [322]. This technique can be 
used to distinguish between unordered (random coil) and ordered (alpha-helix or beta-sheet) 
secondary structures in a protein [2,3].CD detects wavelength-dependent differences in the 
absorption of right and left circularly polarized light by optically active molecules such as 
peptides and proteins. The CD spectrum of unordered peptides is usually characterized by a 
positive band at 220 nm, whereas alpha-helical structures usually present a negative band at 
208 nm; beta-sheet structures typically shows a negative band at 217 nm.  
CD spectra were recorded using a spectrophotometer (JASCO,Model J-1500, USA) equipped 
with a Peltier temperature controller. Spectra were obtained from 190 to 250nm at a scanning 
speed of 10nm/min at 25 °C. CD data are reported as mean residue ellipticity ([Θ], 
degree·cm2·dmol−1)  
8.2.5 Biodegradation study 
The degradation of the GCB0 30 and GCB5 30 scaffolds was studied by placing them in 
phosphate buffer saline (PBS) at 37˚C for up to 28 days. The detailed procedure was 
mentioned in Chapter4 in section 4.4.12. 
 
8.2.6 MTT analysis 
Cell viability of MSCs cultured onto the GCB0 30 and GCB5 30 scaffolds were determined 
after performing [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) 
assay. The detailed procedure was mentioned in Chapter4 in section 4.4.13.4. 
8.3 Statistical Analysis 
Quantitative data were presented as mean ± standard deviation (SD). The two-dimensional 
student t-test (T-test) was employed to obtain p values, which determined the level of 
significance of the data. Differences between groups were statistically significant if p≤ 0.05 
and highly significant if p≤ 0.01. 
8.4.Results and Discussion 
8.4.1 XRD analysis of cryo-treated GCB scaffold 
X-ray analysis of the GCB0 30 and GCB5 30 are shown in Figure. 8.1. Increase in peak 
intensity and decrease in the hump area from 15-35o in GCB030 to 19-32o in GCB5 30 is 
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associated with increase in crystallinity of polymeric matrix after treatment in liquid nitrogen 
upto 5h.  
 
Figure.8.1. XRD analysis of untreated GCB30 and 5 hour cryo treated GCB30 scaffold. 
8.4.2 FTIR analysis of cryo-treated scaffold 
Figure 8.2(a) demonstrates FTIR spectra of freeze dried untreated and 5-hour liquid nitrogen 
treated scaffold. The absorption band at 3219cm-1 is associated with the characteristic 
stretching vibration of OH-. The absorption bands at 1076 cm-1 and 661cm-1 describe the Si-
O-Si and P-O stretching vibration of bioactive glass in GCB0 30 scaffold [265]. The bands at 
2876 cm-1 and 1552 cm-1 show the C-H stretching of gelatin and N-H stretching vibration of 
amide in GCB030 scaffold. However, shifting of amide bond to higher wave number from 
1648 cm-1 in untreated scaffold to 1667 cm-1 in 5 hour cryo treated scaffold as well as similar 
shift in amine bond from 1552 cm-1 in untreated scaffold to 1568 cm-1 in GCB530 scaffold 
signifies strengthening of corresponding bonds in polymer matrix after cryogenic treatment. 
Absorption at higher wavenumber with high intensity occurs in FTIR spectra due to shorter 
and stronger bonds between consecutive atoms. This is because, cryogenic environment 
freezes the thermal oscillation of atoms, leading to shortening in C-O,C-C, C-N bonds and 
strengthens the hydrocarbon matrix.  
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Figure.8.2. FTIR plot of (a) Freeze dried GCB030 scaffold and liquid nitrogen treated GCB5 30 scaffold 
(b) shift of amide peak in GCB530 scaffold in the wave number region of 1500-1700 cm-1. 
8.4.3. Compressive behaviour of cryo-treated GCB scaffold 
Figure 8.3 represents the characteristic stress-strain curve of original and 2, 5, 8 hours cryo-
treated GCB530 scaffold under compression. The untreated GCB0 30 scaffold exhibited a 
linear elastic region upto a peak stress of 2.2MPa after which a plateau region started where 
pore walls touched each other causing collapse of the hydrocarbon matrix. The compressive 
yield stress was higher (4.5 MPa) after 2h liquid nitrogen treatment, and was even higher (5.5 
MPa) after 5h treatment at 77 K. Comparative data analysis shows that 5 hours cryo treated 
GCB5 30 scaffold had the highest compressive strength of 5.5 MPa beyond that a gradual 
reduction of compressive strength was observed. The continuous increase and then decrease 
in compressive strength after 5 hours of liquid nitrogen treatment was due to a combination 
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of shortening in hydrocarbon bond length and internal stress associated with thermal 
conductivity mismatch at such low temperature. Micro cracking occurred in the polymer 
matrix due to generation of internal stress and mismatch between thermal expansion co-
efficients of bioactive glass and biopolymers at 77K. This factor dominated over the strength 
enhancement due to shortening in hydrocarbon bond length from decrease in thermal 
oscillation in atoms of polymer matrix after 5 h treatment at cryogenic temperature. 
 
 
Figure 8.3. Stress -strain curve of untreated and liquid nitrogen treated scaffold for 2,5,8 hours. 
8.4.4 In vitro biodegradability 
Figure.8.4 demonstrates the bio-degradation study of GCB530 and GCB030 scaffold in PBS 
buffer solution at 37oC and pH 7.4 up to 14 days of immersion. Weight loss percentage for 
untreated scaffold was significantly higher as compared to 5 hours treated scaffold at all 
period of immersion in PBS. The rate of degradations of GCB30 scaffolds though slower 
upto 5 days, enhanced after that period of immersion in PBS. The lower rate of degradation in 
5 hours treated scaffold may be explained on the basis of its higher bond strength and higher 
capability to resist water penetration after 5 hours of treatment in liquid nitrogen.  
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Figure.8.4. Biodegradation study of cryo-treated GCB530 and untreated GCB030 scaffold with variation 
in incubation time in PBS. 
8.4.5 Compressive behaviour after in vitro ageing of GCB5 30 scaffold in PBS 
Since gelatin polymer is bioresorbable, degradation of the polymer occurs over time. This 
results in polymer matrix losing strength and stability in the implant. It is well known that, in 
some cases migration of water through the interface can cause spontaneous degradation 
[323]. 
 
Figure.8.5. Stress-strain curves of the GCB0 30 and GCB5 30 after 2 days of incubation in PBS solution. 
 
Figure.8.5 demonstrates the stress-strain curve of GCB0 30 and GCB5 30 scaffold immersed 
in PBS solution up to 2d. The result showed that for both the scaffolds the mechanical 
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strength decreased noticeably after 2d of ageing. However compressive strength of GCB305 
scaffold was significantly higher than GCB030 after ageing for 2ds in PBS. After 5 h of 
exposure to cryogenic environment bond strength between inorganic and organic phases was 
enhanced that was reflected in marked differences in the stress vs. strain curves for cryo 
treated and untreated scaffold. The higher compressive strength of GCB30 scaffold after 2 
days of ageing in PBS might be because of its lower rate of degradation and hence lesser 
strength retardation in PBS solution as compared to untreated scaffold.  
 
8.4.6. Circular Dichroism of cryo-treated gelatin protein  
 
Figure.8.6 describes the CD spectrum of untreated and liquid nitrogen treated gelatin based 
scaffold for the conformational analysis of gelatin proteins, which indicates relative 
proportion of various secondary structures present in gelatin. Table.8.2 shows the percentage 
of various secondary unit (α-helix, β-turn, β-sheet and random coil) of treated and untreated 
sample. It indicates that there were very negligible changes in relative proportions of α-helix, 
β-turn, β-sheet and random coil content in secondary structure of gelatin after cryo treatment 
for 5 hours at 77K. It has been reported that upon complete denaturation of gelatin, the 
positive peak at 222 nm disappears completely while the negative band shifts to nearly 230 
nm . However, our results showed that the increase in treatment time of gelatin did not cause 
the positive band at 222 nm to disappear, and there was negligible change in the negative 
elipticity in CD spectrum of gelatin in GCB530 scaffold. 
This shows that liquid nitrogen treatment brought about a very little change in conformations 
of secondary structure and did not change the triple helical conformation of gelatin. 
Maintaining the triple helical conformation of gelatin or collagen-based biomaterials during 
preparation is important in eliciting the desired biomedical functions of both. 
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Figure.8.6. CD spectrum of GCB0 and liquid nitrogen treated (GCB2 30,GCB5 30) gelatin sample. 
 
Table.8.2: Relative content of secondary structures in gelatin in GCB530, GCB230, GCB030 from CD 
analysis. 
Secondary 
structure GCB030 GCB230 GCB530 
α-helix 1.9 1.2 1.6 
β-sheet 23.5 20.6 19.1 
β-turn 19.4 19.3 20.4 
Random coil 55.2 58.9 58.9 
 
8.4.7 Secondary structure analysis of Gelatin protein 
The secondary structure of gelatin in GCB0 30 treated with liquid nitrogen upto 5h was 
analysed using FTIR spectroscopy as shown in Figure 8.7. The relative content as shown in 
Table.8.3 after deconvoluting FTIR peak at 1600 cm-1 to 1700 cm-1 of untreated and cryo 
treated in liquid nitrogen for 5 hours. There was very little difference between the values 
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obtained from CD spectroscopy and FTIR peak deconvolution. Both from CD and FTIR data 
it is clear that there was minor change in secondary structure in gelatin after 5 hours of liquid 
nitrogen treatment of GCB30 at77 K. 
 
Figure.8.7. Infrared spectra of gelatin in the amide I region and their gaussian curve-fitting (a) untreated 
gelatin in GCB0 30 and (b) treated gelatin in GCB5 30 sample for 5h. 
Table.8.3. Relative content of secondary structures in gelatin in GCB530 and GCB030 from FTIR 
analysis 
Secondary 
structure GCB030 GCB530 
α-helix 1.8 1.7 
β-sheet 25.7 23.2 
β-turn 21.4 20.4 
Random coil 51.1 54.7 
8.4.8. MTT assay of cryo-treated GCB5 30 scaffold 
Metabolic activity of MSCs cultured onto 5 hours cryo treated and untreated GCB530 
scaffold was analysed using MTT assay after 3, 5, and 7 days of cell culture using tissue 
culture plate with TritonX100 in cell culture media as negative control. The rate of 
proliferation of MSCs in both cryo treated and untreated scaffold was higher as compared to 
negative control. From the MTT assay it is evident that there was no significant difference (p 
> 0.05) in number of viable MSCs or MSCs density on 5 hour cryo treated and untreated 
GCB30 scaffold upto 7 days of culture. This signifies that proliferation ability of MSCs 
cultured onto GCB30 scaffold did not vary significantly after cryogenic treatment of the 
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scaffold upto 5 hours as shown in Figure.8.8. 
 
Figure.8.8. MTT assay for cell proliferation study in GCB030, GCB530 and negative control scaffold 
using human Mesenchymal stem cell on days 3, 7, and 14. * indicates significant difference at p ≤ 0.05. 
8.5 Conclusions 
Gelatin polymer is very prone to degrade in physiological media for its strong hydrophilic 
nature, which is a concern for its application as bone graft. In this study, a simple method was 
used to enhance the mechanical property of GCB scaffold without compromising on its 
bioactivity and to improve its strength retention capacity in contact with physiological 
environment. Five hours cryo treated GCB5 30 scaffolds developed the highest compressive 
strength of 5.5 MPa in comparison to its counterpart untreated GCB0 30 scaffold. This 
increase in compressive strength was associated with slower degradation of GCB5 30 scaffold 
in physiological medium. FTIR and CD analysis of the proteina structure present in cryo 
treated scaffold proved that there was hardly any change in conformations of secondary 
structures after 5 hours of cryo treatment. MTT assay of the cultured MSCs onto cryo treated 
scaffold showed that there was no significant difference in viable cell density as compared to 
that on untreated scaffold after 7 days of cell culture. 
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You just can't beat the person who never gives up.  
Babe Ruth 
 
 
 
 
Chapter 9-Conclusions 
Highly porous composite scaffolds from gelatin, chitosan biopolymer and 
nanoparticulates of bioactive ceramic such as hydroxyapatite, β-tricalcium phosphate, 58s 
bioactive glass was successfully prepared using the method lyophilisation and characterized 
both in vitro and in vivo for a possible biomedical application in reconstructing 
musculoskeletal disorder in human system. First, GCH scaffolds with varying compositions 
were prepared and optimization of phase composition in scaffold was performed after 
measuring their physicochemical and mechanical properties. HAp- chitosan nanoparticles in 
different weight ratios were synthesized in situ and used for the fabrication of GCH scaffolds. 
GCH scaffolds having gelatin content fixed at 30 wt% and HAp content ≤ 28 wt% were 
found to possess desirable pore size distribution for scaffolds to exhibit osteoinduction. With 
increase in HAp-chi nanoparticulate contents in the prepared GCH scaffolds, average pore 
size in the scaffold found to decrease. GCH 30 scaffold with a phase composition of 
(gel:chi:HAp) 30: 42: 28 showed an optimum pore size distribution between 75-110 µm with 
high degree of interconnected porosity and maximum mechanical strength of 3.46 MPa. HAp 
phase content in the scaffold greater than 30 wt% led to a decrease in compressive strength 
due to agglomeration of ceramic particulate as well as non-homogeneous phase distribution 
in the scaffold. On the other hand, gelatin content greater than 30 wt% in the scaffold showed 
a decrease in average pore diameter below 75 µm which is not optimum for bone cell 
ingrowth and exhibition of osteoinduction by the scaffold. GCH scaffolds showed an increase 
in compressive strength compared to neat GC scaffold because of reinforcement from 
nanoparticulate HAp with varying composition from 10-30wt%. β-TCP and 58S bioactive 
glass based scaffold was thus studied using a phase composition of gelatin fixed at 30 wt% 
and varying the bioactive ceramic phase content from 10-30 wt.%. With increase in 
bioceramic phase content from 10-30 wt%, compressive strengths of all the prepared 
scaffolds increased. In general, with increasing bioactive ceramic phase content from 10-30 
wt%, bioactivity of the scaffold increased which was evident from MTT assay, confocal 
microscopic images for RUNX2 osteocalcin expressions from cultured MSCs onto the 
scaffolds.  
Thus, physicochemical, mechanical and biological properties of the scaffolds were 
studied and compared after preparing scaffolds from 30 wt% of nano bioceramic content. 
GCH 30 showed the maximum compressive strength of 3.46 MPa while a lowest average 
compressive strength of 2.2MPa was recorded for GCB 30 scaffolds. Most frequent pore size 
of GCT 30 was the highest of 120 µm whereas that for GCH 30 was the lowest of 94 µm 
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among 30 wt% bioceramic based scaffolds. GCB 30 scaffold showed the highest protein 
adsorption capacity of 24mg/cm3 and a lowest of 19mg/cm3 exhibited by GCH 30 primarily 
because of higher proportion of exposed hydrophilic sites in GCB 30 scaffold compared to 
GCT 30 and GCH 30. The rate of biodegradation did not vary in a significant manner with 
change in bioceramic phase content at 30 wt%, but certainly all GCB 30, GCT 30, GCH 30 
scaffolds showed a lower rate of biodegradation as compared to neat GC scaffold. Higher 
extent of expression of osteoblast differentiation marker genes such as osteocalcin, RUNX2 
were identified after 1,7, and 14 days of MSC’s culture onto GCB 30, GCT 30 and GCH 30 
scaffolds as compared to neat GC scaffold. All the composite scaffolds exhibited higher 
capacity in differentiating MSCs into osteoblast as compared to neat gelatin-chitosan 
scaffold. Moreover, MSCs cultured onto GCB 30 produced higher level of osteocalcin 
expression than that onto GCT30 and GCH 30 upto 14 days demonstrating higher efficiency 
of GCB 30 in differentiating MSCs into osteoblast. The result from rtPCR analysis of the cell 
cultured scaffold clearly demonstrated that the expression level of both OPN and OCN in 
hMSC’s cultured on GCB 30 scaffolds were higher than that on GCT 30 and GCH 30 
scaffold after 14 days of culture. As a whole, GCB 30 appeared to be a better scaffold to 
differentiate MSCs into osteoblast within shorter time period. 
Histology study on GCB 30, GCH 30, GC T30 scaffold implanted in rabbit tibia for 1 
month demonstrated a well organised bony plate characterised by formation of a clusters of 
bony osteoblast, osteoclast, and numerous osteocytes. Angiogenesis was visible at certain 
points at the centre of the bony plate in implanted sites of all the scaffolds. All the GCH 30, 
GCT 30 and GC B30 scaffolds, as well as neat GC scaffold showed considerable ability of 
new bone formation after 3 months of implantation in rabbit tibia. Based on the histological, 
radiological and flurochrome labelling results, 58s bioactive glass reinforced GCB30 scaffold 
showed higher efficiency in enhanced early-stage bone formation at the defect site of rabbit 
tibia as compared to other scaffolds. 
Cryo treatment on GCB 30 scaffold using liquid nitrogen was carried out to increase its 
compressive strength and improve its strength retention capability in physiological 
environment. Five hours of liquid nitrogen treatment to GCB 30 proved to be effective in 
increasing the compressive strength of GCB30 up to 5.6 MPa with improved strength 
retention capability in PBS solution up to 2 days. MTT assay of cryo treated GCB 30 scaffold 
exhibited no significant difference in cell proliferation up to 14 days of cell culture.
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